The Role of MicroRNA Regulation of Cardiac Ion Channel in Arrhythmia by Luo, Xiaobin
 Université de Montréal 
 
 
The Role of MicroRNA Regulation of Cardiac Ion 
Channel in Arrhythmia 
 
 
 
par 
Xiaobin Luo 
 
 
Département de Médecine 
Faculté de Médecine 
 
 
 
Thèse présentée à la Faculté des études supérieures 
en vue de l’obtention du grade de  
Philosophiae Doctor (Ph.D.) 
en Sciences Biomédicales 
 
 
 
Août 2012 
 
© Xiaobin Luo, 2012 
  
 
Université de Montréal 
Faculté des études supérieures et postdoctorales 
 
 
 
 
Cette thèse intitulée: 
 
The Role of MicroRNA Regulation of Cardiac Ion Channel in Arrhythmia 
 
 
 
 
Présentée par : 
Xiaobin Luo 
 
 
 
 
a été évaluée par un jury composé des personnes suivantes : 
 
 
   Dr Eric Thorin Président-rapporteur 
Dr Stanley Nattel        Directeur de recherche 
Dr Lucie Parent  Membre du jury 
Dr Alvin Shrier  Examinateur externe 
Dr Jacques Turgeon  Représentant du doyen de la FES 
 
 
 
iii 
 
 
RÉSUMÉ 
La fibrillation auriculaire (FA) est le trouble du rythme le plus fréquemment 
observé en pratique clinique. Elle constitue un risque important de morbi-mortalité. Le 
traitement de la FA reste un défi majeur en lien avec les nombreux effets secondaires 
associés aux approches thérapeutiques actuelles. Dans ce contexte, une meilleure 
compréhension des mécanismes sous-jacents à la FA est essentielle pour le développement 
de nouvelles thérapies offrant un meilleur rapport bénéfice/risque pour les patients. La FA 
est caractérisée par i) un remodelage électrique délétère associé le plus souvent ii) à un 
remodelage structurel du myocarde favorisant la récurrence et le maintien de l’arythmie. La 
diminution de la période réfractaire effective au sein du tissu auriculaire est un élément clef 
du remodelage électrique. Le remodelage structurel, quant à lui, se manifeste 
principalement par une fibrose tissulaire qui altère la propagation de l’influx électrique dans 
les oreillettes. Les mécanismes moléculaires impliqués dans la mise en place de ces deux 
substrats restent mal connus. Récemment, le rôle des microARNs (miARNs) a été pointé du 
doigt dans de nombreuses pathologies notamment cardiaques. Dans ce contexte les 
objectifs principaux de ce travail ont été i) d'acquérir une compréhension approfondie du 
rôle des miARNs dans la régulation de l’expression des canaux ioniques et ii) de mieux 
comprendre le rôle de ces molécules dans l’installation d’un substrat favorable a la FA. 
Nous avons, dans un premier temps, effectué une analyse bio-informatique 
combinée à des approches expérimentales spécifiques afin d’identifier clairement les 
miARNs démontrant un fort potentiel de régulation des gènes codant pour l’expression des 
canaux ioniques cardiaques humains. Nous avons identifié un nombre limité de miARNs 
cardiaques qui possédaient ces propriétés. Sur la base de ces résultats, nous avons  
démontré que l’altération de l'expression des canaux ioniques, observée dans diverse 
maladies cardiaques (par exemple, les cardiomyopathies, l’ischémie myocardique, et la 
fibrillation auriculaire), peut être soumise à ces miARNs suggérant leur implication dans 
l’arythmogénèse. 
La régulation du courant potassique IK1 est un facteur déterminant du remodelage 
électrique auriculaire associée à la FA. Les mécanismes moléculaires sous-jacents sont peu 
connus. Nous avons émis l’hypothèse que l'altération de l’expression des miARNs soit 
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corrélée à l’augmentation de l’expression d’IK1 dans la FA. Nous avons constaté que 
l’expression de miR-26 est réduite dans la FA et qu’elle régule IK1 en modulant 
l’expression de sa sous-unité Kir2.1. Nous avons démontré que miR-26 est sous la 
répression transcriptionnelle du facteur nucléaire des lymphocytes T activés (NFAT) et que 
l’activité accrue de NFATc3/c4, aboutit à une expression réduite de miR-26. En 
conséquence IK1 augmente lors de la FA. Nous avons enfin démontré que l’interférence in 
vivo de miR-26 influence la susceptibilité à la FA en régulant IK1, confirmant le rôle 
prépondérant de miR-26 dans le remodelage auriculaire électrique. 
La fibrose auriculaire est un constituant majeur du remodelage structurel associé à 
la FA, impliquant l'activation des fibroblastes et l’influx cellulaire du Ca2 +. Nous avons 
cherché à déterminer i) si le canal perméable au Ca2+, TRPC3, jouait un rôle dans la fibrose 
auriculaire en favorisant l'activation des fibroblastes et ii) étudié le rôle potentiel des 
miARNs dans ce contexte. Nous avons démontré que les canaux TRPC3 favorisent l’influx 
du Ca2 +, activant la signalisation Ca2 +-dépendante ERK et en conséquence activent la 
prolifération des fibroblastes. Nous avons également démontré que l’expression du TRPC3 
est augmentée dans la FA et que le blocage in vivo de TRPC3 empêche le développement 
de substrats reliés à la FA. Nous avons par ailleurs validé que miR-26 régule les canaux 
TRPC3 en diminuant leur expression dans les fibroblastes. Enfin, nous avons montré que 
l'expression réduite du miR-26 est également due à l’activité augmentée de NFATc3/c4 
dans les fibroblastes, expliquant ainsi l’augmentation de TRPC3 lors de la FA, confirmant 
la contribution de miR-26 dans le processus de remodelage structurel lié à la FA. 
En conclusion, nos résultats mettent en évidence l'importance des miARNs dans la 
régulation des canaux ioniques cardiaques. Notamment, miR-26 joue un rôle important 
dans le remodelage électrique et structurel associé à la FA et ce, en régulant IK1 et 
l’expression du canal TRPC3. Notre étude démasque ainsi un mécanisme moléculaire de 
contrôle de la FA innovateur associant des miARNs. miR-26 en particulier représente apres 
ces travaux une nouvelle cible thérapeutique prometteuse pour traiter la FA.  
 
Mots clés : Arythmie, fibrillation auriculaire, microARN, miR-26, IK1 et TRPC3 
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ABSTRACT 
Atrial fibrillation (AF) is the most frequently-encountered arrhythmia in clinical practice 
and constitutes a major cause of cardiac morbidity and mortality. The management of AF 
remains a major challenge as current therapeutic approaches are limited by potential 
adverse effects and high rate of AF recurrence/persistence. A better understanding of the 
mechanisms underlying AF is of great importance to improve AF therapy. AF is 
characterized by impaired electrical and structural remodeling, both of which favors the 
recurrence and maintenance of the arrhythmia. A key feature in electrical remodeling is the 
reduced atrial effective refractory period, due to ion channel alteration. Structural 
remodeling, on the other hand, mainly results from atrial fibrosis. However, the precise 
molecular mechanisms underlying these remodeling processes are still incompletely 
understood. The importance of microRNAs (miRNAs) in various pathophysiological 
conditions of the heart has been well established, but little is known with regard to cardiac 
arrhythmias. Emerging evidence suggests that dysregulation of miRNAs may underlie heart 
rhythm disturbances. The aim of the present work was to acquire a comprehensive 
understanding of miRNA-mediated regulation of ion channels in cardiac arrhythmias. 
Notably, we will focus on the mechanistic insights of miRNAs related to the control of AF.  
Currently available experimental approaches do not permit thorough 
characterization of miRNA targeting. For this purpose, we performed bioinformatic 
analyses in conjunction with experimental approaches to identify miRNAs from the 
database that potentially regulate human cardiac ion channel genes. We found that only a 
subset of miRNAs target cardiac ion channel genes. Based on these results, we further 
demonstrated that the dysregulation of ion channel gene expression observed in various 
cardiac disorders (e.g. cardiomyopathy, myocardial ischemia, and atrial fibrillation) can be 
explained by the dysregulation of miRNAs. These findings further support the potential 
implication of miRNAs in arrhythmogenesis under these cardiac conditions.  
The upregulation of the cardiac inward rectifying potassium current, IK1, is a key 
determinant of adverse atrial electrical remodeling associated with AF. The molecular 
mechanisms underlying this ionic remodeling are poorly understood. We hypothesized that 
altered miRNA expression is responsible for IK1 upregulation in AF. We found that miR-26 
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is significantly downregulated in AF and regulates IK1 by controlling the expression of its 
underlying subunit Kir2.1. Moreover, we demonstrated that miR-26 is under the 
transcriptional repression of the nuclear factor of activated T cells (NFAT) and enhanced 
activities of members of the NFAT family, NFATc3/c4, results in miR-26 downregulation, 
which accounts for IK1 enhancement in AF. Furthermore, we observed that in vivo 
interference of miR-26 affects AF susceptibility via the regulation of IK1, suggesting an 
important role of miR-26 in atrial electrical remodeling. 
Atrial fibrosis is a major constituent in AF-associated adverse atrial structural 
remodeling, involving the activation of fibroblasts and cellular Ca2+ entry. Here, we sought 
to determine whether the Ca2+ permeable channel, TRPC3, plays a role in AF-induced 
fibrosis by promoting fibroblast activation. Furthermore, we investigated the potential role 
of miRNAs in this context. We found that TRPC3 channels promote Ca2+-entry, which 
results in activation of Ca2+-dependent ERK-signaling and consequently fibroblast 
activation. We also demonstrated that TRPC3 is upregulated in AF and in vivo TRPC3 
blockade suppresses the development of AF-promoting substrate. Furthermore, we 
observed that miR-26 regulates TRPC3 channels via controlling the expression of the 
underlying channel subunit and is downregulated in AF-fibroblasts. Finally, we showed 
that the reduced expression of miR-26 is also due to the enhanced NFATc3/c4 activities in 
AF-fibroblasts and accounts for AF-induced upregulation of TRPC3, suggesting the 
potential contribution of miR-26 in AF-related adverse structural remodeling process. 
In conclusion, our findings emphasize the importance of miRNAs in the regulation 
of cardiac ion channels. Notably, miR-26 plays a crucial role in AF-associated electrical 
and structural remodeling via the regulation of IK1 and TRPC3 channel genes. Thus, our 
study unravels a novel molecular control mechanism of AF at the miRNA level, suggesting 
miR-26 as a new and promising therapeutic target for AF. 
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1.1 Overview of Atrial Fibrillation 
Atrial fibrillation (AF) represents the most clinically-encountered sustained cardiac 
arrhythmia and contributes significantly to cardiac morbidity and mortality. AF increases 
the risk of developing congestive heart failure (CHF) and stroke, leading to an increased 
demand on healthcare, and thereby posing a significant socioeconomic burden [1, 2].  
 
1.1.1 Epidemiology of AF 
Approximately 0.5% to 1% of the general population is affected by AF [3, 4]. According to 
a retrospective study in the United States (US), it is estimated that 3.03 million Americans 
were suffering from AF in 2005 and this number will reach 7.56 million by 2050 [5]. 
Several epidemiological studies have suggested that the prevalence and incidence of AF 
increases dramatically in aging population [6-9]. The prevalence of AF increases from 1% 
in people under 60 to 8% in the population aged 80 or older [4]. It is predicted that the 
number of AF patients will likely increase by two or three fold within the next two or three 
decades [10]. The incidence of AF also displays a gender-specific disparity. Based on the 
Framingham Heart Study, the likelihood of developing AF in men is 1.5 fold greater than 
that in women with the corrections for age and other predisposing conditions [6]. However, 
the total number of female AF patients is actually equal to or greater than that of male AF 
patients because women have longer lifespan [11]. The racial discrepancy of AF has also 
been reported in several studies, showing that AF is more prevalent in whites than in blacks 
among the populations either with or without cardiac complications [12-14]. However, the 
reason for this discrepancy is complex and remains unclear [12, 13, 15].  
   
1.1.2 Classification of AF 
The classification of AF was well defined in the 2006 guideline laid out by the joint effort 
of ACC (American College of Cardiology), AHA (America Heart Association) and ESC 
(European Society of Cardiology) [16-18]. According to this guideline, AF is classified 
based on the duration and responses to treatments, which generally falls into three main 
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categories: paroxysmal, persistent and permanent [16-18]. Paroxysmal AF occurs 
periodically and is able to self-terminate within a short period (as short as a few seconds or 
as long as a few hours or days). Persistent AF does not terminate spontaneously but it can 
be ceased upon proper treatments (either pharmacologic or direct-current electrical 
cardioversion). Permanent AF, which is irreversible, shows no response to either 
medication or electrical cardioversion, and hence lasts indefinitely. Permanent AF can arise 
from paroxysmal and persistent AF [19]. Paroxysmal AF is believed to represent the natural 
origin of AF. It can gradually develop into persistent or permanent forms through a process 
termed “atrial remodeling”, in which, the changes in the electrical and structural properties 
of the atria is caused by AF itself and/or the underlying cardiac conditions [19, 20].  In 
addition to the above classification, AF can also be classified by the features of the patients: 
lone AF (AF patients aged under 60 in the absence of underlying cardio-pulmonary 
disease), valvular AF (AF in these patients is caused by structural changes in the mitral 
valve or congenital heart diseases), non-valvular AF (AF patients with no sign of rheumatic 
mitral valve disease, prosthetic heart valve, or mitral valve repair), and secondary AF (AF 
occurs as a secondary event under pre-existing cardiac disorders) [16-18]. 
    
1.1.3 Signs, Symptoms and Predisposing Factors of AF 
1.1.3.1 Signs and Symptoms of AF 
AF patients can be symptomatic or asymptomatic depending on their awareness of the rapid 
and irregular heart rate. Clinical presentations of symptomatic AF patients include 
palpitation (the most common symptom in AF), dizziness, fainting, weakness, fatigue, 
breath shortness, or angina (chest pain caused by lack of blood supply) [16-18]. 
 
1.1.3.2 Predisposing Factors for AF  
Substantial evidence has indicated that age is one of the most important risk factors for AF 
[4-11, 21-23]. Meanwhile, at any given age, gender is also considered as a predisposing 
factor for AF [8, 9, 21-25]. Other important risk factors predisposing to AF include 
hypertension [8, 9, 26-29], coronary artery disease [8, 30-32], congestive heart failure [8, 9, 
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33, 34], valvular heart disease [8, 9, 35, 36], cardiomyopathies [37, 38], myocardial 
infarction [9, 39-41], diabetes mellitus [8, 9, 42, 43], pulmonary disease [8, 44], 
postoperative state [45, 46] and hyperthyroidism [47, 48]. AF-promoting phenomenon as 
seen under the above cardiac conditions is likely due to the accompanied augmentation of 
atrial pressure and/or atrial dilation [49]. Nonetheless, detailed mechanisms remain largely 
unknown and merit further investigations. 
 
1.1.4 Current Management and Challenges in Treatment of AF  
The goals of AF treatment and management are to correct chaotic and irregular atrial 
contraction and to prevent thromboembolism and stroke [16-18]. In clinical practice, two 
main strategies (rhythm control and rate control) are commonly applied to restore normal 
atrial activities [16-18, 50]. Rhythm control aims to restore and maintain sinus rhythm, 
whereas rate control focuses on maintenance of normal ventricular response (or the 
effective heart rate). Furthermore, anticoagulation therapy serves as an important strategy 
to prevent thromboembolism and stroke during AF treatment and is recommended as a 
mandatory procedure for both rhythm and rate control treatments [16-18, 50]. Approaches 
adopted in AF treatment generally fall into two main categories: pharmacological and non-
pharmacological. Pharmacological approaches primarily involve using anti-arrhythmic 
drugs that preferentially control rhythm (Class I and III) or ventricular rate (Class II and 
IV) or, in some cases, control both rhythm and rate depending on the principle actions of 
the drug. Non-pharmacological approaches, on the other hand, refer to interventions with 
attempts to terminate arrhythmia without using pharmacological agents; these include direct 
current cardioversion (electrical cardioversion), catheter ablation, and other surgical 
therapies (maze procedure and left atrial appendage obliteration). In general, 
pharmacological approaches (except amiodarone) are considered as the first-line treatments 
of AF because of their non-invasive properties, whereas most of the non-pharmacological 
approaches involve invasive intervention, and thus are considered as the second-line 
treatment for AF.  
In spite of the availability of various approaches for rhythm and rate control strategies, 
there has been a long debate for clinicians in the choice of intervention. From the 
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theoretical point of view, rhythm control seems to be a better option. This is based on a 
notion that reduced ventricle function manifested during AF is able to be reversed once the 
regular cardiac rhythm is restored, and consequently, the normal heart rate would be 
retained and thromboembolism would be prevented [51]. However, data from several 
comparative studies [52-56] and meta-analysis [57] have suggested that rhythm control is 
suboptimal in terms of mortality due to adverse cardiovascular events [52-56]. In fact, none 
of these studies showed the expected outcomes from rhythm control [52-56]. Instead, in 
Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study, lack 
of anticoagulants appeared to be the strongest risk factor for stroke, with increased incident 
of stroke in patients for whom the oral anticoagulation treatment was discontinued while 
their sinus rhythm was restored [56]. The suboptimal outcome of rhythm control in AF 
treatment is, probably, in part due to the poor tolerability, limited efficacy, and the potential 
pro-arrhythmic effect of presently available anti-arrhythmic drugs. Moreover, re-analysis of 
the cause-specific mortality in AFFIRM study further revealed that several of the anti-
arrhythmic drugs used for rhythm control were also correlated with significant increase in 
mortality due to non-cardiovascular causes [58]. Collectively, it seems that rate control is 
more preferable than rhythm control in AF treatment. Nevertheless, this conclusion might 
be oversimplified, given the fact that the currently available population study is limited and 
that none of these studies shows clear advantages between the two strategies [59]. Taken 
together, it appears that neither of rate-control, rhythm-control, or anticoagulation strategies 
is mutually exclusive of each other. 
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1.2 Mechanisms of AF 
1.2.1 Physiological Basis of Cardiac Action Potential  
 
Figure 1. Schematic representation of atrial (A) and ventricular (B) action potentials with 
underlying principle ionic currents. Inward currents (with downward arrows): INa-sodium 
current; ICaL-L-type calcium current; Outward currents (with upward arrows): Ito-transient 
outward current; IKur-ultra rapidly activating delayed rectifier current; IKr and IKs-rapidly 
and slowly activating delayed rectifier current; IK1-inward rectifier current; Note that IKur is 
presented only in the atria. Numbers in black indicate the different phases of action 
potential. ERP: effective refractory period. (Adapted from Ravens U. et al. [60] with 
modifications). 
The normal electrophysiological behavior of the heart is determined by the orderly 
propagation of electrical impulses resulting in rapid depolarization and slow repolarization, 
thereby generating action potentials in individual cardiac cells. In order to better understand 
AF mechanisms, it is essential to review the basic physiology of the cardiac action potential 
(AP). As the key determinant of the rhythmical contraction of cardiac cells, cardiac AP 
reflects the alterations of transmembrane potentials which are determined by inward 
(depolarizing) and outward (repolarizing) currents (Figure 1). Both atrial (Figure 1A) and 
ventricular (Figure 1B) APs last several hundred milliseconds and consist of five phases: 
Phase 0, Phase 1, Phase 2, Phase 3, and Phase 4. A rapid depolarization occurs during the 
phase 0 of AP, which is the result of a large inward current carried by voltage-gated sodium 
channels (INa) (Figure 1). This rapid depolarization is followed by a phase 1 early 
repolarization, which is primarily due to the inactivation of INa as well as the activation of 
the transient outward potassium current (Ito) and the ultra-rapidly activating delayed 
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rectifier potassium current (IKur) (in atria) (Figure 1A). Repolarization continues in phase 2 
of AP, where inward L-type calcium current (ICaL) counteracts with a gradually-increasing 
outward repolarizing potassium currents that are mainly composed of the rapid delayed 
rectifier potassium current (IKr) (Figure 1A&B). This results in a long lasting repolarization, 
constituting a morphological “plateau” shape in cardiac AP (Figure 1A&B). It is 
noteworthy that the shape of atrial AP (Figure 1A) is normally triangular because of the 
relatively short plateau phase compared with ventricular action potential (Figure 1B). Phase 
3 is the final repolarization step in AP. Both IKr and slow delayed rectifier potassium 
current (IKs) contribute to terminate the repolarization during this phase. Once 
repolarization is complete, cardiac cells return to resting membrane potential during phase 
4 of AP. The maintenance of the resting membrane potential in phase 4 is determined by 
the inward rectifier potassium current (IK1). Collectively, increase in inward currents will 
tend to prolong the action potential duration (APD), whereas increased outward currents 
abbreviate it. It is important to note that cardiac cells are refractory to the initiation of new 
APs during phases 0, 1, 2, and part of phase 3 (Figure 1A&B). This is termed the effective 
refractory period (ERP). During this period, no stimulus regardless of its strength is able to 
initiate a propagated AP until cells return to phase 4. The ERP acts as a protective 
mechanism to keep the heart rate in check and coordinate the cardiac muscle contraction, 
thereby preventing arrhythmia. It is directly correlated with APD. For example, the shorter 
ERP is often associated with shorter APD. 
 
1.2.2 Overview of AF Pathophysiology 
AF is defined as a supraventricular tachyarrhythmia with characteristic chaotic and 
uncoordinated contraction of atrium, which results in a mechanical dysfunction of the atria. 
The first modern notions about the mechanism of AF was introduced in the early twentieth 
century [49]. Over the past century, researches have greatly increased our knowledge in 
understanding of AF mechanisms; it is now believed that focal ectopic activity (or triggered 
activity) and reentry (single-circuit reentry or multiple-circuit reentry) are the underlying 
pathophysiological mechanisms for AF initiation and maintenance [49, 61, 62], as shown in 
Figure 2.  
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Figure 2. Arrhythmogenic mechanisms underlying AF. A. Ectopic focus. B. Single-circuit 
reentry. C. Multiple-circuit reentry. (Adapted from Iwasaki Y. et al. [61]).  
 
1.2.2.1 Ectopic Mechanism 
Up until Haissaguerre et al. [63] discovered that ectopic beats originating in the pulmonary 
veins played a pivotal role in AF initiation, the multiple-circuit reentry remained the sole 
dominant theory for AF mechanism. Abnormal automaticity, delayed afterdepolarization 
(DAD), and early afterdepolarization (EAD) constitute the principle mechanisms 
underlying focal ectopic activity as demonstrated in Figure 3 [62].  
 
Figure 3. Cellular mechanisms underlying focal ectopic activity. A. Abnormal automaticity. 
B. Delayed afterdepolarization. C. Earlier afterdepolarization. Numbers in panel C indicate 
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the different phases of action potential. (Adapted from Wakili R. et al. [62] with 
modifications).    
 
1.2.2.1.1 Abnormal Automaticity 
Normal atrial cells are fired through the sinoatrial (SA) node pacemaking system, and then 
return to negative potential (resting potential, ~ -80mV) until the next firing from SA node 
(Figure 3A, black line). However, when the cell membrane reaches critical potential (or 
threshold potential, ~ -60mV) before the next normal impulse from SA node, an abnormal 
spontaneous depolarization may occur, resulting in abnormal automaticity (Figure 3A, red 
line). It is worth noting that the role of abnormal automaticity as a proarrhythmic 
mechanism during AF remains unclear [62]. 
 
1.2.2.1.2 Delayed Afterdepolarization 
Delayed afterdepolarizations (DADs) occur after the complete repolarization of the 
triggering action potential and account for the most important mechanism underlying focal 
ectopic activity in AF (Figure 3B) [62]. DADs are caused by excessive diastolic Ca2+ 
released from sarcoplasmic reticulum (SR, the main cardiac Ca2+ storage organelle). The 
excessive diastolic Ca2+ are handled by transmembrane Na+/ Ca2+ exchanger (NCX) in an 
electrogenic manner, extruding one Ca2+ ion while pumping 3 Na+ into the cell. This 
creates a net inward current, which can depolarize the cell, resulting in an 
afterdepolarization. Therefore, both increased diastolic Ca2+ and enhanced NCX activity 
may contribute to DADs. The DAD-related AF is associated with congestive heart failure 
[64] and genetic defect [65]. 
 
1.2.2.1.3 Early Afterdepolarization 
Early afterdepolarizations (EADs) occur during phase 2 or 3 of the action potential (Figure 
3C). This type of afterdepolarization is primarily caused by recovering of L-type Ca2+ 
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channels from inactivation during the plateau phase due to the excessively-prolonged APD. 
EAD-related AF has been seen in patients with congenital long-QT syndrome [66]. 
  
1.2.2.2 Re-entrant Mechanisms 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Mechanisms for reentry. A. An unidirectional block occurs when an ectopic 
impulse dies out in a still-refractory region. B. Conditions for maintenance of reentry. C. 
Conditions favoring multiple-circuit reentry. RP: refractory period; CV: conduction 
velocity. Blue-shadow area represents still-refractory region. (Panel C adapted from Nattel 
S et al. [67] with modifications).      
Reentry is conventionally initiated by a premature ectopic beat (Figure 4A). This ectopic 
beat fails to conduct through a still-refractory region in one direction (“unidirectional 
block”) (Figure 4A), while conducting in the other direction through a region that is no 
longer refractory (Figure 4A). However, if enough time has elapsed for the recovery of 
excitability in the refractory region, the impulse can re-enter this region, resulting in reentry 
(Figure 4B). Accordingly, shorter refractory period (allowing faster recovery of 
excitability) and/or slower conduction velocity (gaining more time for the non-refractory 
region to regain excitability) may favor the maintenance of reentry (Figure 4B). Reentry 
can sustain either as a single circuit form (Figure 1B) or a multiple-circuit form (Figure 
1C). For single circuit reentry, the irregular activity is maintained by rapid regular firing 
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(Figure 1B), whereas for multiple-circuit reentry, the irregularity is determined by the co-
existence of multiple dyssynchronous reentry circuits (Figure 1C). There are two leading 
theoretical models that conceptualize the mechanism of reentry: leading circuit [68] and 
spiral wave [69]. While both models predict the presence of vulnerable substrates as the 
key determinant in reentry sustainability, the leading circle theory fails to explain the 
clinical observation that blocking of Na+ channel effectively terminates AF [70]. 
Nevertheless, leading circle theory still remains the widely-accepted notion to explain 
reentry mechanism. An important concept of leading circle theory is the “wavelength of 
reentry” [49, 68]. The wavelength (WL) of a reentry circuit refers to the shortest pathlength 
by which a reentry can be established. It is given as the distance that an electrical impulse 
travels in one refractory period and is critically determined by refractory period (RP) and 
conduction velocity (CV), as shown in the equation: WL=RP × CV [70, 71]. Accordingly, a 
shorter wavelength (as the result of abbreviated RP and/or reduced CV) may allow more 
available reentry circuits to be accommodated in a given atria, favoring multiple-circuit 
reentry that sustains AF (Figure 4C). 
  
1.2.2.3 Relation of basic AF mechanisms to different forms of clinically-encountered 
AFs 
The natural course of AF is believed to begin as the paroxysmal form, which is triggered by 
the ectopic foci originated from pulmonary vein sleeves [63].With time, AF tends to 
become persistent if ectopic firing is sustained or reversible reentry substrates are 
developed [62]. If the reentry substrates further become irreversible or fixed, AF becomes 
permanent [62]. 
 
1.3 Atrial Remodeling in AF 
The introduction of the concept “atrial remodeling” over the past two decades has greatly 
advanced our understanding of AF mechanisms. Atrial remodeling refers to the process by 
which AF, once initiated, alters atrial electrophysiological (in a short term) and/or structural 
(over a long term) properties in ways that sustain itself [72].  
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1.3.1 Electrical Remodeling in AF 
AF-induced electrical remodeling, which results in trigger activity and functional reentry 
substrates by altering ion channel/transporter expression and/or function, occurs normally 
within a short time after AF initiation [73]. Both focal ectopic activity and functional 
reentry are primarily caused by increased Ca2+ loading due to the very rapid atrial rate 
(tachycardia) during AF [73]. Therefore, more recently, AF-induced electrical remodeling 
has been termed as atrial tachycardia remodeling (ATR) [67]. Evidence from animal 
models and clinical studies has highlighted the importance of ATR in pathogenesis of AF 
and in the transition from paroxysmal AF to persistent AF [72, 74-81]. A prominent finding 
in ATR is the abbreviation of refractoriness as the result of APD shortening. Consistently, a 
shorter atrial APD is found in AF patients compared to patients with sinus rhythm [78-81]. 
Similar observations have also been seen in animal models of AF [72, 74-76].  
The ionic mechanisms underlying APD shortening primarily involve downregulation 
and/or inactivation of L-type calcium current (ICaL) and enhancement of inward rectifier 
potassium currents (IK1 and/or IKACh). The functional implication of the deregulation of 
other ion channels in APD shortening remains obscure. Details regarding the 
pathophysiological significance of these changes will be described below. 
 
1.3.1.1 Upregulation of IK1 
One of the most important electrophysiological changes in AF-related ATR is the 
upregulation of inward-rectifier potassium channel, particularly, IK1. Increased IK1 has been 
consistently observed in isolated atrial cardiomyocytes from AF patients [82-89] and 
experimental AF animal models [90-92]. Interestingly, the functional change of IK1 in AF is 
in parallel with increased expression of its underlying subunits Kir2.1 at both mRNA and 
protein levels [83, 85]. The pathophysiological significance of IK1 upregulation in AF is 
believed to enhance AF sustainability by substantiating reentrant substrates [20, 73]. This is 
likely attributable to the crucial roles of IK1 in maintenance of resting potential and 
termination of action potential [67, 73]. Increased IK1 hyperpolarizes the atrial cells, which, 
on one hand, inhibits the abnormal automaticity, whereas on the other hand, shortens APD 
and ERP, thereby favoring the reentrant substrates for AF [67, 73, 93, 94]. Recently, 
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genetic evidence from familial AF as the result of a Kir2.1 gain-of-function mutation 
further indicates the pivotal role of IK1 upregulation in AF pathogenesis [95]. Nevertheless, 
the underlying molecular mechanism responsible for enhanced IK1 in AF is largely 
unknown. Interestingly, a new class of recently-discovered small non-coding RNA, namely 
microRNAs (miRNAs), has been suggested to be responsible for the upregulation of IK1 in 
AF [96]. 
   
1.3.1.2 Downregulation of ICaL 
Another key finding in AF-related ATR is the downregulation of ICaL. ICaL has been 
consistently found to be downregulated in both clinical and experimental AF paradigms [76, 
82, 87, 97-100], accompanied by corresponding decreases of its α-subunit Cav1.2 at mRNA 
level [101-107]. However, discrepant changes for Cav1.2 protein have been reported [99, 
101, 103, 104, 107, 108], implying the complicated underlying mechanisms as well as 
uncontrollable variables in clinical studies [67]. The observed ICaL reduction in AF is 
believed to be an adaptive response of atrial cardiomyocytes to calcium overload as a 
consequence of rapid atrial rate during AF [49]. This adaptive response, in a short term, 
tends to reduce channels activity, but over a longer term, tends to decrease the expression 
of the channels at the gene level [49]. As a result, reduced ICaL decreases APD and 
wavelength, creating reentry substrate for AF perpetuation [49]. Although the molecular 
mechanism underlying ATR-induced ICaL downregulation has been extensively investigated 
by many research groups, it is still not completely understood. While some studies 
indicated that the transcriptional downregulation of Cav1.2 α-subunit is likely due to the 
activation of Ca2+/calmodulin/calcineurin/NFAT signaling pathway caused by Ca2+ 
overload [107, 109], others suggested the possible involvements of the downregulation of 
accessory β1-, β2a-, β2b-, β3- and α2δ2-subunits, impairment of Cav1.2 protein trafficking, 
and dephosphorylation of the channels due to enhanced PP1 and PP2A activities [85, 99, 
102, 110-112]. Furthermore, a recent study demonstrated that miRNAs may potentially 
contribute to the downregulation of ICaL in AF through a post-transcriptional regulatory 
mechanism [113]. Taken together, the underlying molecular mechanism for AF-induced 
ICaL downregulation appears to be a very complex process, involving both transcriptional 
and post-transcriptional regulations. 
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1.3.1.3 Abnormal Ca2+ Handling 
In addition to the reduction of ICaL, AF-induced electrical remodeling also causes abnormal 
intracellular Ca2+ handling, which primarily promotes spontaneous diastolic SR Ca2+ 
release that enhances NCX-mediated Ca2+ extrusion. The NCX-mediated Ca2+ extrusion is 
an electrogenic process, which produces a net inward (depolarizing) current, causing DADs 
[62, 73].  Several studies have suggested that the spontaneous diastolic SR Ca2+ release is 
attributed to the dysfunction of ryanodine receptor 2 (RyR2, cardiac Ca2+ release channel 
on SR) [114-117], which is likely due to hyperphosphorylation caused either by increased 
activities of protein kinase A (PKA) and Ca2+/calmodulin-dependent kinase II (CaMKII) 
[115-118] or by decreased activities of phosphatases [119]. Additionally, abnormal RyR2 
release can also be a result of excess SR Ca2+ loading due to abnormal enhancement of SR 
Ca2+ uptake mediated through SR Ca2+ ATPase (SERCA, Ca2+ uptake pump on SR), which 
is activated by hyperphophorylated phospholamban [119]. 
  
1.3.1.4 Alterations of other K+ currents 
IKACh, another important inward rectifier potassium current, is activated upon the 
stimulation of acetylcholine released from vagal nerve and is responsible for cardiac vagal 
effects. Activation of the channels hyperpolarizes the cell membrane and shortens APD, 
contributing to AF pathogenesis. Several studies have shown that the agonist-dependent 
IKACh is reduced, whereas constitutively-active IKACh (agonist-independent) is significantly 
enhanced during AF-induced ATR [83, 91, 120, 121]. However, mRNA and protein levels 
of its underlying subunit Kir3.1 and Kir3.4 are found unaltered in experimental AF animal 
models [120, 121] but decreased in AF patients [122]. The enhanced constitutively-active 
IKACh is attributable to increased single channel open probability, which is controlled by the 
balance between different protein kinase C (PKC) isoforms [123, 124]. 
     Consistent reduction of Ito along with the mRNA and protein of its underlying α-subunit 
Kv4.3 is found in both AF patients and experimental AF animal models [76, 86, 101, 104]. 
However, the functional implication of Ito reduction in AF remains to be unclear [67, 73]. 
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     Inconsistent changes of IKur have been reported in both experimental AF animal models 
and AF patients [67], indicating the lack of pathological relevance of this channel in AF. 
However, given the atrial specific property of IKur, it still remains as a very attractive 
therapeutic target for the treatment of AF [49]. 
     No changes of delayed rectifier currents IKs and IKr were observed in a canine model of 
AF [76] and there is lack of information regarding the changes of these currents in humans 
due to the technical difficulty in acquiring human samples and cell isolation [125]. 
  
1.3.2 Structural Remodeling in AF 
Atrial structural remodeling (ASR) is another major aspect of atrial remodeling in AF. It is 
a relatively slower remodeling process compared to electrical remodeling, primarily 
comprising morphological changes to atrial myocardial structure and atrial architecture [20, 
126]. ASR has been observed in AF from both clinical settings and experimental models, 
and significantly contributes to form the reentry substrates for AF. Consequences of ASR 
include increased atrial fibrosis, altered connexin expression, myocyte hypertrophy, 
myocyte apoptosis, and atrial dilation, among which, the first three aspects have been 
extensively studied. 
 
1.3.2.1 Atrial Fibrosis 
Atrial fibrosis, although not exclusively related to AF but appears as a common feature of 
clinical AF. It is one of the most important arrhythmogenic contributors to AF [73]. Atrial 
fibrosis has been commonly observed in lone AF [127, 128] and AF-associated 
pathophysiological conditions, including congestive heart failure (CHF) [129, 130], 
valvular diseases [131], rheumatic heart disease [132, 133], dilated and hypertrophic 
cardiomyopathy [134, 135], and senescence [136, 137]. Moreover, a reduced AF stability 
and delayed atrial structural remodeling process have been observed in some experimental 
and clinical studies using compounds with known anti-fibrotic effect, such as statins 
(HMG-CoA reductase inhibitors) [138, 139], angiotensin II type 1 receptor (AT1R) blocker 
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[140], and fish oil [141]. However, the observed beneficial outcome of these compounds 
may be a result of the improvements in hemodynamic [73]. Together, these findings 
suggest an important association between atrial fibrosis and AF but fail to establish a causal 
significance of atrial fibrosis in AF occurrence and perpetuation. It is also important to note 
that AF may itself promote atrial fibrosis, which in turn sustains AF [142, 143]. Evidence 
supporting this notion came from the observations that the quantity of fibrosis positively 
correlates with the persistence of AF in patients [144], and that atrial tachypacing alone 
causes atrial fibrosis in a canine ATP model with well-controlled ventricular rate [145]. 
     Cardiac fibrosis is either a reparative or reactive process, which primarily involves 
excessive accumulation of extracellular matrix (ECM) proteins secreted by myofibroblasts 
(cells derived from fibroblasts in the presence of various stimuli) [142, 143]. Reparative 
fibrosis maintains tissue structural integrity by replacing dead cardiomyocytes, whereas 
reactive fibrosis occurs in response to various cardiac insults and causes interstitial 
expansion, separating muscle bundles [142, 143]. The resultant fibrotic tissue creates an 
obstacle to interfere with normal impulse propagation and thus causes conduction 
abnormalities [129]. In addition, recent studies have suggested that cardiac fibroblasts can 
electrically influence adjacent cardiomyocytes and thus alter cardiac electrical function 
[143]. Taken together, the fibrotic remodeling manifested during AF may cause conduction 
abnormalities and increase fibroblast-cardiomyocyte electrical interaction, favoring AF 
occurrence and maintenance. 
  
1.3.2.1.1 Profibrotic Factors and Atrial Fibrosis 
The precise molecular mechanisms underlying ECM formation during atrial fibrosis remain 
incompletely understood. Emerging evidence has suggested that several cardiomyocyte 
and/or fibroblast secreted factors with known profibrotic effects are critically involved 
[142]. Among these factors, angiotensin II (AngII) and its downstream mediator 
transforming growth factor β1 (TGF-β1) have been well characterized to contribute to 
fibroblast differentiation and proliferation, whereas platelet-derived growth factor (PDGF) 
and connective tissue growth factor (CTGF) have just emerged as potential fibrosis 
mediators [20, 142].  
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     It has been shown that increased production of AngII as a consequence of cardiac-
specific overexpression of angiotensin converting enzyme (ACE) may cause severe atrial 
dilation accompanied by atrial fibrosis and AF in mice [146]. AngII promotes cardiac 
fibrosis via signaling cascades coupled to AT1R and AT2R, which have distinct and 
sometimes opposite effects (eg. AT1R facilitates fibrosis while AT2R counteracts the effect 
of AT1R); the net outcome of these opposite effects is an activation of mitogen-activated 
protein kinase (MAPK) that is considered as an important mediator for fibrotic remodeling 
[142, 147]. In addition, stimulation of AT1R can also activate protein kinase C (PKC) and 
increase intracellular Ca2+ release, together contributing to AngII-mediated fibrotic 
remodeling [147]. 
     TGF-β1 has been suggested to play a central role in signaling cascades involved in 
cardiac fibrosis [142, 148]. TGF-β1 is a primary downstream mediator upon AngII 
stimulation and is secreted by both fibroblasts and cardiomyocytes [149]. Cardiac-specific 
overexpression of constitutively-active TGF-β1 in mice causes atrial fibrosis and atrial 
conduction heterogeneity and increases AF vulnerability [150]. TGF-β1 primarily acts 
through the SMAD signaling pathway, stimulating fibroblast activation and collagen 
production [151]. 
     More recently, a study showing the presence of cardiac fibrosis in mice with cardiac-
specific PDGF overexpression has indicated the potentially-important role of PDGF in the 
genesis of cardiac fibrosis [152, 153]; however, the link between PDGF and fibrosis-related 
AF susceptibility was missing, given that AF vulnerability was not assessed in these 
animals [142, 152]. CTGF is also found to be an important mediator in cardiac fibroblast 
activation upon AngII stimulation [154]. Moreover, pathway analysis in a genomic study of 
CHF-related AF substrate has suggested a possible involvement of CTGF in this process 
[155]. 
   
1.3.2.1.2 Potential role of TRP Channels in Atrial Fibrosis 
There is a growing body of evidence suggesting that fibrotic susceptibility is more 
profound in atria than in ventricle [129, 146, 150, 156, 157]. Atrial fibroblasts show greater 
proliferative response and faster myofibroblast differentiation upon growth stimuli, as 
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compared to ventricular fibroblasts [149]. Fibroblast proliferation and differentiation into 
myofibroblasts are the characteristics of fibrogenesis and numerous studies have suggested 
that Ca2+ entry is essential for fibroblast proliferation and fibroblast function [158-162]. 
Interestingly, however, the absence of voltage-gated Ca2+ channels in cardiac fibroblasts 
suggests the existence of other Ca2+-permeable ion channels that are responsible for Ca2+ 
entry in these cells [163]. The presence of transient receptor potential (TRP) channels in 
cardiac fibroblasts has shed light on this matter. TRP channels are well-known to be 
responsible for Ca2+ entry in a variety of cell types and are activated upon mechanical 
stretch, oxidative stress, and metabolic disturbance, conditions commonly observed in AF 
[164-166]. Hence, it is very likely that TRP channels may participate in atrial fibrogenesis 
in AF, particularly via stimulation of fibroblast proliferation and differentiation.  To date, 
28 mammalian TRP channel genes have been identified [164]. Based on sequence 
homology, they are categorized into six subfamilies: TRPC subfamily (canonical, TRPC1-
7), TRPM subfamily (melastatin, TRPM1-8), TRPV subfamily (vanilloid, TRPV1-6), 
TRPA subfamily (ankyrin, TRPA1), TRPP subfamily (polycystin, TRPP1-3), and TRPML 
subfamily (mucolipin, TRPML1-3). However, only subsets of these families are detectable 
in cardiac fibroblasts. For instance, TRPC1-3, TRPC5-7, TRPM7 and TRPV4 are 
expressed in rat and human cardiac fibroblast as measured by RT-PCR [167, 168]. Of note, 
a recent study has highlighted the potentially important role of TRP channels in AF 
fibrogenesis [168]. This study showed that atrial fibroblasts from AF patients are more 
prone to myofibroblast differentiation with concomitant increases of TRPM7 expression 
and Ca2+ influx. Moreover, in vitro knockdown of TRPM7 largely attenuates AF fibroblast 
differentiation, suggesting an essential role of TRPM7 in AF fibrogenesis [168]. 
  
1.3.2.2 Dysregulation of Gap junction protein 
The conduction abnormality in AF can also result from altered and/or heterogeneous 
expression of the gap junction proteins, namely connexins, which are responsible for cell-
to-cell conduction [67, 73]. Connexin40 (Cx40) and connexin43 (Cx43) are two main 
subunits in atria, whereas, in ventricular tissue, Cx43 appears to be the sole underlying 
subunit [169, 170]. Several studies have reported inconsistent changes of Cx40 and Cx43 in 
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AF, as some found increased while others found unaltered or decreased expression [67, 73]. 
Nevertheless, heterogeneous expression of Cx40 and Cx43 has been consistently 
documented in both experimental and clinical AF [171-174]. The increased connexin 
heterogeneity may contribute to abnormal conduction, thereby favoring reentry substrates 
for AF. 
 
1.4 Inward Rectifier Potassium Channel (IK1)  
1.4.1 Biophysical Properties and Cellular Functions of IK1 
IK1 is the main component of inward rectifier basal currents in human atrial myocytes [175, 
176]. It plays two key roles in cardiac electrophysiology: 1) to maintain the cellular resting 
membrane potential; and 2) to terminate repolarization of cardiac AP [93, 177]. These are 
largely due to its “inwardly rectifying” property, which allows the channels selectively 
support the flow of positively-charged K+ into the cells (inward current), when membrane 
potential is negative to potassium equilibrium potential (or reversal potential)  [93, 177]. A 
simpler way to understand this is that the channels pass inward current more easily than 
outward current. Because the inward rectification of IK1 is strong, this allows the channels 
to carry substantial inward current at negative potentials (even more negative than the K+ 
reversal potential), thereby stabilizing the membrane resting potential [177, 178]. On the 
other hand, when cell membrane depolarizes or is positive to K+ reversal potential, the large 
conductance for inward current is progressively shut down as a result of “rectification”, 
eliciting a relatively small but significant outward current, which helps to terminate the 
cardiac AP [177, 178]. The phenomenon of inward rectification of IK1 is the result of the 
block of the channel pore by intracellular Mg2+ and polyamines at positive potentials, 
resulting in a decrease of outward current [179, 180]. IK1 is constitutively active and 
extracellular Ba2+ and Cs+ selectively block the channels in a voltage-dependent manner. 
This selective blockade by Ba2+ and Cs+ is often used to distinguish IK1 from other currents 
in voltage clamp experiments [181]. 
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1.4.2 Molecular Basis of IK1 
Substantial evidence has indicated that native cardiac IK1 is carried by channels that appear 
as heterotetramers consisting of Kir2 subunits (Kir2.1, Kir2.2, and Kir2.3) [182, 183]. Each 
of these subunits consists of two transmembrane domains (TM1 and TM2) [184]. As 
defined by human genome organization, genes encoding Kir2 subunits are given name 
KCNJ, i.e., KCNJ2 (encoding Kir2.1), KCNJ12 (encoding Kir2.2), and KCNJ4 (encoding 
Kir2.3) [185]. In human, Kir2.1 is the most abundantly-expressed subunit underlying IK1 
[186, 187]. The predominant role of Kir2.1 as the main molecular identity underlying IK1 
was elucidated by using Kir2.1 and Kir2.2 knockout mice [188, 189]. No detectable IK1 was 
recorded in the isolated cardiomyocytes from Kir2.1 knockout mice, whereas, ~ 50% 
reduction of IK1 was observed in the myocytes from Kir2.2 knockout littermates, suggesting 
a crucial role of Kir2.1 in genesis of IK1 and functional IK1 channels are likely heteromeric 
[188, 189]. Indeed, this is supported by subsequent biochemical studies, confirming the co-
assembly of different Kir2 subunits in cardiomyocytes [190, 191]. 
 
1.4.3 Regulation of IK1 
In addition to the direct regulation of the channel pore by intracellular Mg2+ and 
polyamines, native IK1 can also be regulated by many other factors including 
phosphatidylinosital-4, 5-bisphosphate (PIP2), adrenergic stimulation, protein kinases 
(PKA and PKC), and pH [192]. While circumstantial evidence has suggested that IK1 can be 
activated by PIP2 through its direct interaction with a group of positively charged residues 
located in the transmembrane domain 2 (TM2) region of Kir2.1 [193-195], other studies 
have suggested that residues harbored in cytoplasmic NH2 and COOH termini also 
contribute to PIP2 activation of Kir2.1 [196]. Adrenergic stimulation is also reported to 
regulate the native IK1 [197, 198]. In isolated human cardiomyocytes, stimulations of both 
α1- and β-adrenergic receptors strongly inhibite native IK1 [197, 198]. This inhibitory effect 
upon stimulation of α1- adrenergic receptors is attributable to PKC activation [197], 
whereas β-adrenergic inhibition of the channel primarily is mediated by a PKA-dependent 
pathway [198]. Furthermore, modulation of IK1 can be achieved via phosphorylation of the 
channel subunits by protein kinases such as PKA and PKC [192]. PKC activators were 
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shown to repress IK1 associated with Kir2.2 and Kir2.3 but not that with Kir2.1 [123, 199]. 
Activation of PKA, however, increases currents carried by Kir2.1 or Kir2.2 [200, 201]. The 
native IK1 is also affected by intracellular pH. Decreased intracellular pH was shown to 
cause significant reduction of IK1 [202]; this is likely due to the abolishment of channel-
PIP2 interaction [203]. Interestingly, a recent study has clearly demonstrated an 
involvement of microRNA in the regulation of IK1. In this study, the authors showed that 
microRNA-1 (a type of cardiac-enriched muscle-specific non-coding small RNA) is able to 
repress native IK1 current through a post-transcriptional repression of the channel subunit 
Kir2.1, suggesting a potentially-important novel regulatory mechanism for IK1 [204]. 
 
1.4.4 Dysregulation of IK1 and its pathophysiological implication in AF 
 
Figure 5. Schematic representation of pathophysiological significance of IK1 upregulation in 
AF. APD: action potential duration; ERP: effective refractory period; WL: wavelength; AF: 
atrial fibrillation. 
A schematic illustration of the pathophysiological significance of IK1 upregulation in AF is 
shown in Figure 5. As discussed in Section 3.1.1, upregulated IK1 has been consistently 
observed during AF [82-89], and this upregulation was accompanied with the increased 
expression of its underlying subunit Kir2.1 at both mRNA and protein levels [83, 85]. 
Given the crucial role of IK1 in setting the cellular membrane resting potential and 
terminating cardiac AP, the upregulation of IK1 in AF, may have two pathophysiological 
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consequences: 1) the increased IK1 may favor the maintenance of cellular membrane resting 
potential, thereby preventing the abnormal automaticity (Figure 5); 2) the enhanced IK1 may 
contribute to the shortening of APD and ERP, favoring the maintenance of reentrant 
substrates for AF (Figure 5). However, little is known about the molecular mechanism 
underlying AF-induced upregulation of IK1. Recently, a study provided a novel insight into 
this matter. In this study, the authors evaluated the correlation between the changes of miR-
1 and the alterations of IK1 as well as Kir2.1 expression in the left atrium of the valvular 
heart disease patients with persistent AF [96]. IK1 was found to be significantly upregulated 
with a corresponding increase in Kir2.1 protein expression in the atrial samples from these 
AF patients [96]. Conversely, miR-1 levels were found to be significantly reduced [96]. 
The authors proposed that AF-induced upregulation of IK1 and its underlying subunit 
(Kir2.1) expression is likely attributable to the reduction of miR-1 [96], because miR-1 was 
previously reported to post-transcriptionally repress KCNJ2 (gene encoding Kir2.1) [204]. 
The findings of this study are valuable in the sense that they suggest a potentially-important 
novel regulatory mechanism for AF-induced IK1 upregulation. However, the evidence 
provided in this study to support the role of miR-1 downregulation in AF-induced IK1 
upregulation is only suggestive. Further studies are required to establish a direct role of 
miR-1 in AF. Moreover, it is important to determine whether there are other miRNAs 
involved in this AF-induced ionic remodeling process. 
    
1.5 Transient Receptor Potential Canonical Channel Type 3 
(TRPC3) 
TRPC3 belongs to a group of TRPC channels, a classical or canonical subclass in TRP 
channels superfamily. The human TRPC family consists of six isoforms (TRPC1, 3-7), 
which can be grouped into two subfamilies: TRPC1/4/5 and TRPC3/6/7, based on sequence 
homology and functional similarities [205-207]. For example, TRPC3 shares ~75% 
sequence identity with TRPC6 and TRPC7 [208]. 
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1.5.1 Biophysical Properties and Cellular Functions of TRPC3 
Owing to the high degree of similarities among all TRPC isoforms and the lack of specific 
pharmacological blockers, it is technically difficult to record the currents carried by TRPC3 
channels in a native environment; thus, the biophysical properties of TRPC3 channels are 
mainly characterized in either homologous or heterologous expression systems [205, 209, 
210]. TRPC3 as well as its homologues TRPC6 and TRPC7 typically assemble as homo- or 
heterotetramer to form functional channels permeable to cations (Ca2+ and Na+) [205, 209, 
210]. The resultant currents show voltage independence and dual rectifications in both 
inward and outward directions [208, 211]. Moreover, TRPC3 channels are constitutively 
active and are effectively blocked by La3+ and Gd3+ ions, which also block the other TRPC 
channels. Interestingly, a recent study found a pyrazole compound (Pyr3) to be a selective 
blocker for TRPC3 channels [212]. This compound may serve as a powerful tool for the in 
vivo functional study of TRPC3 channels [212]. 
     TRPC3 channels broadly exist in a variety of cell types including excitable and non-
excitable cells and are predominantly located on the plasma membrane [205, 206, 209]. 
Their primary cellular function is thought to be non-voltage-gated Ca2+ entry [205-207, 
213]. There are two types of Ca2+ entry mechanisms: store-operated Ca2+ entry (SOCE) and 
receptor-operated Ca2+ entry (ROCE). However, the participation of TRPC channels in 
these mechanisms is controversial [205-207, 213]. 
   
1.5.2 Molecular Basis of TRPC3 
Functional TRPC3 channels are comprised of four TRPC subunits [209]; however, it is 
unclear whether the native TRPC3 channels exist as homotetramers or heterotetramers 
[209]. Typical structure of TRPC3 subunit includes six transmembrane domains (TM1-
TM6), a putative pore region constituted by TM5 and TM6 together with their connecting 
loop, and intracellular N and C termini that are functionally important for channel 
trafficking, anchoring, localization, and gating [214, 215]. Of note, the lack of voltage 
sensing in TM4 makes the channels non voltage-dependent [206, 209, 215]. The TRPC3 
gene was originally cloned from human embryonic kidney cell line (HEK293) and consists 
of 11 exons that locate on chromosome 4 in the human genome [215]. The regional 
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expression profile of TRPC3 in the heart is incompletely known, although evidence has 
indicated its broad expression in a variety of cardiac cells such as cardiac endothelial cells, 
cardiac smooth muscle cells, and cardiomyocytes [206, 216]. 
 
1.5.3 Regulation of TRPC3 
The activity of TRPC3 channels can be regulated by mechanical stretch and various ligands 
and plasma membrane receptors [206, 209]. Substantial evidence suggests that mechanical 
stress may enhance TRPC3 channel activation and/or expression [217, 218]. It has been 
shown that TRPC3 channels are constitutively active and this basal activity of TRPC3 
channel is attributable to the glycosylation status, which is increased upon stimulation of G 
protein-coupled receptor (GPCR) or receptor tyrosine kinase [211, 219-221]. Consequently, 
ligands such as AngII and ET-1, which can stimulate GPCR, were found to increase 
TRPC3 channel activity [222, 223]. Increased phospholipase C (PLC) activity as a result of 
activated GPCR-dependent signaling also enhances TRPC3 channel activity [224, 225]. 
This is primarily due to a direct activation of TRPC3 channels by diacylglycerol (DAG), a 
lipid mediator that is generated by the GPCR-PLC signaling pathway [224-226]. In 
addition to GPCR, several other studies have suggested that activation of inositol 1,4,5-
trisphosphate (IP3) receptor may indirectly activate TRPC3 channels through a 
displacement of inhibitory calmodulin from a common binding domain on the channel 
[227, 228]. Despite the regulation by plasma membrane receptors, TRPC3 channel activity 
as well as its expression can also be regulated by a redox-dependent alteration in membrane 
lipids, more specially, cholesterol [229-232]. Mechanistically, the agonist effect of 
cholesterol on TRPC3 channels is attributable to the association between TRPC3 and 
scaffolding protein, caveolin-1 [233]. Additionally, an interaction between immunophilin 
and TRPC3 protein has been suggested to be essential for channel activation, as there is a 
direct binding domain for immunophilin in the C-terminal proline-rich region of TRPC3 
protein [234]. Finally, protein kinases have also been suggested to regulate TRPC3 channel 
activity [235, 236]. Indeed, PKC was found to negatively regulate TRPC3 through direct 
phosphorylation of serine at position 712 [236], whereas enhanced PKA activity was able 
to increase TRPC3 expression [235].  
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1.5.4 Dysregulation of TRPC3 and its potential pathophysiological 
implication in AF 
As discussed in Section 3.2.1.2, TRP channels may likely contribute to Ca2+-mediated atrial 
fibrogenesis in AF. Indeed, a recent study has highlighted an important role of TRPM7 
channels in AF-associated fibrotic remodeling [168]. However, it is important to determine 
whether other TRP channels also participate in this remodeling process, given that several 
TRP channels including TRPM7 are abundantly expressed in cardiac fibroblasts and many 
of them are functionally and structurally similar [164, 168]. Interestingly, it has been shown 
in a recent study that, unlike other TRP members, TRPC3 is mainly enriched in freshly-
isolated atrial fibroblasts and this enrichment diminishes upon fibroblast differentiation to 
myofibroblasts [237]. These findings suggest a potentially-important role of TRPC3 in 
mediating fibroblast function, which contributes importantly to fibrogenesis. In this regard, 
any deregulation of TRPC3 occurring during AF may potentially contribute to the AF-
associated atrial fibrosis. Further studies are required to determine the changes of TRPC3 in 
AF as well as the underlying mechanisms responsible for this deregulation.  
 
1.6 MicroRNA Biology 
1.6.1 Historical View of MicroRNAs 
MicroRNAs (miRNAs) belong to a new class of non-coding RNAs. The discovery of the 
first microRNA (miRNA), lin-4 occurred almost twenty years ago [238, 239]. However, 
this discovery was initially considered an anomaly. These small non-coding RNAs were not 
brought into attention until the identification of a second miRNA, let-7, which was found to 
be crucially involved in the development of Caenorhabditis elegans (C elegans) [240]. 
Subsequent studies soon revealed that let-7, as well as many other newly-identified 
miRNAs, broadly exist in various vertebrate species including humans, suggesting that 
these miRNAs are not only evolutionarily conserved but also ubiquitously expressed across 
different species [241-244]. Since then, miRNAs have increasingly attracted interest, 
leading to the discovery of many more mammalian miRNAs. A pioneer study showing the 
correlation between miRNAs and human disease appeared in 2002 [245]. 3 years later, in 
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2005, the first cardiac miRNA study was conducted, revealing that miRNA is essential 
during cardiogenesis [246]. During the past 6 years, the roles of miRNAs have been 
increasingly appreciated in the cardiovascular system by researchers, as these tiny 
molecules appear to be essential in controlling a wide range of biological processes. Recent 
studies in the field have clearly demonstrated that aberrant expression of miRNA is tightly 
correlated with the onset and progression of cardiovascular diseases [247, 248]; and in 
some cases, correcting an aberrantly-expressed miRNA is able to prevent or attenuate the 
progression of certain cardiac diseases [247, 248]. Together, these findings have greatly 
advanced our current understanding of the potential pathophysiological implications of 
miRNAs in various cardiac conditions [247, 248]. Hence, miRNAs may potentially serve as 
new diagnostic tools and therapeutic targets for cardiovascular diseases. 
  
1.6.2 MiRNA Biogenesis 
MiRNA biogenesis is a multi-step process that requires synergistic participation of a variety 
of enzymes and regulatory proteins [249, 250]. Similar to protein-coding genes, the primary 
transcripts of miRNAs, namely pri-miRNAs, are initially transcribed from genomic 
sequences by RNA polymerase II in the nucleus [251, 252], as shown in Figure 6. Of note, 
depending on the locations of original miRNA-coding genes, miRNAs can be classified 
into three different categories: intergenic miRNAs (miRNA coding genes not belonging to 
any annotated transcripts), intronic miRNAs (miRNA coding genes falling within an intron 
of a host protein coding gene), and exonic miRNAs (miRNA coding genes overlapping 
with an exon of a known protein coding gene)  [247, 253] (Figure 6). For intronic and 
exonic miRNAs, an extra step of trimming by spliceosome is required to release the pri-
miRNAs from their host gene transcripts [253] (Figure 6). In addition, pri-miRNAs can 
give rise to either a single or multiple miRNAs, so-called “polycistronic miRNAs”, a 
cluster of miRNAs with similar sequences [247, 253]. Unlike protein-coding genes, the 
primary transcripts of miRNAs (or pri-miRNAs), with length ranging from hundreds to 
thousands of nucleotides (nt), subsequently fold into imperfectly base-paired stem-loop 
structures that are further excised by RNase III endonuclease Drosha and the double-
stranded RNA binding protein DGCR8, resulting in ~70- to 100-nt hairpin-shaped 
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precursor miRNA (pre-miRNA) [254-256] (Figure 6). It is noteworthy that the processing 
of intronic miRNAs from their pri-miRNAs to pre-miRNAs escapes the Drosha pathway, 
but uses an alternative splicing-mediated mechanism and the resultant hairpin pre-miRNAs 
are named “mirtron” [257, 258] (Figure 6). Through incorporating with the nuclear export 
factor exportin 5 [259-261], the pre-miRNAs are then translocated from the nucleus to the 
cytoplasm, where they are further cleaved by another RNase III endonuclease Dicer to 
generate ~19- to 25-nt  mature miRNA duplex [252, 262] (Figure 6). 
 
Figure 6. Biogenesis and actions of miRNA. TF: transcription factor; Pri-miRNA: primary 
transcript of miRNA; Pre-miRNA: precursor miRNA; RISC: RNA-induced silencing 
complex; ORF: open reading frame. Adapted from Wang Z et al. [263] with modification. 
 
1.6.3 Action and Biological Functions of MiRNAs 
1.6.3.1 Action of MiRNAs 
The primary action of miRNAs is to repress the translation output from the target mRNAs 
[252]. As the first step leading to this action, the mature miRNA duplex is incorporated into 
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the protein complex known as RNA-induced silencing complex (RISC) [264, 265] (In 
Figure 6). Only one strand of the mature miRNA (guide strand) remains in RISC, whereas 
the other strand (passenger strand) is often degraded [264, 265] (Figure 6). This single-
stranded miRNAs-RISC primarily binds to the 3’-untranslated region (3’UTR) of their 
target mRNAs according to Watson and Crick base-paring rule [266, 267]. Unlike short 
interfering RNAs (siRNAs), the majority of miRNAs : mRNAs bindings are partially 
complementary [266-269]. However, a perfect complementary between the first 2- to 8- nt 
5’ sequence of a miRNA (also known as the “seed site” region of a miRNA) and the target 
mRNA is essential for the miRNA action [266-269]. Finally, depending on the degree of 
complementarity between miRNAs and their target mRNAs, miRNAs either inhibit the 
translation of the encoded proteins (by partial complementarity, Figure 6) or lead to mRNA 
degradation (by perfect complementarity, Figure 6) [269, 270]. 
       
1.6.3.2 Biological Functions of MiRNAs 
Since the discovery of the first functional miRNA, research over the past twenty years has 
generated substantial evidence showing the essential roles of miRNAs in various 
fundamental biological processes such as development, apoptosis, cell differentiation and 
proliferation, cell growth and cell death, and aging [249, 250]. Another major advancement 
in our understanding of the biological functions of miRNAs is that miRNAs have emerged 
not only as indicative but also causative factors in numerous diseases, including cancer, 
heart diseases, diabetes, and neurological diseases [248-250, 271-273]. 
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1.6.4 MiRNA Nomenclature 
 
Table 1. MiRNA nomenclature. 
 miRNA Nomenclature Example 
Mature form of miRNA The prefix “miR” is followed by 
a dash and a number, which is 
designated sequentially 
miR-1 was likely discovered 
before miR-26 
miRNAs with nearly identical 
sequences 
Denoted with an additional 
lowercase letter 
miR-26a/miR-26b; miR-
29a/miR-29b  
miRNA originated from 
different species 
The three-letter prefix 
representing the species of 
origin is followed by “miR” 
has-miR-26 (Homo sapiens) 
mmu-miR-26 (Mus musculus) 
 
According to the guideline of miRNA registry [274], the designation of mature miRNAs is 
given as number that follows a chronological order based on the time of their discoveries 
(Table 1). Exceptions are seen for some of the earliest discovered miRNAs, such as lin-4 
and let-7, whose name are defined according to their target genes. Similar miRNAs that 
differ only in one or two oligonucleotides in 3’ region of their sequences are classified as a 
family and are denoted with an extra letter for their designations (Table 1). Since the 
majority of miRNAs are highly conserved across different species, a three-letter prefix 
representing their species of origin is adopted in miRNA nomenclature (Table 1). 
 
1.6.5 Determination of MiRNA Targets 
To date, over 900 human miRNAs have been identified [248]; it has been predicted that the 
human genome may encode more than 1000 miRNAs, which may regulate two thirds of all 
human protein coding genes [250, 253, 275, 276]. Given that a single miRNA could 
theoretically target hundreds or thousands of potential targets, and conversely, one mRNA 
could be simultaneously targeted by multiple miRNAs,  identification and validation of 
authentic miRNAs targets inevitably represents the major challenges in miRNA research 
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[250, 275]. Current practice to overcome these problems involves a two-step procedure, 
including an initial computational target prediction followed by an experimental validation. 
     
1.6.5.1 Computational Prediction of MiRNA Targets  
There is an array of tools that are currently available for miRNA target prediction, which 
are presented as website-based interfaces for an easy-access purpose. Of note, most of these 
tools are developed by using seemingly distinct but actually similar algorithms that follow a 
series of important standards in regards to the identification and ranking of potential targets 
[247, 250]. For example, most of the programs primarily rely on sequence complementarity 
between the 5’ seed region (2-8 nt of the 5’ sequence) of a miRNA and the 3’UTRs of 
target mRNAs to determine the likelihood of miRNA targets [247, 250, 275]. The ranking 
of these predicted targets is based on the degree of overall complementarity as well as the 
conservation of both miRNA and 3’UTR target sequences across species [247, 250, 275]. 
Currently, three most commonly and widely used programs are TargetScan [267], PicTar 
[277], and miRanda [278], which differ in prediction sensitivity and specificity [250]. A 
practice to combine the results generated from different programs could theoretically 
enhance the sensitivity and/or specificity and, hence, becomes increasingly favorable for 
miRNA researchers [247]. There are two advantages of using in silico approach for miRNA 
target prediction prior to the experimental identification. First, the inherent high throughput 
feature allows researchers to easily portray a more thorough picture of the miRNA 
candidates for a given gene or the genes targeted by a given miRNA. Second, it serves as a 
powerful mean to predict a potential cellular function of a miRNA or a cluster of miRNAs. 
         
1.6.5.2 Experimental Validation of MiRNA Targets  
A common scheme to experimentally validate miRNA targets includes two parts [247, 
279]: 1) to verify the binding ability of a miRNA to its predicted 3’UTR binding site by 
using luciferase reporter assay; i.e., insert the partial or full length of 3’UTR of a target 
gene containing the predicted binding site for a given miRNA into the luciferase reporter 
vector; by this way, any physical interaction between the miRNA and the 3’UTR can affect 
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the production of the luciferase protein; therefore, the effectiveness of the binding can be 
determined by measuring of the fluorescent signal generated by the luciferase [247, 279]. 2) 
to observe whether an endogenous protein encoded by a given miRNA target gene, is 
indeed affected by the miRNA in a native cellular environment [247, 279].  
     Two strategies are commonly used in the luciferase study to validate the miRNA targets 
[247, 279]. The first strategy involves the construction of a luciferase report vector that 
contains either the wild-type 3’UTR (bearing the intact putative binding for a specific 
miRNA) or the mutant 3’UTR (bearing the mutated binding site for the same miRNA); 
these constructs are then separately transfected into a cell line that abundantly expresses the 
miRNA of interest; if the luciferase activity from cells transfected with wild-type 3’UTR is 
reduced and indeed this reduction is absent in cells transfected with mutant construct, the 
binding site is likely to be authentic for the miRNA [247, 279]. Of note, an additional 
experiment to inhibit the endogenously expressed miRNA by anti-miRNA oligos (miRNA 
inhibitor) in the same settings can further prove the specificity [247]. The second strategy 
relies on a cell line, in which the miRNA of interest is modestly or poorly expressed [247, 
279]. Instead of knocking down the endogenous miRNA, a specific miRNA is 
overexpressed in the cells by using the synthetic “miRNA mimic” or the miRNA 
overexpression vector [279]. Consequently, if cells transfected with wild-type 3’UTR show 
a dose-dependent reduction of the luciferase activity in response to the miRNA 
overexpression while this effect is absent in cells transfected with the mutant 3’UTR, the 
tested binding site is considered to be responsive to the given miRNA [247, 279].  
     Unlike luciferase reporter assay, western blotting allows a direct measurement of the 
effect of a miRNA on the level of its target protein. Similar to luciferase study, transfection 
of the synthetic miRNA mimic or the miRNA overexpression vector can be used as an 
overexpression approach, whereas inhibition can be achieved by using anti-miRNA oligos 
[279, 280]. It should be noted that choosing a proper cell type with relatively-high 
expression levels of the target protein and the corresponding miRNA is important for a 
successful western blotting verification [279, 280]. Ideally, the selected cell type should 
modestly express the miRNA of interest because the changes of the protein expression in 
response to either miRNA knockdown or overexpression can be more accurately reflected 
when the background level of the studied miRNA in the cells is modest. 
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1.6.6 MiRNA Expression in the Heart 
1.6.6.1 Cardiac Selectivity of MiRNA Expression 
Under the normal conditions, expression of miRNAs in heart displays a distinct pattern 
comparing to the other organs [281]. Of ~ 900 miRNAs identified in human, only a subset 
of these miRNAs is abundantly expressed in heart. Based on a recent study, the top 20 most 
abundant miRNAs in human heart are miR-1, miR-133a/b, miR-26a/b, miR-125a/b, let-
7a/b/c/f/g, miR-16, miR-100, miR-126, miR-145, miR-195, miR-199, miR-20, miR-21, 
miR-23, miR-24, miR-29a/b, miR-27a/b, miR-30a/b/c, miR-92a/b, and miR-99 [281]. 
Interestingly, the majority of these cardiac-enriched miRNAs are ubiquitously expressed in 
various organs except for miR-1 and miR-133a/b [281], both of which are preferentially 
expressed in cardiac and skeletal muscle [282]. In addition to miR-1 and miR-133a, some 
less abundantly-expressed miRNAs, miR-208a/b and miR-499, are also found to be 
cardiac-specific [283], as they are co-transcribed with the cardiac-specific genes, MYH6 
(encoding the α-myosin heavy chain, miR-208a), MYH7 (encoding the β-myosin heavy 
chain, miR-208b), and MYH7b (encoding isoforms b of the β-myosin heavy chain, miR-
499), respectively [283]. 
         
1.6.6.2 Cell Type Specification of MiRNA Expression in the Heart 
Although the majority of cardiac-enriched miRNAs are ubiquitously expressed in various 
organs, many of them exhibit cell-type preferential expression. For example, miR-1 and 
miR-133a/b are muscle-specific miRNAs that are preferentially expressed in cardiac and 
skeletal muscle cells [282]; miR-21 and miR-29a/b are preferentially expressed in 
fibroblasts [284, 285]; miR-126, miR-24, and miR-92a are largely enriched in endothelial 
cells [286]; miR-145 is detectable mainly in smooth muscle cells [287]. 
   
1.6.6.3 MiRNA Detection and Quantification 
Current methods for miRNA detection primarily focus on the detection of mature miRNAs. 
This is due to the fact that the expression level of pri-miRNAs is generally not in linear 
33 
 
 
relation with the expression level of their corresponding mature miRNAs [247]. To date, a 
variety of techniques have been employed to determine the abundance and/or presence of 
miRNAs. Microarray and deep sequencing serve as profiling approaches to determine the 
global expression of miRNAs, whereas the expression of individual miRNA can be more 
precisely quantified by real-time RT-PCR and Northern blotting. 
       
1.6.6.3.1 Detection of MiRNAs by Microarray 
One of the most significant advantages of using microarray for miRNA detection is that it 
allows a large number of miRNAs in a given tissue or cell sample to be simultaneously 
analyzed [288, 289]. Owing to this high through-put feature, microarray analysis is 
generally considered as the most practical approach for miRNA screening. However, given 
that the principle for microarray is based on the hybridization between capture probes 
(synthetic oligonucleotides) and targeted miRNAs, and that the binding affinities towards 
the capture probes differ among miRNAs, microarray should not be considered as a 
quantitative method to determine the expression level of miRNAs [290-292]. Instead, it can 
serve as a comparative approach to show the relative changes of miRNAs expression 
between 2 states or the presence of miRNAs between different tissues or cell-types [290-
292]. For example, it will be ideal to use microarray analysis to compare the miRNA 
expression profiles between diseased and non-diseased hearts [247, 289]. Currently, there 
are several commercially available miRNA microarray platforms, which differ in 
sensitivity and specificity due to the different designs of capture probes [290]. Although 
microarray represents a practical and easy approach for miRNA screening, there are several 
inherent limitations: 1) relatively low sensitivity of the capture probes may fail to detect the 
low abundant miRNAs; 2) owing to the low specificity of the hybridization, a false positive 
result is unavoidable; and 3) microarray results represent the relative changes between 
samples and are unable to conduct quantitative analysis. Therefore, the microarray results 
should be confirmed by other detection methods [288, 289, 293]. 
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1.6.6.3.2 Detection and Quantification of MiRNAs by Deep Sequencing 
Similar to microarray analysis, deep sequencing is also a high through-put approach for 
profiling a large number of miRNAs [292]; however, unlike microarray that is solely based 
on hybridization, deep sequencing relies on the PCR-based parallel sequencing, which can 
capture miRNAs with low copy numbers (few molecules per cell) that are normally 
undetectable by microarray [292, 294]. In addition to the superior sensitivity, deep 
sequencing can measure the absolute abundance of the miRNAs, and thus the result is 
quantitative [294]. Despite the advantages over microarray as a miRNA profiling method, 
deep sequencing can also serve as a powerful tool for new miRNA discovery [294, 295]. 
This is due to the fact that this sequencing based-technique can theoretically capture any 
known and unknown miRNAs or even structurally-similar RNA fragments during the 
robust PCR reactions [294, 296]. However, a proper interpretation of the massive 
information generated by deep sequencing poses a great challenge for subsequent 
bioinformatic analysis and experimental verification, which are normally costly and time-
consuming [292, 294]. Therefore, deep sequencing still remains as a second option for 
miRNA profiling in comparison to microarray. 
    
1.6.6.3.3 Quantification of MiRNAs by Real-time RT-PCR 
Although the overview of global miRNA expression provided by microarray or deep 
sequencing is useful and informative, the accuracy of the results needs to be further 
validated by more specific approaches that allow individual quantification of the miRNA 
expression [297, 298]. To date, real-time RT-PCR is the most commonly used quantitative 
method for the assessment of individual miRNA expression [299-301]. Unlike detection of 
protein-coding RNA, detection of miRNA by real-time RT-PCR is bound with difficulties, 
particularly for the synthesis of first strand cDNA (reverse transcription).  These are largely 
due to the unique features of miRNAs, i.e., the lack of poly (A) tail, short length (~22nt), 
and the presence of mature miRNA sequence in its precursor and primary transcript [300-
302]. Therefore, over the past several years, researchers in the field have developed two 
different methods for reverse transcription (RT) of miRNAs, namely miRNA-specific RT 
or universal RT [300]. During miRNA-specific reverse transcription, miRNAs are reversely 
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transcribed individually by using miRNA-specific primers, which are designed to form a 
“stem loop” structure, as shown in Figure 7A [300, 302]. Each stem loop primer is 
composed of three parts: 1) a short single-stranded part of the stem containing sequence 
that is complementary to the 3’ end of a target miRNA; 2) double-stranded part of the stem; 
and 3) a loop region that contains the sequence for binding of the universal primer during 
real-time PCR [300, 302]. The purpose of this stem-loop design is to reduce the annealing 
of the primers to pre- or pri-miRNAs, thereby enhancing the specificity of the primers [300, 
302]. Of note, as each stem-loop RT primer is specifically designed for its targeted miRNA, 
the RT reactions should be performed individually for the corresponding miRNAs [300, 
302]. For universal reverse transcription, all miRNAs are first tailed with a common 
sequence (normally a ploy (A) tail) and then are reversely transcribed with a universal 
primer (Figure 7B) [298, 300]. Based on this principle, one reaction by universal methods 
could theoretically transcribe all the miRNAs in a given sample [298, 300].   
 
Figure 7. Different approaches for miRNA quantification by real-time RT-PCR. A. Reverse 
transcription of miRNAs by “stem loop” RT primers. B. Reverse transcription of miRNAs 
by universal RT primers; note that miRNAs are first tailed with poly “A” sequence prior to 
reverse transcription. Adapted from van Rooij E et al.  [247]. 
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1.6.6.3.4 Quantification of MiRNAs by Northern blot 
Northern blotting is another technique that allows individual quantification of specific 
miRNAs [303-305]. One obvious advantage of using northern blotting to detect a given 
miRNA is that it allows the visualization of both mature miRNA and precursor miRNA 
[304, 305]. However, this technique is generally time-consuming and requires large 
amounts of RNA sample (8ug or more), which poses a challenge for experiments with 
limited amount of samples [303]. Another potential drawback of the technique is the cross 
reaction of the detection probe with miRNAs that share high sequence homology [303]. 
Consequently, results obtained from northern blotting should ideally be verified by other 
detection methods, for example, real-time RT-PCR. 
 
1.6.7 Regulation of MiRNA Expression and MiRNA Interference 
1.6.7.1 Transcriptional Regulation of MiRNA Expression 
Similar to protein-coding genes, the transcription of miRNA genes is also tightly controlled 
by their 5’ proximal regulatory sequences (promoters) in coordination with a variety of 
DNA-binding factors (transcription factors, TFs) [252, 306]. However, depending on the 
type of miRNAs, miRNA genes can be transcribed by using either their own promoters (for 
intergenic miRNAs) or their host gene promoters (for exonic and intronic miRNAs) [307, 
308]. Interestingly, it appears that the promoters of miRNA genes and protein coding genes 
share many similarities, such as initiator elements, the presence of TATA box, transcription 
factor II B (TFIIB) recognition, the occurrence of CpG islands and histone modifications 
[252, 306, 308]; and more importantly, the TFs that regulate the transcription of miRNA 
genes or protein coding genes can largely overlap [252, 253, 306]. For example, the proto-
oncogene c-myc is found to positively regulate transcription of miR-17, while it can also 
promote the transcription of E2F1 [309]. Another example is p53, a well defined pro-
apoptotic factor, which has been found to control both the transcription of miR-34 genes 
and various tumor genes [310]. 
     In cardiomyocytes, several cardiac-specific TFs have been implicated in the control of 
miRNA transcription. For example, serum response factor (SRF) and myocytes enhancer 
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factor 2 (MEF2) have been well characterized to transcriptionally activate the expression of 
two muscle-specific miRNAs, miR-1 and miR-133, during cardiac development [246, 282, 
311].  GATA-4, another important TF in the heart, directly binds to the promoters of miR-
144 and miR-451 and promotes the transcription of these two miRNAs [312]. Nkx2.5 
regulates the transcription of miR-143 and miR-145, which are important for the 
differentiation of cardiac progenitor cells [287].    
     In addition to the cardiac-specific TFs, many of other non cardiac-specific TFs have also 
been found to regulate the transcription of miRNAs in cardiomyocytes. A typical example 
is nuclear factor of activated T cells (NFAT). A recent study has shown that NFAT 
transcriptionally activates miR-23a expression [313], and similarly, in another recent study, 
NFAT was found to be a direct transcriptional activator for miR-199b [314]. 
       
1.6.7.2 MiRNA Interference 
1.6.7.2.1 In Vitro MiRNA Interference 
Transient overexpression or inhibition of miRNA in a cell-based system is the initial step 
towards functional studies of miRNAs. Several transfection-based approaches are currently 
used to overexpress miRNA in vitro: synthesized double-stranded miRNA mimics [279, 
280, 282, 315], miRNA precursors [316, 317] or vectors that overexpress the miRNA of 
interest [247, 315]. For cells with low transfection efficiency, such as adult cardiomyocytes, 
a virus-based infection approach can be used [248, 279, 315]. For in vitro miRNA 
inhibition, the most commonly used strategy is to transfect cells with the miRNA antisense, 
namely antimiRs, which are the modified DNA oligos with the perfect complementarity to 
the guide-strand of a given miRNA that can antagonize the endogenous mature miRNAs 
and prevent them from binding to their targets [279, 282, 315, 317].  Alternatively, 
knockdown can be achieved by using either a regular vector or a viral-vector that expresses 
transcripts containing multiple miRNA target sites, by which the miRNA of interest can be 
functionally blocked or decoyed thereby being prevented from affecting its endogenous 
targets [318-321]. 
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1.6.7.2.2 In Vivo MiRNA Interference 
The in vivo function of a specific miRNA can be elucidated by gain- and/or loss-of-
function studies, which generally rely on three different approaches: 1) generation of 
transgenic animals with genetic modifications (either overexpression or knockout/down) of 
the targeted miRNA; 2) application of virus-based overexpression or knockdown 
techniques; and 3) the oligos-based antimiRs knockdown technique [247, 248, 321, 322]. 
Although many studies have revealed that genetic manipulation is a powerful approach to 
define the function of miRNA in vivo, some potential drawbacks with this approach should 
be taken into account. In some cases, forced overexpression of a miRNA could result in 
off-target effects due to the supraphysiological level of the miRNA expression [247, 248, 
315, 317]. In other cases, genetic deletion of a miRNA could cause fetal lethality because 
the deletion might also disrupt a protein-coding gene, given that ~40% of miRNA genes are 
located within the introns of the protein coding genes that are potentially important for 
development [247, 248, 315, 317]. To overcome these problems, one alternative strategy is 
to overexpress or knockdown a miRNA by systemic delivery of the adenoviral vector 
expressing transcripts that contain either the miRNA precursor or multiple miRNA binding 
sites in the adult animals [247, 248, 315, 317]. However, due to the lack of tissue-specific 
expression inherent to the regular adenoviral approach, there is a growing interest of using 
different serotypes of adeno-associated viruses (AAVs) to achieve the tissue-specific 
expression, among which, AAV serotype 9 (AAV9) has been found to preferentially target 
cardiac tissues [248, 321, 322]. In addition to the genetic manipulation and viral expression 
approaches, a series of recently-developed miRNA knockdown oligos (antimiRs) have 
emerged as potent in vivo miRNA inhibitors with great therapeutic potential [248, 322]. 
Generally, these synthetic antimiRs are chemically-modified antisense oligos bearing the 
full or partial reverse complementary sequence of a mature miRNA that can either degrade 
or functionally block the endogenous miRNA upon binding [321, 323, 324]. The most 
commonly-used chemical modifications include 2’-O-methyl (2’-OMe)-modified 
oligonucleotides (Figure 8B) and locked nucleic acid (LNA)-modified oligonucleotides 
(Figure 8C), in which the 2’-O-oxygen is connected to the 4’ position by a methylene linker 
to form a tight bicycle and is locked into the C3’-endo (RNA) sugar conformation, favoring 
the formation of a thermodynamically strong duplex with the complementary RNA [323, 
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324]. Both 2’-OMe and LNA modifications aim to increase the stability of 
oligonucleotides, improve the nuclease resistance, and enhance binding affinity to the target 
RNA [323, 324]. They can also be combined with some other chemical modifications to 
further improve cellular stability or uptake [247, 321]. For example, addition of 
phosphosrothioate backbone (Figure 8D) between nucleotides makes the oligonucleotides 
more resistant to nuclease [325]; the use of cholesterol conjugated oligonucleotides is 
proven to facilitate cellular uptake [326]. 
 
 
Figure 8. Different chemical modifications of in vivo miRNA knockdown oligos. A. 
Conformation of unmodified RNA. B. Conformation of 2’-O-methyl RNA (a methyl group 
bound to the 2′ oxygen of the ribose, highlighted in grey). C. Conformation of LNA 
monomer (methylene bridge between 2’-O and 4’ in the ribose, highlighted in grey). D. 
Conformation of phosphorothioate RNA (S indicates sulfur substitution of a non-bridging 
oxygen to make a phosphorothioate linkage between nucleotides). (Adapted from Ruberti F 
et al. [327] with modifications). 
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1.6.8 Role of MiRNAs in the Heart 
The complexity of the cardiac system is manifested by the fact that the normal function and 
formation of the heart are finely controlled by networks of transcriptional factors and 
signaling systems that govern the expression of cardiac genes that are essential for 
cardiogenesis, morphogenesis, and contractility [328]. The discovery of miRNAs as novel 
gene regulators during various biological processes has added a new layer of complexity to 
the cardiac system [322, 329]. It has now become clear that miRNAs tightly interact with a 
variety of cardiac signaling and transcriptional pathways to regulate cardiac development, 
function, and disease [275, 322, 329]. 
  
1.6.8.1 Implications of MiRNAs in Cardiac Development 
 
Table 2. Summary of miRNAs related to cardiac development. 
miRNAs and cardiac development 
miRNA Cell Type Functions Refs 
miR-1 Cardiomyocytes and 
skeletal muscle cells 
Promotion of myocardial differentiation and 
negative regulation of cardiomyocyte 
proliferation 
333; 334 
miR-133 Cardiomyocytes and 
skeletal muscle cells 
Repression of myocardial differentiation and 
cardiomyocyte proliferation 
334; 335 
miR-17~92 Cardiomyocytes Promotion of myogenic differentiation 336; 337 
miR-126 Endothelial cells Promotion of vasculogenesis 286; 338; 339 
miR-143 Smooth muscle cells Promotion of smooth muscle cell differentiation 
and proliferation; vessel formation 
287; 340; 341 
miR-145 Smooth muscle cells Promotion of smooth muscle cell differentiation 
and proliferation; vessel formation 
  287; 340; 341
miR-138 Cardiomyocytes Cardiac morphogenesis 342 
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The first direct evidence supporting the requirement of miRNAs for cardiac development 
and function came from studies using mice with cardiac-specific deletion of Dicer genes, 
which encode a protein that is essential for miRNAs processing [330-332]. The germline 
deletion of Dicer in myocardium or cardiovascular smooth muscle resulted in an aberrant 
expression of cardiac contractile proteins and embryonic lethality, indicating the crucial 
roles of miRNAs in earlier cardiac development [330, 331]. Interestingly, a subsequent 
study, which aimed to circumvent the embryonic lethality with germline deletion of Dicer 
by using mice with conditional Dicer knockout in postnatal myocardium, also observed the 
premature death of the animals shortly after inducing the deletion [332]. The lethal 
consequence of Dicer knockout is likely due to a joint-function of multiple miRNAs rather 
than a single miRNA, because, thus far, no embryonic lethality was observed when a 
specific miRNA was deleted [322].  
     To date, many of the cardiac-enriched miRNAs have been individually investigated for 
their potential roles in various aspects of cardiac development (e.g. myocardial 
differentiation and vasculogenesis), as summarized in Table 2. Muscle-specific miR-1, the 
most abundantly-expressed miRNA in cardiac tissue, was found to promote the formation 
of cardiac or skeletal muscle cells, whereas another muscle-specific miRNA, miR-133, was 
reported to negatively regulates myocardial differentiation [333-335]. Interestingly, both 
miR-1 and miR-133 were found to negatively regulate cardiomyocyte proliferation [334, 
335]. Several miRNAs that belong to the miR-17-92 cluster, have also been reported to 
play an important role in mediating the myocardial differentiation of cardiac progenitor 
cells [336, 337]. In addition to myocardial differentiation, the involvement of miRNAs has 
also been seen in vasculogenesis during cardiac development. MiR-126, a cardiac-enriched 
miRNA that is selectively expressed in endothelial cells (ECs), was found to be crucially 
involved in angiogenic signaling and contribute importantly to vascular formation [286, 
338, 339]. Interestingly, evidence supporting the potential contribution of miRNAs to 
vascular development has been found not only in ECs but also in smooth muscle cells 
(SMCs). SMC-specific miRNAs, miR-143 and miR-145, were reported to cooperatively 
regulate differentiation and proliferation of vascular smooth muscle cells (VSMCs) and 
determine VSMC cell fate, thereby contributing to the blood vessel formation [287, 340, 
341]. Apart from the above various aspects of cardiac development, miRNAs are also 
42 
 
 
involved in the regulation of cardiac patterning. Evidence from a recent study using a 
genetic approach to delete miRNAs in zebrafish heart suggested that miR-138, a broadly 
conserved miRNA in mammals, is required for the proper formation of heart chambers 
through controlling chamber-specific gene expression patterns during cardiac 
morphogenesis [342]. 
                    
1.6.8.2 Implications of MiRNAs in Cardiac Pathologies 
Although tremendous efforts have been devoted to deciphering the underlying mechanisms 
responsible for a variety of cardiovascular diseases (e.g. cardiac hypertrophy, heart failure, 
ischemia, and arrhythmia), miRNAs have only recently been shown to play important roles 
during these pathological conditions [322, 329, 343]. It has become clear that there is a 
distinct expression pattern of miRNAs associated with different cardiac diseases and in 
some cases, the deregulation of a single miRNA is sufficient to result in a cardiac 
pathological condition [275, 322, 329, 343-346]. 
   
1.6.8.2.1 Roles of MiRNAs in Cardiac Hypertrophy and Heart Failure 
 
Table 3. Summary of miRNAs related to cardiac hypertrophy and heart failure. 
miRNAs in cardiac hypertrophy and failure 
miRNA Disease/Expression Targets Function Refs 
miR-195 CH and HF / 
Upregulated 
Unknown Induction of cardiac 
hypertrophy and failure 
347 
miR-208a CH / Unaltered Myostatin; 
THRAP1 
Essential for hypertrophic 
response 
283; 348 
miR-1 CH / Downregulated IGF1; 
Calmodulin;  
Mef2a 
Inhibition of cellular 
hypertrophy 
320; 349-352 
miR-133 CH and HF / 
Downregulated 
RhoA; CTGF; 
Col1A1 
Anti-hypertrophic (? 
Inconsistent *); anti-fibrotic 
320; 334; 347; 
353; 355-357 
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miR-23a CH and HF / 
Upregulated 
MuRF1 Promotion of cellular 
hypertrophy 
313 
miR-199b CH and HF / 
Upregulated 
Dyrk1a Promotion of cellular 
hypertrophy 
  314 
miR-21 CH / Upregulated Spry1 Profibrotic  284; 354 
miR-29b CH and HF / 
Downregulated 
Col1A1; Col1A2; 
Col3A1; FBN1; 
ELN 
anti-fibrotic 285 
CH: Cardiac hypertrophy; HF: Heart Failure. 
* Note that inconsistent results were reported for the anti-hypertrophic role of miR-133.   
 
To date, the contribution of miRNAs to pathogenesis of cardiac hypertrophy and heart 
failure has been highlighted in numerous studies, as summarized in Table 3. The first study 
was done in mice subjected to transverse aortic constriction (TAC) or cardiac 
overexpression of activated calcineurin [347]. A series of deregulated miRNAs exhibiting a 
distinct expression pattern was observed in the cardiac tissues from these mice [347]. 
Interestingly, among these deregulated miRNAs, the cardiac-specific overexpression of 
miR-195 recapitulated the phenotypic changes associated with cardiac hypertrophy and 
heart failure, suggesting the pathogenetic role of miRNAs in these disease conditions [347]. 
Subsequently, a cardiac-specific miRNA, miR-208a, was found to play an essential role in 
cardiac hypertrophy [283, 348]. Mice with genetic deletion of miR-208a failed to 
demonstrate hypertrophic response to stress and hypothyroidism [283], whereas cardiac-
specific overexpression of miR-208a induced cardiac hypertrophy [348]. Subsequent 
experiments demonstrated that the pro-hypertrophic effect of miR-208a is attributable to 
the repression of its targets, thyroid hormone receptor associated protein 1 (THRAP1) and 
myostatin, both of which function as negative regulators of muscle growth and hypertrophy 
[283, 348]. In addition to miR-208a, other cardiac-specific miRNAs, miR-1 and miR-133, 
have been reported to be involved in cardiac hypertrophy and failure [320, 349, 350]. The 
expression of miR-1 and miR-133 has been consistently found to be downregulated during 
cardiac hypertrophy in animal models and humans [320, 349, 350]. In vivo and in vitro 
inhibition of miR-1 in cardiomyocytes resulted in the increases in cell size and cell mass, 
suggesting an anti-hypertrophic role of miR-1 [320, 350]. The anti-hypertrophic effect of 
miR-1 may be attributed to its targeting of several signaling factors that are known to be 
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important to the development of cardiac hypertrophy, including insulin-like growth factor-1 
(IGF-1) [351, 352], calmodulin [349], and myocytes enhancer factor 2A (MEF2A) [349]. 
As for miR-133, several studies have consistently documented a reduced expression of this 
miRNA in hypertrophied heart [320, 347, 353]. In vivo knockdown of miR-133 by 
systemic administration of its antagomir in the normal mouse hearts, was found to induce 
cardiac hypertrophy, presumably through the release of inhibition on its target, RhoA, a 
guanosine diphosphate-guanosine triphosphate exchange protein that can induce cardiac 
hypertrophy when its expression is elevated [320]. However, the exact role of miR-133 in 
cardiac hypertrophy remains controversial, as a subsequent study reported that mice with 
cardiac-specific knockout of miR-133 fail to develop cardiac hypertrophy [334]. The causes 
for this obvious discrepancy remain yet to be determined. More recently, two separate 
studies have suggested that miR-23a and miR-199b might also play important roles in 
cardiac hypertrophy and failure [313, 314]. The expression of both miRNAs was found to 
be profoundly increased in hypertrophied and failing hearts [313, 314]. In vivo inhibition of 
miR-23a completely abrogated the hypertrophic response upon isoproterenol stimulation 
[313]. The pro-hypertrophic effect of miR-23a is thought to be mediated by an anti-
hypertrophic protein, muscle specific ring finger protein 1 (MuRF1), which is 
experimentally established as a target for miR-23a [313]. Similarly, miR-199b was also 
reported to positively regulate cardiac hypertrophy and failure, presumably through a relief 
of its repression on nuclear NFAT kinase dual-specificity tyrosine-(Y)-phosphorylation 
regulated kinase 1a (Dyrk1a), which functions as a negative regulator for cardiac 
hypertrophy [314]. Indeed, transgenic mice with overexpression of miR-199b demonstrated 
an enhanced hypertrophic response to pressure overload, whereas in vivo inhibition of miR-
199b was able to reverse the phenotypic changes (cellular hypertrophy and fibrosis) 
observed in the mouse models of heart failure [314].  
     In addition to the direct pathogenetic roles in cardiac hypertrophy and failure, miRNAs 
have also been found to participate in fibrogenesis during cardiac hypertrophy and failure. 
The first documented fibrosis-related miRNA during cardiac hypertrophy is miR-21 [284]. 
A significant increase of miR-21 expression was observed during cardiac hypertrophy and 
this increase was found more profound in myofibroblasts than in myocytes [284]. In vivo 
inhibition of miR-21 with its antagomir in mice successfully prevented the fibrosis and 
45 
 
 
cardiac hypertrophy in response to pressure overload, suggesting a profibrotic role of miR-
21 during cardiac hypertrophy [284]. The profibrotic effect of miR-21 is likely attributable 
to its targeting of sprouty homolog 1 (Spry1), which functions as a negative regulator for 
extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation and myofibroblast 
survival [284]. However, a recent study questioned the necessity of miR-21 in hypertrophy-
induced fibrosis. In this study, in vivo interference of miR-21 in the hearts was found to 
have no impact on fibrosis in three different mouse models of cardiac hypertrophy [354]. 
Thus, further studies are needed to resolve these obvious contradictions. Expression levels 
of miR-133 and miR-29b have also been repeatedly reported to be downregulated in 
hypertrophied and failing hearts [285, 355, 356].  Restoration of miR-133 to normal levels 
in mouse models of cardiac hypertrophy was able to prevent the fibrosis [356]. The anti-
fibrotic effect of miR-133 is likely due to its repression on collagen 1A1 (Col1A1) and 
connective tissue growth factor (CTGF), a well-known profibrotic factor [355, 357]. 
Similarly, miR-29b has also been found to play an anti-fibrotic role during cardiac 
hypertrophy through direct targeting of multiple collagen isoforms, fibrillin, and elastin 
[285]. Accordingly, in vivo inhibition of miR-29b in mice was able to promote fibrogenesis 
in the heart [285]. 
      
1.6.8.2.2 Roles of MiRNAs in Myocardial Ischemia 
Table 4. Summary of  miRNAs related to myocardial ischemia.  
miRNAs in cardiac ischemia 
miRNA Expression Targets Function Refs 
miR-199a Downregulated Hif-1α Anti-apoptotic 358 
miR-320 Downregulated HSP-20 Anti-apoptotic 359 
miR-21 Downregulated (in CMs) PDCD4; PTEN;  
FasL 
Anti-apoptotic 360; 361 
 Upregulated (in MFs) PTEN Profibrotic 370 
miR-494 Downregulated PTEN; ROCK1; 
CAMKIIδ 
Anti-apoptotic 362 
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miR-24 Downregulated (in CMs) Bim Anti-apoptotic 364 
 Upregulated (in ECs) GATA2; PAK4 Proapoptotic and 
anti-angiogenic 
363 
miR-15 Upregulated Bcl2; Arl2 Proapoptotic 365-367 
miR-29 Downregulated Col1A1; Col1A2; 
Col3A1; FBN1; 
ELN 
Anti-fibrotic 285 
miR-92a Downregulated (in ECs) ITGA5 Anti-angiogenic 369 
miR-126 Upregulated (in ECs) Spred1 Proangiogenic 286; 368 
CMs: cardiomyocytes; MFs: myofibroblasts; ECs: endothelial cells 
 
Aberrant miRNA expression has been repeatedly observed in cardiac ischemia. Cardiac 
ischemia is a result of insufficient supply of blood flow to the heart, which may cause many 
abnormalities, affecting apoptosis, angiogenesis, fibrosis and contractile dysfunction in the 
myocardium. Several miRNAs that affect cell viability were reported to be perturbed 
during cardiac ischemia, including miR-199a [358], miR-320 [359], miR-21 [360, 361], 
miR-494 [362], miR-24 [363, 364], and miR-15 [365], as summarized in Table 4. Among 
these deregulated miRNAs, reduced expression of miR-199a, miR-21, miR-494, and miR-
24 was found within the infarct zone [358, 360-362, 364]. Interestingly, when restoring the 
expression of these miRNAs in the ischemic heart, a reduced infarct size and improved cell 
viability were observed [358, 360-362, 364]. At the cellular level, overexpression of miR-
199a, miR-21, miR-494, or miR-24 alone was able to inhibit hypoxia-induced apoptosis in 
cardiomyocytes [358, 361, 362, 364]. The underlying mechanisms responsible for their 
anti-apoptotic effects are likely attributable to the inhibition of various proapoptotic factors, 
such as hypoxia-inducible factor 1 alpha (Hif-1α, target of miR-199a) [358], phosphatase 
and tensin homolog (PTEN, target of miR-21 and miR-494) [361, 362], Fas ligand (FasL, 
target of miR-21) [361], programmed cell death 4 (PDCD4, target of miR-21) [361], Rho-
associated coiled-coil containing protein kinase-1 (ROCK1, target of miR-494) [362], 
calcium/calmodulin-dependent protein kinase II delta (CAMKIIδ, target of miR-494) [362], 
and BH3-only protein (Bim, target of miR-24) [364]. Unlike the decrease of miR-199a, 
miR-21, miR-494, or miR-24, which deteriorates cell viability during ischemia, the 
observed downregulation of miR-320 during myocardial ischemia appears to be 
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cardioprotective, as  in vivo suppression of this miRNA was found to reduce infarct area 
after ischemia reperfusion (IR) [359]. The cardioprotective effect of miR-320 
downregulation during IR is likely due to an increased expression of heat shock protein 20 
(HSP20), a well known cardioprotective protein that is targeted by miR-320 [359]. 
Upregulated miRNAs are also seen within the infarct zone, one example is miR-15b. In 
vivo inhibition of miR-15b during ischemia resulted in reduced infarct size and improved 
cardiac function [365]. The mechanism underlying the beneficial role of miR-15b 
knockdown is likely related to the increased levels of cell death suppressor proteins, ADP-
ribosylation factor-like 2 (Arl2) and B-cell lymphoma 2 (Bcl2), both of which are validated 
targets of miR-15b [366, 367].  
     Deregulated miRNAs seen in myocardial ischemia are implicated not only in cell 
viability but also in angiogenesis. A typical example is miR-126, which was found to be 
highly enriched and upregulated in endothelial cells during cardiac ischemia [368]. The 
enhanced expression of miR-126 was proven to be required for reparative angiogenesis in 
response to ischemic insult through repression of an anti-angiogenic protein, sprouty-
related EVH1 domain-containing protein 1 (Spred-1) [286, 368]. Interestingly, for miR-24, 
in contrast to its downregulation in cardiomyocytes during myocardial ischemia, a 
significant increase in its expression was observed in endothelial cells, where it induced 
apoptosis of these cells [363]. Accordingly, in vivo inhibition of miR-24 during myocardial 
ischemia was found to prevent endothelial cells from undergoing apoptosis and increases 
angiogenesis, suggesting an anti-angiogenic role of miR-24 [363]. The observed anti-
angiogenic effect of miR-24 is likely caused by an increased expression of miR-24 
conserved targets, GATA2 and p21-activated kinase-4 (PAK4), both of which are known to 
positively regulate angiogenesis [363]. MiR-92a was also found to be downregulated 
during myocardial ischemia [369]. This downregulation was shown to promote reparative 
angiogenesis, which is likely due to an increased level of alpha-5 integrin (ITGA5), a 
proangiogenic protein that is targeted by miR-92a [369]. 
     Similar to cardiac hypertrophy, miRNAs are also involved in fibrogenesis during 
myocardial ischemia. Two miRNAs have so far been implicated in control of fibrosis 
during cardiac ischemia: miR-21 and miR-29. Both of these miRNAs are highly enriched in 
fibroblasts [285, 370]. While miR-21 was reported to be dramatically increased in the 
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infarcted region during cardiac ischemia [370], downregulation of miR-29 was consistently 
observed in the same context [285]. Increased level of miR-21 in cardiac fibroblasts during 
cardiac ischemia was found to promote fibrosis by repressing the expression of PTEN (a 
validated target of miR-21), which in turn stimulates the synthesis of metalloproteinase-2 
(MMP-2), a well-known profibrotic factor [370]. Likewise, decreased expression of miR-
29 in the ischemic heart is also thought to promote fibrosis [285]. This is likely attributable 
to an increased expression of various ECM proteins that are validated as targets of miR-29, 
including collagens, fibrillins, and elastin [285]. 
                        
1.6.8.2.3 Roles of MiRNAs in Arrhythmia 
Table 5. Summary of  miRNAs related to cardiac arrhythmia. 
Roles of miRNAs in cardiac arrhythmia 
miRNA Disease/Expression Targets Function Refs 
miR-1 Ischemia / Upregulated Cx43; KCNJ2 Proarrhythmic 204 
 AF / Downregulated KCNJ2 To be determined              96 
 HF / Upregulated Ppp2r5a;  Abnormal Ca2+ handling 373; 374 
miR-133 CH / Downregulated KChIP2 Prolongation of QT interval 356 
 Nicotin-induced AF / 
Downregulated 
TGF-β1; TGF-
βRII 
Atrial fibrosis 375 
miR-590 Nicotin-induced AF / 
Downregulated 
TGF-β1; TGF-
βRII 
Atrial fibrosis  375 
miR-328 AF / Upregulated CACNA1C; 
CACNB1 
Overexpression promotes 
AF 
 113 
CH: Cardiac hypertrophy; HF: Heart Failure; AF: Atrial Fibrillation. 
 
Accumulating evidence has suggested that miRNAs are implicated in arrhythmogenesis 
under different disease paradigms such as cardiac hypertrophy, heart failure, myocardial 
ischemia, and atrial fibrillation, as summarized in the Table 5. The first arrhythmia-related 
miRNA was discovered in a study aimed at elucidating the molecular mechanism 
responsible for ischemia-related arrhythmia [204]. MiR-1 was found to be dramatically 
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upregulated during coronary artery disease in humans and ischemic rat hearts, which 
coincided with an increased incidence of arrhythmia [204]. Inhibition of miR-1 in the 
ischemic rat heart resulted in a reduced occurrence of arrhythmia, whereas overexpressing 
miR-1 in the healthy rat heart induced arrhythmia [204]. This proarrhythmic effect of miR-
1 in ischemic conditions is attributed to its targeting and suppression of two proteins, 
Connexin 43 (encoded by GJA1, the main form of cardiac gap junction proteins) and Kir2.1 
(encoded by KCNJ2, subunit of K+ channels carrying IK1) [204], as the deregulation of 
these proteins was reported to promote arrhythmia [371, 372]. Likewise, a significant 
increase of miR-1 was also observed in cardiomyocytes isolated from both rat and dog 
failing hearts [373, 374]. Subsequent in vitro studies demonstrated that this increased level 
of miR-1 could result in abnormal Ca2+ handling, which may contribute to 
arrhythmogenesis in failing hearts [373, 374]. In this case, miR-1 exerts its effect via 
suppressing the regulatory subunits of protein phosphatase 2A (Ppp2r5a), which is 
important for Ca2+/calmodulin-dependent protein kinase (CaMKII)-mediated 
phosphorylation of ryanodine receptors (RyR2) [374].  
     In cardiac hypertrophy, one consistent finding is the downregulation of miR-133. In fact, 
a recent study suggested that this downregulation is responsible for the reduced expression 
of Ito channel accessory subunit, KChIP2, which may indirectly contribute to prolonged QT 
interval, thereby promoting arrhythmogenesis [356]. 
     The first evidence indicating a direct role of miRNAs in AF was obtained from a study 
using nicotine-induced AF dogs [375]. Severe fibrosis was observed in the atrial tissue 
from these dogs, accompanying with significant increase of transforming growth factor-β1 
(TGF-β1) and TGF-β receptor type II (TGF-βRII), and reduced expression of miR-133 and 
miR-590 [375]. Further in vivo and in vitro experiments confirmed that the reduction of 
miR-133 and miR-590 is responsible for the enhanced expression of TGF- β1 and TGF- β 
RII, as these proteins are validated as targets of miR-133 and miR-590 [375]. While the 
above study highlights the potential role of miRNAs in atrial structural remodeling under 
AF [375], evidence from two other studies suggests miRNAs may also contribute to atrial 
electrical remodeling associated with AF [96, 113]. Upregulation of IK1 and downregulation 
of ICaL represent the two most prominent findings during ionic remodeling associated with 
AF. Interestingly, a recent study indicated that miR-1 levels are significantly reduced in 
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persistent AF patients and this reduction may contribute to upregulation of Kir2.1 subunits 
(validated target of miR-1), thereby leading to increased IK1 [96]. Nonetheless, further in 
vivo experiments are needed to establish a potential mechanistic link between miR-1 and 
AF. In another study, miR-328 was found to be upregulated in human AF patients with 
rheumatic disease, as well as in a canine model of AF [113]. Subsequent in vivo 
experiments in dogs demonstrated that overexpression of miR-328 by intracardial injection 
of miR-328-overexpressing adenovirus increases AF susceptibility [113]. Likewise, 
transgenic mice with miR-328 overexpression were more susceptible to AF induction, 
whereas inhibiting the overexpression of miR-328 in these mice reduced AF inducibility 
[113]. Mechanistically, the increased incidence of AF is attributable to the reduction in ICaL, 
as both the α1c and β1 subunits of the L-type calcium channel were experimentally 
established as the targets of miR-328 [113].  
 
1.7 Rationale for Present Studies 
Atrial fibrillation is the most clinically-encountered arrhythmia, representing a major cause 
of morbidity and mortality. Over the past two decades, a major advancement in our 
understanding of the pathogenesis of AF is the recognition that AF induces both electrical 
and structural remodeling in the atria, which in turn promotes the recurrence and 
maintenance of AF. A key feature in electrical remodeling is the abbreviation of atrial 
effective refractory period, which is primarily due to shortening of action potential as the 
result of ion channel alterations. Structural remodeling, on the other hand, is mainly 
manifested by atrial fibrosis which may also result from the deregulation of ion channels. 
Interventions that prevent deregulation of ion channels and/or atrial fibrosis may adequately 
serve as an effective approach to prevent AF occurrence. However, the precise molecular 
mechanisms underlying these remodeling processes are still poorly understood. Of note, the 
recent discovery of miRNAs as an important regulator in various cardiac pathologies has 
shed light on this matter. Emerging evidence has suggested that miRNAs can directly 
regulate the expression of ion channel genes. More importantly, deregulation of ion 
channels as a result of the aberrant miRNA expression has been implicated in 
arrhythmogenesis under several cardiac pathological conditions. Therefore, the goals of the 
51 
 
 
studies presented herein were to gain an appreciation for the importance of miRNA in 
regulation of cardiac ion channel and its pathophysiological implication in AF, to improve 
our understanding of the basic mechanisms for electrical and structural remodeling 
pertaining to AF, and to ultimately identify a potential therapeutic target for the treatment 
of AF. To this end, three separate studies with specific focus were carried out as below: 
1. As discussed in Section 1.6.5 of the introduction, currently-available experimental 
approaches do not permit thorough characterization of miRNA targeting. In order to 
acquire a comprehensive view of the miRNA regulation of cardiac ion channel in 
arrhythmia, a rationally-designed bioinformatics analysis was performed in conjunction 
with experimental approaches to identify the miRNA from the currently available 
miRNA databases which have the potential to regulate human cardiac ion channel genes 
and to validate the analysis with several pathological settings associated with the 
deregulated miRNAs and ion channel genes in the heart. 
2. As discussed in Section 1.3.1 and 1.4.4 of the introduction, upregulation of IK1 is a key 
component of AF-related electrical remodeling. In order to study the role of miRNAs in 
this AF-related ionic remodeling process. Both in vitro and in vivo approaches were 
used to identify a deregulated miRNA in experimental and clinical AF, to test whether 
the deregulated miRNA can target KCNJ2 (gene encoding Kir2.1 subunit for IK1), to 
investigate the arrhythmogenic potential of the deregulated miRNA, and to explore the 
molecular mechanisms underlying the deregulation of the selected miRNA.  
3. As discussed in Section 1.3.2 and 1.5.4 of the introduction, TRP channels may 
contribute to fibroblast proliferation and differentiation, which are central to AF-induce 
fibrotic remodeling. In order to test whether TRPC3 channels play a role in AF-induce 
fibrosis and whether miRNAs are involved in this process. Both in vitro and in vivo 
approaches were used to investigate whether TRPC3 channels are deregulated during 
AF and whether this deregulation play a role in AF-induced fibrotic remodeling, to 
identify a miRNA candidate responsible for the deregulation of TRPC3, and to study 
the molecular mechanisms underlying the change of the selected miRNA. 
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CHAPTER 2.   Overview of the Role of MiRNAs in 
Regulation of Cardiac Ion Channel Genes and its 
Potential Arrhythmogenic Implication 
 
As discussed in Section 1.6.5 of the Introduction, a single miRNA could theoretically target 
hundreds or thousands of potential targets, and conversely, a given protein-coding gene 
could be simultaneously targeted by multiple miRNAs. Currently-available experimental 
approaches do not permit thorough characterization of miRNA targeting; thus, 
bioinformatic analysis represents an ideal approach for the thorough and rapid 
characterization of miRNA targeting.  In order to acquire a comprehensive view of the 
miRNA regulation of cardiac ion channel in arrhythmia, in this chapter, we carried out a 
rationally-designed bioinformatics analysis in conjunction with experimental approaches to 
identify the miRNAs from the currently-available miRNA databases which have the 
potential to regulate human cardiac ion channel genes and to validate the analysis with 
several pathological settings (e.g. cardiac hypertrophy/heart failure, myocardial ischemia, 
and atrial fibrillation) associated with the deregulated miRNAs and ion channel genes in the 
heart. 
This work has been published in Cellular Physiology and Biochemistry. 
Luo X, Zhang H, Xiao j, Wang Z. Regulation of Human Cardiac Ion Channel Genes by 
MicroRNAs: Theoretical Perspective and Pathophysiological Implications. Cell. Physiol. 
Biochem. 2010;25(6):571-86. 
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Abstract 
Excitability is a fundamental characteristic of cardiac cells, which is delicately determined 
by ion channel activities modulated by many factors. MicroRNA (miRNA) expression is 
dynamically regulated and altered miRNA expression can render expression deregulation of 
ion channel genes leading to channelopathies−arrhythmogenesis.  Indeed, evidence has 
emerged indicating the crucial role of miRNAs in controlling cardiac excitability by 
regulating expression of ion channel genes at the post-transcriptional level. However, the 
very limited experimental data in the literature hinder our understanding of the role of 
miRNAs and the often one-to-one interaction between miRNA and ion-channel gene in the 
published studies also casts a doubt about fullness of our view. Unfortunately, currently 
available techniques do not permit thorough characterization of miRNA targeting; 
computational prediction programs remain the only source for rapid identification of a 
putative miRNA target in silico. We conducted a rationally designed bioinformatics 
analysis in conjunction with experimental approaches to identify the miRNAs from the 
currently available miRNA databases which have the potential to regulate human cardiac 
ion channel genes and to validate the analysis with several pathological settings associated 
with the deregulated miRNAs and ion channel genes in the heart.  We established a matrix 
of miRNAs that are expressed in cardiac cells and have the potential to regulate the genes 
encoding cardiac ion channels and transporters. We were able to explain a particular ionic 
remodeling process in hypertrophy/heart failure, myocardial ischemia, or atrial fibrillation 
with the corresponding deregulated miRNAs under that pathological condition; the changes 
of miRNAs appear to have anti-correlation with the changes of many of the genes encoding 
cardiac ion channels under these situations. These results indicate that multiple miRNAs 
might be critically involved in the electrical/ionic remodeling processes of cardiac diseases 
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through altering their expression in cardiac cells, which has not been uncovered by previous 
experimental studies.    
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Introduction 
Cardiac cells are excitable cells that can generate and propagate excitations; excitability is a 
fundamental characteristic of cardiac cells. Cardiac excitability is conferred by three basic 
elements: automaticity, cardiac conduction, and membrane repolarization. Automaticity is a 
measure of the ease of cells to generate excitations or spontaneous membrane 
depolarization. Conduction refers to the propagation of excitation within a cell and between 
cells, and cardiac conduction velocity is determined by the rate of membrane depolarization 
and the intercellular conductance. The rate of membrane repolarization determines the 
length of action potential duration (APD) and effective refractory period (ERP) thereby the 
timeframe of availability for generation of a next excitation in a cardiac cell. These three 
intrinsic properties are reflected by electrical activities in cardiac cells. The electrical 
activities of the heart are orchestrated by a matrix of ion channels and transporters, the 
transmembrane proteins that control the movement of ions across the cytoplasmic 
membrane of cardiomyocytes. Sodium (Na+) channels determine the rate of membrane 
depolarization and connexins (Cxs) are critical for gap junction communication, being 
responsible for excitation generation and inter-cell conductance of excitations, respectively. 
Calcium channels (mainly L-type Ca2+ channels) account for the characteristic long plateau 
phase of cardiac action potentials and excitation-contraction coupling, and also contribute 
to pacemaker activities. Potassium (K+) channels govern the membrane potential and rate 
of membrane repolarization. Pacemaker channels, which carry the non-selective cation 
currents, are essential in generating sinus rhythm and ectopic heart beats as well. Intricate 
interplays of all these ion channels maintain the normal heart rhythm thereby contraction. 
Channelopathies, diseases caused by dysfunction of the ion channels, which may result 
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from either genetic alterations in ion channel genes or aberrant expression of these genes, 
can render electrical disturbances predisposing to cardiac arrhythmias [1]. 
Evidence has emerged indicating the crucial role of microRNAs (miRNAs) in 
regulating expression of ion channel genes at the post-transcriptional level. The muscle-
specific miRNA miR-1 was shown to produce cardiac conduction disturbance in 
myocardial infarction [2] and in genetic knockout animal [3]; these studies opened up the 
new opportunity for studying the pathogenesis of miRNAs in the heart [4,5]. While the role 
of miRNAs in oncogenesis and cardiac development has been well appreciated over the 
past few years, the involvement of miRNAs in the pathological process of cardiovascular 
system has only been recognized very recently. It is now clear that in addition to their role 
in cardiac development [6–12], miRNAs are also critically involved in the pathological 
processes of adult hearts, including cardiac hypertrophy [13–19], heart failure [14,19], 
cardiomyopathy [20], angiogenesis [21] and arrhythmogenesis [2,22–26]. In addition to 
myocardial infarction, we have also demonstrated the participation of miRNAs in other 
pathological settings. miR-133, another muscle-specific miRNA, was shown to regulate 
pacemaker channel HCN2 and HCN4 and contributes to the re-expression  of these 
channels in hypertrophy heart [23]. This miRNA had also been shown to repress HERG K+ 
channel gene KCNH2 contributing to the abnormal QT prolongation in an animal model of 
diabetes mellitus [24]. Both miR-1 and miR-133 may be involved in the spatial patterns of 
tissue distribution of ion channels [25].  
An important message brought about by previous studies is that miRNA expression 
is dynamically regulated and altered miRNA expression can render expression deregulation 
of ion channel genes leading to channelopathies. Functional or mature miRNAs are around 
22-nucleotides in length. In order for a miRNA to elicit functional consequences, its 5’–end 
58 
 
 
7 to 8 nts must have exact or nearly perfect complementarity to the target mRNA, the so-
called ‘seed’ region, and partial complementarity with rest of its sequence [27–31]. A 
miRNA can either inhibit translation or induce degradation of its target mRNA or both, 
depending upon at least the following factors: (1) the overall degree of complementarity of 
the binding site, (2) the number of binding sites, and (3) the accessibility of the bindings 
sites (as determined by free energy states). The greater the complementarity of the 
accessible binding sites, the more likely a miRNA degrades its targeted mRNA, and those 
miRNAs that display imperfect sequence complementarities with target mRNAs primarily 
result in translational inhibition [27–31]. With better complementarity to the accessible 
binding sites, a miRNA could more likely degrades its targeted mRNA, and those miRNAs 
that display imperfect sequence complementarities with target mRNAs primarily result in 
translational inhibition. Greater actions may be elicited by a miRNA if it has more than one 
accessible binding site in its targeted miRNA, owing to the potential cooperative miRNA-
mRNA interactions from different sites. 
miRNAs are abundant non-coding mRNAs in terms of the species of miRNAs 
existing in a cell: to date, ~6400 vertebrates mature miRNAs have been registered in 
miRBase, an online repository for miRNA [32], among which ~5100 miRNAs are found in 
mammals which include 718 human miRNAs. These miRNAs are predicted to regulates 
~30% of protein–coding genes [33,34]. One common concern that somewhat subsides 
researchers’ inner confidence on the published experimental data on miRNA-target 
interactions with high-level skeptics and thus hinders our understanding of the function of 
miRNAs is the possibility that a single protein-coding gene may be regulated by multiple 
miRNAs and vice versa an individual miRNA has the potential to target multiple protein-
coding genes. For instance, in our previous study, miR-1 was shown to target GJA1 
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(encoding gap junction channel protein connexin43) and KCNJ2 (encoding the Kir2.1 K+ 
channel subunit) to cause slowing of cardiac conduction leading to ischemic 
arrhythmogenesis [2]. However, it is conceivable that GJA1 and KCNJ2 are not the only 
ion channel targets for miR-1; it is also able to repress other genes such as SCN5A, 
CACNA1C, KCND2, KCNA5 and KCNE1 [4] and whether the repression of these genes 
other than GJA1 and KCNJ2 also contributes to the ischemic arrhythmogenesis remained 
unclear. On the other hand, GJA1 is predicted to be regulated by other miRNAs in addition 
to miR-1 (including miR-101, miR-125, miR-130, miR-19, miR-23, and miR-30); whether 
these miRNAs are also involved in the deregulation of GJA1 in myocardial infarction 
remained unknown either. This same uncertainty or confusion expectedly exists in the 
interactions between literally all miRNAs and protein-coding genes. The only way to tackle 
this problem is the proper experimental approaches. 
However, given the laborious nature of experimental validation of targets and the 
limited available experimentally validated data, computational prediction programs remain 
the only source for rapid identification of a putative miRNA target in silico. While 
currently available experimental approaches do not allow for thorough elucidation of the 
complete set of target genes of a given miRNA or of the complete array of mRNAs that 
regulate a given protein-coding genes, appropriate theoretical analyses might aid to resolve 
this intricate problem. The present study aims to shed light on the issue by performing a 
rationally designed bioinformatics analysis in conjunction with experimental approaches to 
identify the miRNAs from the currently available miRNA databases which have the 
potential to regulate human cardiac ion channel genes and to validate the analysis with 
several pathological settings associated with the deregulated miRNAs and ion channel 
genes in the heart.     
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Materials and Methods 
Canine model of atrial fibrillation (AF) 
Mongrel dogs (22 to 28 kg) of either sex were randomly divided into two groups: sham 
control (Ctl, n=6) and atrial tachypacing (n=7) groups. For animals in the A-TP group, dogs 
were sedated and anesthetized with morphine (2 mg/kg SC) and α-chloralose (120 mg/kg 
IV load, 29.25 mg/kg/h infusion), for electrode implantation via the jugular veins and 
atrioventricular (AV) block was created with radiofrequency ablation. A programmable 
pacemaker was inserted in a subcutaneous pocket with sterile techniques, and a tined atrial 
pacing lead was positioned in the right atrial appendage under fluoroscopic guidance. The 
dogs were subjected to continuous right atrial pacing at 400 bpm for 56 days (8 weeks) 
before experimental studies. The control dogs were sham-operated in the same way as atrial 
tachypaced dogs but without tachypacing. On study days, dogs were anaesthetized with 
morphine and α-chloralose and ventilated to maintain physiological arterial blood gases. 
Body temperature was maintained at 37°C. A median sternotomy was performed, and 
bipolar, Teflon-coated, stainless steel electrodes were hooked into the right and left atrial 
appendages for recording and stimulation. A programmable stimulator was used to deliver 
2-ms pulses at twice-threshold current. The surface ECG and direct atrial activation 
electrograms were recorded.  
 AF vulnerability was tested at a basic cycle length (S1−S1 interval) of 300 ms, with 
single premature S2 extrastimuli delivered at each site by setting the coupling interval 
initially to 200 ms and decreasing by 10 ms decrements until AF was induced or failure to 
capture occurs. For the purpose of measuring AF duration, AF was induced by burst atrial 
pacing with 4x threshold 4-ms pulses at 20 Hz at a basic cycle length (BCL) of 300 ms. AF 
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was considered sustained if it required electrical cardioversion for termination 
(cardioversion was performed after 30 min AF). To estimate the mean duration of AF, AF 
was induced 10 times if AF duration was <5 min, 5 times for AF between 5 and 20 min and 
3 times for AF >20 min.  
 
Rat model of myocardial infarction (MI) 
Male Wistar rats (220-250 g) were randomly divided into control and MI groups. MI was 
established as previously described [2]. The rats were anesthetized with diethyl ether and 
placed in the supine position with the upper limbs taped to the table. A 1–1.5 cm incision 
was made along the left side of the sternum. The muscle layers of the chest wall were 
bluntly dissected to avoid bleeding. The thorax was cut open at the point of the most 
pronounced cardiac pulsation and the right side of the chest was pressed to push the heart 
out of the thoracic cavity. The left anterior descending (LAD) coronary artery was occluded 
and then the chest was closed back. All surgical procedures were performed under sterile 
conditions. Twelve hours after occlusion, the heart was removed for Langendorff perfusion 
experiments or the tissues within ischemic zone (IZ), boarder zone (BZ) and non-ischemic 
zone (NIZ) distal to the ischemic zone were dissected for measurement of miRNA levels. 
Control animals underwent open-chest procedures without coronary artery occlusion.  
 
Microarray analysis 
The hearts were then removed from the dogs or rats and total RNA samples were extracted 
with Ambion’s mirVana miRNA Isolation Kit for miRNA expression analysis. The RNA 
samples were also isolated from left ventricular walls of healthy human hearts. miRNA 
expression profiles were analyzed using the miRNA microarray technology miRCURY™ 
LNA Array (Exiqon Company, Denmark). miRCURY™ LNA Array, including 718 mature 
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human miRNAs plus 650 mature rodent miRNAs,  incorporates Locked Nucleic Acid into 
an oligonucleotide probe, which greatly increases the affinity and specificity of that 
oligonucleotide for its complementary DNA or RNA target. Slides were scanned by the 
Genepix 4000B at 635 nm and the expression level was analyzed by Genepix Pro 6.0. The 
array output was received in Excel spreadsheets as lists of raw data and also as “simple 
detectable” data, which were the average of 4 signal values for each miRNA on the array. 
Differentially regulated miRNAs were defined as those with either <0.5- or >2-fold 
changes in expression for both arrays compared with the baseline expression levels from 
sham-operated dogs.  
 
Quantitative real-time RT-PCR analysis  
The mirVana™ qRT-PCR miRNA Detection Kit (Ambion) was used in conjunction with 
real-time PCR with TaqMan for quantification of miRNAs in our study, as previously 
described in detail [2,22,23].  qRT-PCR was performed on a thermocycler ABI Prism® 
7500 fast (Applied Biosystems) for 40 cycles. Fold variations in expression of an mRNA 
between RNA samples were calculated. The threshold cycle (CT) is defined as the 
fractional cycle number at which the fluorescence passes the fixed threshold. To estimate 
copy numbers of transcript in a cardiac cells, a standard curve was generated by using a 
series of concentrations of synthetic miR-1 and converting TaqMan CT values into absolute 
copy numbers using the standard curve assuming 30 pg of total RNA in each cell [35,36]. 
 
Computational prediction of miRNA target 
We used the miRecords miRNA database and target-prediction website for our initial 
analysis. The miRecords is resource for animal miRNA-target interactions developed at the 
University of Minnesota [37]. The miRecords consists of two separate databases. The 
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Validated Targets database contains the experimentally validated miRNA targets being 
updated from meticulous literature curation. The Predicted Targets database of miRecords 
is an integration of predicted miRNA targets produced by 11 established miRNA target 
prediction programs. These algorithms include DIANA-microT, MicroInspector, miRanda, 
MirTarget2, miTarget, NBmiRTar, PicTar, PITA, RNA22, RNAhybrid, and 
TargetScan/TargetScanS. 
 
Results and Discussion 
Initial analysis of miRNAs with the potential to regulate cardiac ion channel genes 
Our study was focused on the genes encoding cardiac cytoplasmic ion channels and 
electrogenic ion transporters (Table 1). The list includes Na+ channel, Ca2+ channel, inward 
rectifier K+ channel subunits, voltage-gated K+ channel pore-forming α-subunits, ACh-
activated K+ channel α-subunits, ATP-sensitive K+ channel α-subunit and receptor subunit, 
pacemaker hyperpolarization-activated cyclic-nucleotide gated cation channels, gap 
junction channel proteins, transient receptor potential channel subunits, chloride channel 
subunits, K+ channel β-subunits, Na+/Ca2+ exchanger NCX1, and Na+/K+-ATPase. These 
cytoplasmic ion channels and electrogenic ion transporters play the fundamental roles in 
generating, maintaining and shaping cardiac electrical activities (Table 1). Dysfunction of 
these proteins has been associated with a variety of pathological conditions of the heart.    
As an initial “screening” process, we performed miRNA target prediction through 
the miRecords database [37]. This miRNA database integrates miRNA target predictions by 
11 algorithms, as detailed in Methods section. Four of the 11 algorithms (microInspector, 
miTarget, NBmiRTar, and RNA22) were removed from our data analysis because they 
failed to predict; these websites require manual input of 3’UTR sequences of the genes. 
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Thus, our data analysis was based upon the prediction from seven algorithms (TargetScan, 
DIANA-miT3.0, miRanda, PicTar, PITA, RNAHybrid, and miRTarget2) [38-44]. These 
prediction techniques are based on algorithms with different parameters (such as miRNA 
seed:mRNA 3’UTR complementarity, thermodynamic stability of base-pairing (assessed by 
free energy), evolutionary conservation across orthologous 3’UTRs in multiple species, 
structural accessibility of the binding sites, nucleotide composition beyond the seed 
sequence, number of binding sites in 3’UTR, and anti-correlation between miRNAs and 
their target mRNAs) and each of them are expected to provide a unique dataset. Some of 
them have higher sensitivity of prediction but low accuracy and the other weight on the 
accuracy in the face of reduced sensitivity. We collected all miRNAs predicted by at least 
four of the seven algorithms to have the potential to target any one of the selected cardiac 
ion channel and ion transporter genes. Meanwhile, we also collected all ion channel and ion 
transporter genes that contain the potential target site(s) (the binding site(s) with favorable 
free energy profiles) for at least one of the 718 human miRNAs. From the above two 
datasets, we noticed two points. First, out of 718 mature human miRNAs registered in 
miRBase, 429 miRNAs find their potential target site(s) in the 3’UTR(s) of at least one of 
the genes encoding cardiac ion channels and ion transporters. Second, all of the genes 
encoding cardiac ion channels and ion transporters selected for analysis, except for CLCN2, 
are the potential targets for miRNA regulation. 
 
miRNA expression profiling in human cardiac tissue 
Expression of miRNAs in mammalian species under normal conditions is genetically 
programmed with certain spatial (depending on cell-, tissue-, or organ-type) and temporal 
(depending on developmental stage) patterns. This property generates the so-called 
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expression signature of a particular tissue. One approach to decrease the incidence of false 
positive predictions and to narrow down the list of putative miRNA targets would be to 
compare these in silico target predictions to the miRNA transcriptome signatures in the 
biological system of interest. We therefore conducted miRNA microarray analysis of 
miRNAs including all 718 human miRNAs for their expression in left ventricular tissues of 
five healthy human individuals. We found 220 out of 718 human miRNAs being expressed 
in the cardiac tissue (Supplementary Table 1S).  
According to the results reported by Liang et al for human heart [35], the top 20 
abundant miRNAs in human heart are miR-1, miR-133a/b, miR-16, miR-100, miR-125a/b, 
miR-126, miR-145, miR-195, miR-199*, miR-20a/b, miR-21, miR-26a/b, miR-24, miR-23, 
miR-29a/b, miR-27a/b, miR-30a/b/c, miR-92a/b, miR-99, and let-7a/c/f/g (Fig. 1A). We 
verified the expression abundance of several selected miRNAs (miR-1, miR-133a/b, miR-
125a/b, miR-30a/b/c, miR-26a/b, miR-24, miR-27a/b, miR-23, miR-29a/b, miR-101, miR-21, 
miR-150 and miR-328) using RNA samples isolated from left ventricular tissues of healthy 
human subjects (Supplementary Fig. S1). A recent study by Rao et al [45] reported a 
similar array of abundant miRNAs in mouse heart. But differences between the two species 
exist: e.g. miR-1 constitutes ~40% of total miRNA content in mouse, but in human, it is 
ranked the 2nd most abundant miRNA around 1/3 of the miR-133 level; miR-208 was found 
to be one of the top 20 abundant miRNA in mouse but not in human; and miR-22, miR-143, 
miR-499 and miR-451 were considered the most abundant miRNAs in mouse heart but not 
in human heart. Our analysis was focused on the miRNA transcriptome in human heart. 
We considered the miRNAs with the same seed sequence as one single miRNA for 
these miRNAs expectedly have the same set of target genes. This consideration might 
change the relative abundance of miRNAs. For instance, miR-1 was found more abundant 
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than each of the miR-30 or miR-26 isoforms; but was considered less abundant than these 
latter two miRNAs when the seed family was taken as one miRNA, ranked top 4 after miR-
30a/b/c (top 2) and miR-26a/b (top 3). 
 
Detailed analysis of the miRNAs with the potential to regulate cardiac ion channel 
genes 
Using this cardiac miRNA expression profiling data in conjunction with published data 
obtained by real-time RT-PCR by Liang et al [35], we refined the miRNA–target prediction 
by filtering out the miRNAs that are not expressed in the heart. In this way, we generated 
the modified datasets for subsequent analyses (Supplementary Table S2 & Table S3). 
Detailed analysis of these two datasets revealed the following notes.  
(1) One hundred ninety-three out of 718 registered human miRNAs or out of 222 
miRNAs expressed in the heart have the potential to target the genes encoding human 
cardiac ion channels and transporters.  
(2) Only two genes CLCN2 and KCNE2 were predicted not to contain the target site 
for miRNAs expressed in the heart.  
(3) It appears that the most fundamental and critical ion channels governing cardiac 
excitability have the largest numbers of miRNAs for their regulators. These include 
SCN5A for INa (responsible for the upstroke of the cardiac action potential thereby the 
conduction of excitations), CACNA1C/CACNB2 for ICa,L (accounting for the characteristic 
long plateau of the cardiac action  potential and excitation-contraction coupling), KCNJ2 
for IK1 (sets and maintains the cardiac membrane potential), SLC8A1 for NCX1 (an 
antiporter membrane protein which removes Ca2+ from cells), GJA1/GJC1 (gap junction 
channel responsible for intercellular conduction of excitation), and ATP1B1 for Na+/K+ 
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pump (establishing and maintaining the normal electrochemical gradients of Na+ and K+ 
across the plasma membrane). Each of these genes is theoretically regulated by >30 
miRNAs.  
(4) The atrium-specific ion channels, including Kir3.4 for IKACh, Kv1.5 for IKur, and 
CACNA1G for ICa,T, seem to be the rare targets for miRNAs (<5 miRNAs).   
(5) All four genes for K+ channel auxiliary β-subunits KCNE1, KCNE2, KCHiP, 
and KCNAB2 were also found to have less number of regulator miRNAs (<10).   
(6) Intriguingly, 16 of these top 20 miRNAs are included in the list of the predicted 
miRNA-target dataset; the other four cardiac-abundant miRNAs miR-21, miR-99, miR-100 
and miR-126 are predicted unable to regulate the genes for human cardiac ion channels and 
transporters.      
(7) There is a rough correlation between the number of predicted targets and the 
abundance of miRNAs in the heart. It appears that the miRNAs within top 8 separate from 
the rest 12 less abundant miRNAs in their number of target genes (Fig. 1B). The muscle-
specific miRNA miR-1 was predicted to have the largest number of target genes (9 genes) 
among all miRNAs most abundantly expressed in the heart, followed by miR-30a/b/c, miR-
24 and miR-125a/b that have 6 target genes each. The muscle-specific miRNA miR-133 has 
four target genes and three of them (KCNH2, KCNQ1 and HCN2) have been 
experimentally verified [22-25]. 
(8) Comparison of the target genes of the three muscle-specific miRNAs miR-1, 
miR-133 and miR-208 revealed that they might play different role in regulating cardiac 
excitability. It appears that miR-1 may be involved in all different aspects of cardiac 
excitability: cardiac conduction by targeting GJA1 and KCNJ2, cardiac automaticity by 
targeting HCN2 and HCN4, cardiac repolarization by targeting KCNA5, KCND2 and 
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KCNE1, and Ca2+ handling by targeting SLC8A1. By comparison, miR-133a/b mainly 
controls cardiac repolarization through targeting KCNH2 (encoding HERG/IKr) and 
KCNQ1 (encoding KvLQT1/IKs), the two major repolarizing K+ channels in the heart. miR-
208 was predicted to target only KCNJ2 (encoding Kir2.1 for IK1). The non-muscle-specific 
let-7 seed family members seem to regulate mainly cardiac conduction by targeting SCN5A 
(Nav1.5 for intracellular conduction) and GJC1 (Cx45 for intercellular conduction). miR-
30a/b/c and miR-26a/b, miR-125a/b, miR-16, and miR-27a/b were predicted to be L-type 
Ca2+ channel “blockers” through repressing α1c- and/or β1/β2-subunits (Fig. 2).   
 
Application of the theoretical analysis to explaining the electrical remodeling 
processes of cardiac diseases 
Next, we intended to apply the theoretical prediction to explaining some established 
observations of the electrical remodeling related to deregulation of both miRNAs and the 
genes for ion channels and transporters. Three pathological conditions, cardiac 
hypertrophy/heart failure, ischemic myocardial injuries, and atrial fibrillation, were studied 
because the participation of miRNAs in these conditions has previously been investigated.   
Cardiac hypertrophy and heart failure 
The adult heart is susceptible to stress (such as hemodynamic alterations associated with 
myocardial infarction, hypertension, aortic stenosis, valvular dysfunction, etc) by 
undergoing remodeling process, including electrical/ionic remodeling. The remodeling 
process may originally be adaptive in nature, but is in the face of increased risk of 
arrhythmogenesis. The mechanisms for arrhythmogenesis in failing heart involve [46]: (1) 
Abnormalities in spontaneous pacemaking function (enhanced cardiac automaticity) as a 
result of increases in atrial and ventricular If due to increased expression of HCN4 channel 
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may contribute to ectopic beat formation in CHF; (2) Slowing of cardiac repolarization 
thereby prolongation of APD due to reductions of repolarizing K+ currents (including IK1, 
IKs, and Ito1) provides the condition for occurrence of early afterdepolarizations (EADs) 
leading to triggered activities; (3) Delayed afterdepolarizations (DADs) due to enhanced 
Na+-Ca2+ exchanger (NCX1) activity in cardiac hypertrophy/CHF is a consistent finding by 
numerous studies. Upregulation of NCX1 expression is the major cause for the 
enhancement; (4) Reentrant activity due to slowing of cardiac conduction velocity. 
To date, there have been seven published studies on role of miRNAs and cardiac 
hypertrophy [13-19]. The common finding of these studies is that an array of miRNAs is 
significantly altered in their expression, either up- or down-regulated, and that single 
miRNAs can critically determine the generation and progression of cardiac hypertrophy. 
The most consistent changes reported by these studies are up-regulation of miR-21 (6 of 6 
studies), miR-23a (4 of 6), miR-125b (5 of 6), miR-214 (4 of 6), miR-24 (3 of 6), miR-29 (3 
of 6) and miR-195 (3 of 6),  and down-regulation of miR-1, miR-133, miR-150 (5 of 6 
studies) and miR-30 (5 of 6). These miRNAs were therefore included in our analysis of 
target genes encoding ion channel and transporter proteins, as shown in Figure 3. Our 
analyses suggest the following.    
(1) It is known that cardiac myocytes are characterized with re-expression of the funny 
current (or pacemaker current) If that may underlie the increased risk of arrhythmogenesis 
in hypertrophic and failing heart [23], which is carried by HCN2 channel in cardiac 
muscles. We have previously verified that downregulation of miR-1 and miR-133 caused 
upregulation of HCN2 in cardiac hypertrophy [23]. This may contribute to the enhanced 
abnormal cardiac automaticity and the associated arrhythmias in CHF.  
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(2) The NCX1 is upregulated in cardiac hypertrophy, ischemia, and failure. This 
upregulation can have an effect on Ca2+ transients and possibly contribute to diastolic 
dysfunction and an increased risk of arrhythmias [46, 47-51]. Our target prediction 
indicates that SLC8A1, the gene encoding NXC1 protein, is a potential target for both miR-
1 and miR-30a/b/c. The downregulation of miR-1 and miR-30a/b/c in hypertrophy/failure is 
deemed to relieve the repression of SLC8A1/NCX1 since a strong tonic repression miR-1 
and miR-30a/b/c is anticipated considering the high abundance of these miRNAs. On the 
other hand, upregulation of miR-214 tends to repress NCX1, but the expression level of 
miR-214 is of no comparison with those of miR-1 and miR-30a/b/c; its offsetting effect 
should be minimal. Our prediction thus provides a plausible explanation for the 
upregulation of NCX1 through the miRNA mechanism. 
(3) A variety of Na+ channel abnormalities have been demonstrated in heart failure. 
Several studies suggest that peak INa is reduced which can cause slowing of cardiac 
conduction and promote re-entrant arrhythmias [52-55]. It has been speculated that post-
transcriptional reduction of the cardiac INa α-subunit protein Nav1.5 may account for the 
reduction of peak INa [55]. In this study, we found that the only miRNA that can target 
Nav1.5 and is upregulated in cardiac hypertrophy/CHF is miR-125a/b. As an abundantly 
expressed miRNA, upregulation of miR-125a/b could well result in repression of 
SCN5A/Nav1.5.  
(4) The gap junction channel proteins connexin43, connexin45 and connexin40 are 
important for cell-to-cell propagation of excitations. Downregulation of connexin43 
expression is associated with an increased likelihood of ventricular tachyarrhythmias in 
heart failure [56]. Other connexins, including connexin45 [57] and connexin40 [58], are 
upregulated in failing hearts, possibly as a compensation for connexin43 downregulation. 
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Our analysis indicates that the upregulation of miR-125a/b and miR-23a/b should produce 
repression of connexin43 and connexin45 and the down regulation of miR-1, miR-30a/b/c 
and miR-150 should do the opposite. These two opposing effects may cancel out each other.    
(5) Prolongation of ventricular APD is typical of heart failure to enable the 
improvement of contraction strength, thereby supporting the weakened heart. However, 
APD prolongation consequent to decreases in several repolarizing K+ current (Ito1, IKs, and 
IK1) in failing heart often results in occurrence of early afterdepolarizations (EADs) [59-64]. 
Our prediction failed to provide any explanation at the miRNA level: None of the 
upregulated miRNAs may regulate the genes encoding repolarizing K+ channels. On the 
contrary, downregulation of miR-1 and miR-133 predict upregulation of KCNE1/minK and 
KCNQ1/KvLQT1, respectively.  
(6) A majority of published studies showed a decrease in IK1 in ventricular myocytes of 
failing hearts [46, 61-64]. But whether KCNJ2/Kir2.1, the major subunit underlying IK1, is 
downregulated remained controversial in previous studies and the mechanisms remained 
obscured. One study noted decreased KCNJ2 mRNA expression but unaltered Kir2.1 
protein level [64]. With our prediction, the upregulated miRNAs (miR-125, miR-214, miR-
24, miR-29, and miR-195) predict reduction of inward rectifier K+ channel subunits 
including KCNJ2/Kir2.1, KCNJ12/Kir2.2, KCNJ14/Kir2.4, and KCNK1/TWIK1, whereas 
the downregulated miRNAs (miR-1 and miR-30a/b/c) predict increase in KCNJ2/Kir2.1. 
In summary, our analysis of target genes for deregulated miRNAs in 
hypertrophy/CHF may explain at least partly the enhanced cardiac automaticity (relief of 
HCN2 repression and increased NCX1 expression) and reduced cardiac conduction 
(repression of Nav1.5). But the data suggest that miRNAs are hardly involved in the 
abnormality of cardiac repolarization in cardiac hypertrophy and heart failure since the 
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genes for the repolarizing K+ channels were not predicted as targets for the upregulated 
miRNAs. The prediction of NCX1 upregulation as a result of derepression from miRNAs 
may be of particular importance aberrantly enhanced NXC1 activity has also been noticed 
in atrial fibrillation occurring in CHF.  
Myocardial infarction (MI) 
MI, a typical situation of metabolic stress, is presented as cascades of cellular abnormalities 
as a result of deleterious alterations of gene expression outweighing adaptive changes 
[65,66]. MI can cause severe cardiac injuries and the consequences are contraction failure, 
electrical abnormalities and even lethal arrhythmias, and eventual death of the cell. 
Ischemic myocardium demonstrates characteristic sequential alterations in 
electrophysiology with an initial shortening of APD and QT interval during the early phase 
(<15min) of acute ischemia and subsequent lengthening of APD/QT after a prolonged 
ischemic period and chronic myocardial ischemia [46,65,66]. While these alterations may 
be adaptive to the altered metabolic status, they occur at the cost of arrhythmogenesis 
consequent to ischemic ionic remodelling. To exploit if miRNAs could be involved in the 
remodelling process, several original studies have been published. We first identified 
upregulation of miR-1 in acute myocardial infarction and the ischemic arrhythmias caused 
by this deregulation of miR-1 expression [2]. Similar ischemic miR-1 upregulation was 
reproduced by another two groups [67,68]. Subsequently, miRNA expression profiles in the 
setting of myocardial ischemia/reperfusion injuries were reported by three groups [69-71]. 
Here we also present the miRNA transcriptome in a rat model of acute myocardial 
infarction (Supplementary Fig. S2).  
 Extracting of the overlapping results from different laboratories and filtering with 
the cardiac expression profile verified by real-time RT-PCR in human hearts allowed us to 
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identify an array of miRNAs that are likely deregulated in the setting of myocardial 
ischemia. The upregulated miRNAs include miR-1, miR-23, miR-29, miR-20, miR-30, miR-
146b-5p, miR-193, miR-378, miR-181, miR-491-3p, miR-106, miR-199b-5p, and let-7f; the 
downregulated miRNAs include miR-320, miR-185, miR-324-3p, and miR-214 (Fig. 4). 
This analysis excluded some miRNAs that were found deregulated by a study but not by 
others and that were found deregulated in rat heart but was not expressed in human heart. 
Interesting to note is that some of the miRNAs demonstrated the opposite directions of 
changes in their expression between ischemic myocardium and hypertrophic hearts. For 
example, miR-1, let-7, miR-181b, miR-29a and miR-30a/e are upregulated in ischemic 
myocardium, but downregulated in hypertrophy. Similarly, miR-214, miR-320 and miR-351 
are down-regulated in ischemic myocardium, but up-regulated in hypertrophy (Fig. 3). This 
fact further reinforces the notion that different pathological conditions have different 
expression profiles. Our analysis yielded the following notions. 
(1) Six upregulated miRNAs (miR-1, miR-29, miR-20, miR-30, miR-193 and miR-181) 
were predicted to target several Kir subunits (KCNJ2, KCNJ12, KCNJ, and KCNK1), but 
none of the downregulated miRNAs can target these genes (Fig. 4). This is in line with the 
previous finding that IK1 is reduced and membrane is depolarized in ischemic myocardium 
[2,65,66].  
(2) The cardiac slow delayed rectifier K+ current (IKs) is carried by co-assembly of an 
α-subunit KvLQT1 (encoded by KCNQ1) and a β-subunit mink (encoded by KCNE1) 
[72,73]. Loss-of-function mutation of either KCNQ1 or KCNE1 can cause long QT 
syndromes, indicating the importance of IKs in cardiac repolarization. In ischemic 
myocardium, persistent decreases in minK with normalized KvLQT1 protein expression 
have been observed which may underlie unusual delayed rectifier currents with very rapid 
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activation [73,74], resembling currents produced by the expression of KvLQT1 in the 
absence of minK [72,73]. We have experimentally established KCNE1 as a target for miR-1 
repression [25], which was also predicted in the present analysis. Moreover, no other 
miRNAs were predicted to target KCNQ1. This finding is coincident with the observations 
on the diminishment of minK alone without changes of KvLQT1 in ischemic myocardium. 
(3) It has been observed that cells in the surviving peri-infarct zone have discontinuous 
propagation due to abnormal cell-to-cell coupling [76-78]. This is largely due to decreased 
expression and redistribution of gap junction protein connexins (Cxs). In this study, seven 
out of 12 upregulated miRNAs were predicted to target Cxs including GJA1/Cx43, 
GJC1/Cx45, and GJA5/Cx40, but only one downregulated miRNA miR-185 may regulate 
GJA5/Cx40 (Fig. 5). This result clearly points to the role of miRNAs in damaging cardiac 
conduction in ischemic myocardium. Indeed, repression of GJA1/Cx43 to slow conduction 
and induce arrhythmias in acute myocardial infarction has been experimentally verified by 
our previous study [2]. 
(4) In ischemic myocardium, fast or peak INa density is reduced, which may also 
account partly for the conduction slowing and the associated re-entrant arrhythmias [79-81]. 
Our analysis showed that let-7f and miR-378 may target SCN5A/Nav1.5 and upregulation 
of these miRNAs is anticipated to cause reduction of INa via downregulating 
SCN5A/Nav1.5 in myocardial infarction. By comparison, none of the downregulated 
miRNAs may repress SCN5A/Nav1.5 based on our target prediction.    
(5) Ito1 is reduced in myocardial ischemia and in rats, Ito1 decreases correlate most 
closely with downregulation of KCND2-encoded Kv4.2 subunits [82,83]. miR-1 is 
predicted to repress KCND2/Kv4.2, and miR-29 may target KCHiP2 that is known to be 
critical in the formation of Ito1.  
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(6) ICa,L is diminished in border-zone cells of dogs [46,84,85]. miR-30 family has the 
potential to target CACNA1C/Cav1.2 and CACNB2/Cavβ2, and miR-124, miR-181, miR-
320 and miR-204 to target CACNB2. Upregulation of miR-30, miR-124 and miR-181 
therefore would decrease CACNA1C/Cav1.2 and CACNB2/Cavβ2 expression, but 
downregulation of miR-320 and miR-204 tends to increase the expression of these genes. 
Considering the relative abundance of these miRNAs, it seems that the decreasing force 
overweighs the increasing force with a balance towards a net inhibition of ICa,L. 
(7) Na+/K+ ATPase is a sarcolemmal ATP-dependent enzyme transporter that transports 
three intracellular Na+ ions to the extracellular compartment and moves two extracellular 
K+ ions into the cell to maintain the physiological Na+ and K+ concentration gradients for 
generating the rapid upstroke of the action potential but also for driving a number of ion-
exchange and transport processes crucial for normal cellular function, ion homeostasis and 
the control of cell volume.  It is electrogenic, producing a small outward current IP [86].  
We noticed that the ischemia-induced upregulation of miR-29 and miR181 expression 
might render inhibition of Na+/K+ ATPase activity as they possibly target the ATP1B1 β-
subunit of the enzyme. This may contribute to the electrical and contractile dysfunction in 
the ischemic/reperfused myocardium due to the ischemia-induced inhibition of the Na+/K+ 
ATPase and the failure of intracellular Na+ to recover completely on reperfusion [87]. 
In a whole, it appears that the expression signature of miRNAs in the setting of 
myocardial ischemia and the predicted gene targeting of these miRNAs coincide with the 
ionic remodelling process under this pathological condition (Fig. 4). The miRNAs seem to 
be involved in all aspects of the abnormalities of cardiac excitability during ischemia, as 
manifested by the slowing of cardiac conduction due to reduced INa and Cx43, the 
depolarized membrane potential to adversely affect cardiac conduction due to reduced IK1, 
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the impaired excitation-contraction coupling and contractile function due to reduced ICa,L 
and Na+/K+ ATPase, and the delayed cardiac repolarization due to reduced IKs and Ito1. 
Atrial fibrillation (AF) 
AF is the most commonly encountered clinical arrhythmia that causes tremendous health 
problems by increasing the risk of stroke and exacerbating heart failure. It is characterized 
by a process termed atrial electrical remodeling: the rapid atrial activation rate during AF 
can remodel the atrial electrophysiology to promote the recurrence and maintenance of AF 
[46,88]. A prominent finding in atrial electrical remodeling is shortening of atrial effective 
refractory period (ERP) favoring re-entrant arrhythmias, primarily because of the 
shortening of atrial APD as a result of two critical changes. The first change is the 
reduction of L-type Ca2+ current (ICaL) that serves to shorten the plateau duration. And the 
second change is the increase in inward rectifier K+ current IK1, which underlies the 
shortening of the terminal phase [89-91]. Whereas it is known that the expression of the 
genes for these channels is deregulated during AF, the precise molecular mechanisms 
remained unclear. Additionally, expression of other ion channels such as KCND3 
(encoding Kv4.3 for Ito1) and KCNA5 (encoding Kv1.5 for IKur) has been consistently 
found downregulated in AF, though the role of the changes in AF is yet to be elucidated 
[89-91]. The present analysis, however, aids us to get some insight into the issue.  
We first conducted expression profiling to identify deregulated miRNAs in the atrial 
tissues of a canine model of tachypacing-induce AF, using miRNA microarray analysis 
comparing the differential expressions of miRNAs between control and AF dogs. Four 
miRNAs miR-223, miR-328, miR-664 and miR-517 were found increased by >2 folds, and 
six were decreased by at least 50% including miR-101, miR-133, miR-145, miR-320, miR-
373 and miR-499. Real-time quantitative RT-PCR (qRT-PCR) analysis confirmed the 
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significant upregulation of miR-223, miR-328 and miR-664 (miR-517 was undetectable), 
and the significant downregulation of miR-101, miR-320, and miR-499 (Fig. 5). Our 
subsequent analysis was therefore based on the deregulated miRNAs verified by qPCR. 
(1) Our prediction indicates that three miRNA miR-328, miR-145 and miR-320 have the 
potential to repress both the α1c- and β2-subunits of cardiac L-type Ca2+ channel genes, 
CACNA1C and CACNB2, respectively. While increased miR-328 level should upregulate 
L-type Ca2+ channel expression, decreased miR-145 and miR-320 levels should 
downregulate it. In reality, these two opposing actions may offset each other.  
(2) Among the deregulated miRNAs, the only miRNA that may target KCND3 is miR-
328. Hence, upregulation of miR-328 predicts downregulation of Kv4.3 thereby reduction 
of Ito1 in AF. 
(3) Increase in IK1 is a hallmark of atrial electrical remodeling in AF. miR-101 was 
predicted to target KCNJ2/Kir2.1 and downregulation of this miRNA should upregulate 
KCNJ2/Kir2.1 due to a relief of repression. Repression of KCNJ12/Kir2.2 due to miR-328 
upregulation may be canceled out by a derepression upon miR-145 downregulation.  
(4) Impulse initiation by automaticity and triggered activity as well as impulse initiation 
resulting from reentry in AF has been suggested [92]. The hyperpolarization activated 
cation current or funny current If is a candidate for contributing to abnormal automaticity 
[93]. The downregulation of miR-133 in AF predicts enhancement of If through 
derepression of HCN2 to induce abnormal cardiac automaticity.  
(5) Our data did not predict involvement of miRNAs in the alterations of the genes for 
IKur, IKr and IKs.  
Taken together, it appears that the miRNA expression signature identified in a 
canine model of tachypacing-induced AF is related to the atrial ionic remodelling process. 
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Specifically, downregulation of miR-101 and miR-133 may contribute to enhanced IK1 and 
If, respectively, and upregulation of miR-328 may underlie the reduction of Ito1, in AF. 
Whether this upregulation also contributes to the reduction of ICa,L need to be examined 
experimentally. The characteristic decrease of IKur in AF is unlikely related to miRNA 
deregulation.  
Cardiovascular diseases remain the major cause of mortality and morbidity in 
developed countries. Most of the cardiac deaths are sudden, occurring secondary to 
ventricular arrhythmias, the electrical disturbances that can result in irregular cardiac 
contraction. Abnormally altered cardiac excitability suggests that for arrhythmias to arise, 
the normal matrix of ion channels and transporters must be perturbed by arrhythmogenic 
substrates to produce a proarrhythmic conditions to permit rhythmic disturbances caused by 
impaired excitation conduction/propagation, enhanced automaticity, or abnormal 
repolarization. In some cases, abnormalities of these ion channels, channelopathies, can be 
attributed to mutations in the genes encoding the channel proteins, which can predispose to 
arrhythmias. In other cases, malfunction of ion channels can also be ascribed to abnormally 
altered expression. The present study aims to acquire an overall picture about the potential 
expression regulation of ion channel and transporter genes by miRNAs and the possible 
implications of this regulatory mechanism. The theoretical analysis in conjunction with 
experimental demonstration of miRNA expression profiles under various conditions 
performed in this study allowed us to establish a matrix of miRNAs that are expressed in 
cardiac cells and have the potential to regulate the genes encoding cardiac ion channels and 
transporters. These miRNAs likely play an important role in controlling cardiac excitability 
and keeping the normal electrical activities of the heart. In other words, the ion channel 
genes may normally be under the post-transcriptional regulation of a group of miRNAs in 
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addition to the muscle-specific miRNAs miR-1 and miR-133 as already demonstrated 
experimentally. Also were we able to link a particular ionic remodeling process in 
hypertrophy/heart failure, myocardial ischemia, or atrial fibrillation to the corresponding 
deregulated miRNAs under that pathological condition; the changes of miRNAs appear to 
have anti-correlation with the changes of many of the genes encoding cardiac ion channels 
under these situations. Intriguingly, the miRNA targeting under three different conditions 
clearly demonstrated three different patterns with that in hypertrophy/CHF showing 
balanced repression and derepression, in MI showing repression overweighing derepression, 
and in AF showing the opposite: derepression overweighing repression. Another important 
notion revealed by this study is that though we have elucidated role of miR-1 and miR-133 
in controlling cardiac excitability and the associated arrhythmogenesis in the above-
mentioned three pathological conditions, it is now clearly that other miRNAs that are 
deregulated are also likely involved in these processes. In reality, it is conceivable that the 
electrical/ionic remodeling processes under various conditions are caused by many 
miRNAs in addition to other regulatory molecules.  The present study should aid us to 
pinpoint the individual miRNAs that can most likely take part in the remodeling processes 
through targeting particular genes.  
It should be noted, however, that the present computational study is in no way to 
replace experimental approaches for understanding the role of miRNAs in regulating 
expression of genes for cardiac ion channels and transporters; rather it merely presents a 
prediction of the odds of miRNA:mRNA interactions under normal situation and in the 
context of electrical/ionic remodeling under the selected circumstances of the heart. This 
theoretical analysis like all other computational studies needs to be eventually verified with 
the bench-top work and should not be considered original results. Nonetheless, with sparse 
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experimental data published to date and the anticipated difficulties to acquire complete 
experimental data using the currently available techniques, this study can well serve as 
first-hand information, providing a framework and guideline for future experimental studies. 
The second limitation of the study is the possibility of underestimating the number of ion 
channel-regulator miRNAs because of the stringent criterion for inclusion of miRNAs with 
positive prediction of targets by at least four out of 11 algorithms; in the past, we had been 
able to experimentally verified nearly all the target genes predicted by only one algorithm 
miRanda for our pre-experiment analysis. However, the fact that our prediction includes all 
20 most abundant miRNAs and other highly expressed miRNAs in the myocardium 
suggests that this limitation might not have significant negative impact on the accuracy of 
our analysis and inclusion of more miRNAs by more permissive criteria does not guarantee 
their physiological function if they are scarcely expressed in the heart. Yet it should be 
noted that the miRNA expression profiles were obtained from myocardium that also 
includes fibroblasts and caution needs to be taken when interpreting the expression data. 
Another important notion is that despite that our prediction of miRNA targeting coincides 
with the changes of ion channel expression under the pathological conditions, it does not 
imply that miRNAs are necessarily the important or even the only determinant of the 
electrical remodeling processes. Our data to the most indicate the potential contribution of 
miRNAs to such conditions; other molecules like transcription factors must also be 
involved in the regulation of expression of ion channel genes under these conditions. 
Finally, it is also difficult to predict the net outcome when two miRNAs target a same gene 
but alter in their expression in the opposite directions. Yet, with deepened and broadened 
understanding of miRNA targeting and action, these above limitations should eventually be 
worked out.      
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Figure Legends 
Figure 1. miRNA expression signature in the heart. (A) Relative levels of the top 20 most 
abundantly expressed miRNAs in myocardium. (B) Number of predicted target 
genes of the top 20 most abundantly expressed miRNAs in myocardium. Note that 
miR-126, miR-21, miR-99 and miR-100 are not predicted to target any genes 
encoding cardiac ion channels and transporters. 
Figure 2. Predicted gene targeting of the top 20 most abundantly expressed miRNAs in 
myocardium. The arrows indicate repression of the genes by the connected miRNAs. 
The target genes are roughly divided into groups in three different colors: the genes 
for cardiac conduction in blue, the genes for cardiac automaticity in green, and the 
genes for cardiac repolarization in yellow.    
Figure 3. Predicted gene targeting of the miRNAs deregulated in their expression in 
cardiac hypertrophy and congestive heart failure (CHF). The arrows in red indicate 
repression of the genes by the upregulated miRNAs (top row in blue) and those in 
blue indicate derepression of the genes by the downregulated miRNAs (bottom row 
in yellow). The target genes are roughly divided into groups in three different colors: 
the genes for cardiac conduction in blue, the genes for cardiac automaticity in green, 
and the genes for cardiac repolarization in yellow. 
Figure 4. Predicted gene targeting of the miRNAs deregulated in their expression in 
ischemic myocardial injuries. The arrows in red indicate repression of the genes by 
the upregulated miRNAs (top rows in blue) and those in blue indicate derepression 
of the genes by the downregulated miRNAs (bottom row in yellow). The target 
genes are roughly divided into groups in three different colors: the genes for cardiac 
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conduction in blue, the genes for cardiac automaticity in green, and the genes for 
cardiac repolarization in yellow. 
Figure 5. Predicted gene targeting of the miRNAs deregulated in their expression in 
experimental atrial fibrillation. The arrows in red indicate repression of the genes by 
the upregulated miRNAs (top row in blue) and those in blue indicate derepression 
of the genes by the downregulated miRNAs (bottom row in yellow). The target 
genes are roughly divided into groups in three different colors: the genes for cardiac 
conduction in blue, the genes for cardiac automaticity in green, and the genes for 
cardiac repolarization in yellow. 
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Table 1. The genes encoding cardiac cytoplasmic ion channel proteins and 
electrogenic ion transporters selected for this study 
   
Gene Name IUPHAR Name Gene ID Description 
SCN5A Nav1.5 ENSG00000183873
Pore-forming α-subunit of 
voltage-dependent Na+ channel 
carrying TTX-insensitive Na+ 
current (INa) responsible for phase 
0 membrane depolarization of a 
cardiac action potential thereby 
cardiac conduction velocity and 
for type 3 familial long QT 
syndrome (LQT3) when mutated 
SCN4B Navβ4 ENSG00000105711
β-subunit of cardiac Na+ channel 
able to enhance α-subunit 
conductance and is responsible 
for type 10 familial long QT 
syndrome (LQT10) when mutated 
    
CACNA1C Cav1.2 ENSG00000151067
Pore-forming α-subunit of 
voltage-dependent 
dihyropyridine-insensitive Ca2+ 
channel carrying L-type Ca2+ 
current (ICa,L) responsible for 
phase 2 plateau of a cardiac action 
potential and excitation-
contraction coupling and for type 
8 familial long QT syndrome 
leading to Timothy's syndrome 
when mutated 
CACNB1 Cavβ1 ENSG00000067191 β1-subunit of Ca
2+ channel able 
to enhance α-subunit conductance  
CACNB2 Cavβ2 ENSG00000165995 β2-subunit of Ca
2+ channel able 
to enhance α-subunit conductance  
    
CACNA1G Cav3.1c ENSG00000006283
Pore-forming α-subunit of 
voltage-dependent Ca2+ channel 
carrying T-type Ca2+ current 
(ICa,T) contributing to pacemaker 
activity of sino-atrial nodal cells 
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CACNA1I Cav3.3 ENSG00000100346
Pore-forming α-subunit of 
voltage-dependent Ca2+ channel 
carrying T-type Ca2+ current 
(ICa,T) contributing to pacemaker 
activity of sino-atrial nodal cells 
    
KCNJ2 Kir2.1 ENSG00000123700
Pore-forming α-subunit and the 
major molecular component of 
inward rectifier K+ channel 
carrying inward rectifier K+ 
current (IK1) responsible for 
setting the membrane potential 
and late phase repolarization of 
cardiac cells. Mutation of KCNJ2 
leads to type 7 familial long QT 
syndrome (LQT7) and Andersen-
Tawil syndrome. 
KCNJ12 Kir2.2 ENSG00000184185
Pore-forming α-subunit of inward 
rectifier K+ channel carrying 
inward rectifier K+ current (IK1) 
KCNJ4 Kir2.3 ENSG00000168135
Pore-forming α-subunit of inward 
rectifier K+ channel carrying 
inward rectifier K+ current (IK1) 
KCNJ14 Kir2.4 ENSG00000182324
Pore-forming α-subunit of inward 
rectifier K+ channel carrying 
inward rectifier K+ current (IK1) 
KCNJ3 Kir3.1 ENSG00000162989
Pore-forming α-subunit of 
acetylcholine-activated inward 
rectifier K+ channel carrying 
ACh-sensitive K+ current (IKACh) 
KCNJ5 Kir3.4 ENSG00000120457
Pore-forming α-subunit of 
acetylcholine-activated inward 
rectifier K+ channel carrying 
ACh-activated K+ current (IKACh), 
mainly expressed in atrial cells. It 
is an atrium-specific ion current 
KCNJ8 Kir6.1 ENSG00000121361
Pore-forming α-subunit of ATP-
sensitive K+ channel carrying 
ATP-sensitive, inward rectifier K+ 
current (IKATP) 
ABCC9 SUR2 ENSG00000069431 Sulfonylurea receptor β-subunit of ATP-sensitive K+ channel  
KCNK1 TWIK1 ENSG00000135750 Pore-forming α-subunit of two-pore inward rectifier K+ channel  
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KCNA5 Kv1.5 ENSG00000130037
Pore-forming α-subunit of 
voltage-gated K+ channel carrying 
ultrarapid delayed rectifier K+ 
current (IKur), mainly expressed in 
human heart. It is an atrium-
specific ion current 
KCNA4 Kv1.4 ENSG00000182255
Pore-forming α-subunit of 
voltage-gated K+ channel carrying 
transient outward K+ current (Ito1), 
mainly expressed in rabbit heart 
KCND2 Kv4.2 ENSG00000184408
Pore-forming α-subunit of 
voltage-gated K+ channel carrying 
transient outward K+ current (Ito1), 
mainly expressed in rodent hearts 
KCND3 Kv4.3 ENSG00000171385
Pore-forming α-subunit of 
voltage-gated K+ channel carrying 
transient outward K+ current (Ito1), 
mainly expressed in human heart. 
Being responsible for phase 1 
rapid repolarization and the 
“spike and dome” morphology of 
cardiac action potentials 
KCNH2 HERG ENSG00000055118
Pore-forming α-subunit of 
voltage-gated, ether-a-go-go-
related  K+ channel carrying rapid 
delayed rectifier K+ current (IKr) 
responsible for phase 3 
repolarization and drug-induced 
long QT syndrome and type 2 
familial long QT syndrome 
(LQT2) when mutated 
KCNQ1 KvLQT1 ENSG00000053918
Pore-forming α-subunit of 
voltage-gated K+ channel carrying 
slow delayed rectifier K+ current 
(IKs) responsible for phase 3 
repolarization and drug-induced 
long QT syndrome and type 1 
familial long QT syndrome 
(LQT1) when mutated 
KCHIP2 KChIP2 ENSG00000120049
β-subunit of voltage-gated K+ 
channel able to interact with 
Kv4.2 and Kv4.3 α-subunits to 
modulate transient outward K+ 
current (Ito1) 
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KCNE1 minK ENSG00000180509
β-subunit of voltage-gated K+ 
channel carrying slow delayed 
rectifier K+ current (IKs) 
responsible for phase 3 
repolarization and drug-induced 
long QT syndrome and type 5 
familial long QT syndrome 
(LQT5) when mutated 
KCNE2 MIRP1 ENSG00000159197
β-subunit of voltage-gated, ether-
a-go-go-related  K+ channel 
carrying rapid delayed rectifier K+ 
current (IKr) responsible for phase 
3 repolarization and drug-induced 
long QT syndrome and type 6 
familial long QT syndrome 
(LQT6) when mutated 
KCNAB2 Kvβ2 ENSG00000069424
β-subunit of voltage-gated K+ 
channel able to co-assemble with 
Kv1.4 α-subunit carrying 
transient outward K+ current (Ito1) 
    
CLCN2 CIC2 ENSG00000114859
A molecular component of Cl- 
channel thought to play a role in 
sinus nodal cells  
CLCN3 CIC3 ENSG00000109572
A molecular component of 
volume-sensitive outwardly 
rectifying Cl- channel 
CLCN6 CIC6 ENSG00000011021
A molecular component of 
volume-sensitive outwardly 
rectifying Cl- channel 
    
GJA1 Cx43 ENSG00000143140
Connexin43 gap junction channel 
protein mainly expressed in 
ventricular cells, responsible for 
intercellular conduction of 
excitation and the coordinated 
depolarization of cardiac muscle 
GJA5 Cx40 ENSG00000152661
Connexin40 gap junction channel 
protein mainly expressed in atrial 
cells, responsible for intercellular 
conduction of excitation and the 
coordinated depolarization of 
cardiac muscle 
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GJC1 Cx45 ENSG00000182963
Connexin45 gap junction channel 
protein mainly expressed in atrio-
ventricular nodal cells, 
responsible for intercellular 
conduction of excitation  
    
HCN2 HCN2 ENSG00000099822
K+/Na+ hyperpolarization-
activated cyclic nucleotide-gated 
channel 2, the dominant isoform 
for ventricular funny current (If), 
responsible for abnormal 
automaticity of the heart 
HCN4 HCN4 ENSG00000138622
K+/Na+ hyperpolarization-
activated cyclic nucleotide-gated 
channel 4, the major molecular 
component for sinus funny 
current (If), responsible for phase 
4 diastolic spontaneous 
membrane depolarization and 
pacemaker activity 
    
TRPC4 TRPC4 ENSG00000133107
Member of the class C 
(canonical) transient receptor 
potential channels, activated by 
phospholipase C stimulation. Its 
expression is downregulated in 
cardiac hypertrophy  
TRPM4 TRPM4 ENSG00000130529
Member of the class M 
(melastatin) transient receptor 
potential channels, activated by 
intracellular calcium. Its 
expression is downregulated in 
cardiac hypertrophy 
    
SLC8A1 NCX1 ENSG00000183023
Na+/Ca2+ exchanger, an antiporter 
membrane protein which removes 
Ca2+ from cells. The NCX 
removes a single Ca2+ in 
exchange for the import of three 
Na+, generating a net inward 
current believed to account for 
delayed after depolarization 
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ATP1A3 Na/K ATPase α3 ENSG00000105409
The large catalytic α-subunit of 
the Na+/K+ pump, pumping three 
sodium ions out of the cell for 
every two potassium ions pumped 
in after each single action 
potential for establishing and 
maintaining the normal 
electrochemical gradients of Na+ 
and K+ across the plasma 
membrane  
ATP1B1 Na/K ATPase β1 ENSG00000143153
The smaller glycoprotein β-
subunit of the Na+/K+ pump 
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Supplementary Figure 2  
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CHAPTER 3.   The Control of Adverse Electrical  
Remodeling by MiRNAs in AF 
As noted in sections 1.3.1 and 1.4.4 of the Introduction, upregulation of IK1 is a key 
component of the adverse electrical remodeling underlying AF. Although it has been 
suggested that the AF-induced IK1 enhancement is likely due to the increased expression of 
the underlying channel subunit Kir2.1 at protein and mRNA levels, the precise molecular 
mechanisms underlying these expression changes are still poorly understood. Given that 
miRNAs have emerged as an important player in a variety of cardiac pathological 
conditions and a novel regulator for ion channels at post-transcriptional level, the present 
study was designed to study the role of miRNAs in this AF-related ionic remodeling 
process.  
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Abstract  
 
Rationale: Atrial fibrillation (AF) is a highly-prevalent arrhythmia with pronounced 
morbidity and mortality. Inward-rectifier K+-current (IK1) is believed to be an important 
controller of reentrant-spiral dynamics, as well as a major component of AF-related 
electrical remodeling. MicroRNA (miR)-26 is predicted to target the KCNJ2-gene encoding 
IK1. Objectives: To study the potential role of miR-26 in AF.  Findings: MiR-26 was 
downregulated in atrial samples of AF animals and patients, accompanied by upregulation 
of KCNJ2-protein and IK1.  Mir-26 overexpression suppressed, while miR-26 knockdown, 
inhibition or binding-site mutation enhanced, expression of KCNJ2/IK1, establishing 
KCNJ2 as a target for miR-26.  Knockdown of endogenous miR-26 by LNA-modified 
antisense promoted AF in mice, whereas adenoviral-transfer of miR-26 reduced AF-
vulnerability. Anti-AF efficacy was abolished when miR-Masks that bind KCNJ2-specific 
target-sites were employed to eliminate miR-26’s repressive effect on KCNJ2 without 
altering other target-genes.  When a miR-Mimic specifically targeting KCNJ2 was co-
injected into mice to prevent Kir2.1/IK1 increases, LNA-antimiR-26 no longer promoted 
AF.  NFAT, a known actor in AF-associated remodeling, was found to negatively regulate 
miR-26 transcription.  Conclusions: MiR-26 controls the expression of the KCNJ2-gene, 
and its downregulation in AF may play an important role in AF-promotion.  MiR-26 
replacement may be a potentially-valuable novel antiarrhythmic approach.  
111 
 
Recent studies have uncovered an important role of microRNAs (miRNAs) in regulating 
cardiac excitability and arrhythmogenesis in various cardiac diseases, including myocardial 
infarction (1), cardiac hypertrophy (2), diabetic cardiomyopathy (3), atrial fibrillation (4,5), 
and other cardiac conditions (6-8).  These studies have primarily focused on the muscle-
specific miRNAs miR-1 and miR-133, with the exception of miR-328, which also 
contributes to shaping cardiac electrophysiology (5).   
Atrial fibrillation (AF) is a highly prevalent condition associated with pronounced 
morbidity and mortality which can cause or exacerbate heart failure and is an important risk 
factor for stroke (9).  AF is characterized by atrial electrical remodeling (mediated 
predominantly by ion-channel alterations), which favors arrhythmia recurrence and 
maintenance (9,10).  A prominent feature of the electrical remodeling associated with AF is 
abbreviation of the effective refractory period (ERP) favoring reentry, primarily due to 
shortening of atrial action potential duration (APD) (9, 10).  Numerous studies have 
demonstrated that increased inward-rectifier K+ current (IK1), along with increased 
expression of the principal underlying subunit KCNJ2 mRNA and its encoded Kir2.1 
protein, is a prominent feature of AF-related atrial electrical remodeling (10-17).  IK1 is the 
key K+-current responsible for setting the resting membrane potential, controlling cardiac 
excitability and modulating late-phase repolarization and APD in cardiac cells.  
Augmentation of inward-rectifier K+-currents like IK1, which shortens atrial APD and 
stabilizes rotor-dynamics, is an important factor favoring AF-maintenance (18, 19).  
Furthermore, IK1 is a central regulator of cardiac excitability and arrhythmogenesis and a 
promising target for new antiarrhythmic approaches (20). 
The mechanism of IK1-dysregulation in AF is poorly understood.  We performed a 
computational analysis of microRNAs altered in AF to identify microRNA-candidates for 
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IK1 dysregulation (See Online Supplement), which suggested that miR-26 has the potential 
to repress KCNJ2/Kir2.1/IK1.  MiR-26 belongs to a cardiac-enriched (21), but non-cardiac-
specific, miRNA family composed of three members, miR-26a-1, miR-26a-2 and miR-26b, 
sharing identical seed sequences (2-8 nucleotides at the 5’-end determining gene-targeting) 
(22) and with only two nucleotide differences between miR-26a and miR-26b (Online 
Figure 1), suggesting that these miRNAs likely have the same set of target genes.  MiR-26 
sequences are highly conserved across species (Online Figure 1).  The 3’ untranslated 
region (3’UTR) of KCNJ2 mRNA contains two binding sites for miR-26a and miR-26b 
(Online Figure 2).  We therefore hypothesized that miR-26-family miRNAs participate in 
AF pathophysiology by regulating the expression of KCNJ2/Kir2.1/IK1. Both miR-26a and 
miR-26b are downregulated in hypertrophied hearts (23) and aortic-valve disease (24).  
However, the potential roles of miR-26 in cardiomyocyte function and cardiac 
pathophysiology have not been studied. 
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RESULTS 
Dysregulation of miR-26 family miRNAs and KCNJ2/Kir2.1 in atrial fibrillation 
In an effort to explore the roles of miRNAs in AF, we found that miR-26 family members 
were significantly downregulated (>50%) in a canine AF-model (miR-26a, Figure 1A) and 
in AF-patients (miR-26a and miR-26b, Figure 1B; see Online Table 1 for patient 
information), indicating possible involvement in AF pathophysiology.  The level of miR-
26a is approximately 4 times higher than that of miR-26b in our canine and human 
preparations (Online Figure 1).  In contrast, miR-1 and miR-133 levels were unaltered in 
AF-samples (Figures 1A and B).  Moreover, in line with previous studies (10-17), we found 
Kir2.1 protein as well as KCNJ2 mRNA to be upregulated in both AF dogs and patients 
(Figures 1C-F).  These results are consistent with the notion that miR-26 might contribute 
to KCNJ2-dysregulation in AF, a possibility that we proceeded to test directly. 
 
Validation of KCNJ2 as a target for miR-26 
Based on computational analyses revealing two miR-26 binding sites in the 3’untranslated 
region (3’UTR) of KCNJ2 (Online Figure 2), we conducted Western blot analysis and 
luciferase reporter gene assays to experimentally clarify whether KCNJ2 is in fact a target 
for miR-26.  As shown in Figure 2A, transfection of miR-26a (100 nM) into H9c2 rat 
ventricular cells produced marked downregulation of Kir2.1 protein compared to sham-
treated control (Ctl) cells.  This repression was efficiently rescued by suppressing 
expression of miR-26 with its antisense inhibitor AMO-26a (10 nM).  More strikingly, 
upregulation of Kir2.1 protein was consistently seen with AMO-26a or AMO-26b alone to 
knock down endogenous miR-26 and mimic the effect of AF (Figure 2B), indicating the 
relief of tonic repression of Kir2.1 by miR-26.  KCNJ2 mRNA expression was also 
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decreased by miR-26a, reflecting mRNA-destabilization (Figure 2C).  We further went on 
to verify the effects of miR-26 at the functional level.  IK1 was recorded in neonatal rat 
ventricular cells using whole-cell patch-clamp techniques.  As shown in Figure 2D, the 
cells transfected with miR-26 had smaller IK1 density than control cells, and the difference 
was eliminated by co-transfection with AMO-26a.  Application of AMO-26a alone 
increased IK1 density.  The regulation of the KCNJ2-gene by miR-26 was confirmed by 
luciferase assay, which indicated that both of the binding sites for miR-26 responded 
similarly to miR-26a expression-changes (Figure 2E).  Mutation of the binding sites 
(Online Figure 2a) abolished the suppressant effect of miR-26 on the KCNJ2 target-gene in 
luciferase assay (Figure 2E), exposing a small stimulatory effect.  The specificity of miR-
26 action was indicated by an absence of change with the negative control miRNA (miR-
NC) and AMO (AMO-NC) (Online Figure 2b).  The efficacy of miR-26a, AMO-26a or 
AMO-26b transfer in altering miR-26a and miR-26b expression was verified by real-time 
RT-PCR experiments (Figure 2F). 
In subsequent control experiments, we found no effects of miR-26 on the protein 
levels of other K+ subunits such as HERG (encoded by KCNH2) for rapid delayed rectifier 
K+-current, KvLQT1 (encoded by KCNQ1) for slow delayed rectifier K+-current, and 
Kv4.3 (encoded by KCND3) for transient outward K+-current (Online Figure 3).  These 
results are consistent with computational predictions excluding these genes as targets for 
miR-26 and indicate that the effect of miR-26 on KCNJ2/Kir2.1/IK1 is target-specific.   
 
Regulation of AF-vulnerability by miR-26 
Upregulation of Kir2.1 due to downregulation of miR-26 is expected to promote AF.  To 
test this notion, we injected locked nucleic acid-modified AMO-26 (LNA-antimiR-26; 
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Online Figure 4) into mice through tail veins to knock down endogenous miR-26 
(mimicking the AF effect), with an approach that is documented to be highly efficient in 
knocking down targeted miRNAs with long-lasting efficacy under in vivo conditions (25-
27).  This type of LNA-modified molecule has been shown by numerous studies to have 
improved cellular uptake and stability, as well as target affinity and specificity.  Attempts to 
induce AF by intracardiac pacing were then made.  AF vulnerability was substantially 
enhanced in the mice treated with LNA-antimiR-26, as indicated by an increased 
proportion of animals with successful induction of AF by electrical stimulation and 
prolonged AF duration once induced (Figure 3A), as compared with sham-operated, age-
matched wild-type (WT) mice.  In contrast, with miR-26 overexpression by tail vein 
injection of miR-26a-expressing adenovirus (Adv-miR-26a; Online Figure 5), AF incidence 
was significantly reduced (Figure 3A).  Mean AF duration also decreased, albeit without a 
statistically-significant difference from WT, likely because of the very small number of 
miR-26 overexpressing mice that showed quantifiable AF (n=2; Figure 3A).  (Please note 
that for clarity of display, data for AF incidence and duration for relevant corresponding 
groups are shown as separate sets in Figures 3 and 4; however, all statistical comparisons 
were performed simultaneously for all groups, as shown in Online Figure 6).  Effective 
cellular uptake of Adv-miR-26a was verified (Online Figure 7).  Whole-cell patch-clamp 
recordings confirmed increased IK1 density in atrial cells after LNA-antimiR-26a treatment 
and the opposite effect was seen after Adv-miR-26a treatment (Figure 3B).  Corresponding 
effects of LNA-antimiR-26a and Adv-miR-26a on Kir2.1 protein level were confirmed by 
Western blot analysis (Online Figures 8A and B).  The mismatched (MM)-LNA-antimiR-
26 (Online Figure 4) failed to produce the changes described above, as did the adenovirus 
carrying the miR-26a-free vector (Online Figure 5).  qPCR confirmed the downregulation 
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of both miR-26a and miR-26b in atrial samples from the mice injected with LNA-antimiR-
26a, as well as overexpression of miR-26a in the animals infected by Adv-miR-26a (Figure 
3C). Neither miR-26a upregulation with Adv-miR-26a nor downregulation with LNA-
antimiR-26a altered cardiac structure or function as determined echocardiographically 
(Online Table 2). Of the ECG-intervals, miR-26a manipulation affected only the QT-
interval, with forced miR-26a upregulation (which downregulated KCNJ2) increasing QT-
interval and miR-26a downregulation decreasing QT-interval (Online Table 3). 
While the above results suggested a significant role for miR-26 in controlling AF 
initiation and maintenance in mice, whether the effects are attributable specifically to 
targeting of KCNJ2/Kir2.1/IK1 remained to be determined.  To shed light on this issue, we 
conducted the following two types of experiments.  First, we wanted to see if knockdown 
of miR-26 is still able to promote AF if Kir2.1 upregulation resulting from miR-26 
downregulation is prevented by using the miRNA mimic (miR-Mimic) techniques 
developed in previous work (28) to specifically retain miR-26 downregulation of Kir2.1.  
We designed a miR-Mimic to specifically target the 3’UTR of KCNJ2 without interacting 
with potential miR-26 target sites of any other transcripts of known function (Online Figure 
9), thus mimicking the effect of miR-26 on KCNJ2 without altering other targets.  We 
began by co-injecting LNA-antimiR-26 and LNA-miR-Mimic into mice and assessed 
changes in vulnerability to AF.  Whereas LNA-antimiR-26 enhanced AF incidence and 
duration relative to WT control-animals, this effect was eliminated by co-injection with 
LNA-miR-Mimic (Figure 4A).  The ability of the miR-Mimic to prevent the Kir2.1-
expression enhancement caused by LNA-antimiR-26 was confirmed by Western blot 
analysis showing reductions of atrial Kir2.1 protein levels to WT levels (Figure 4B).  The 
mismatched LNA-miR-Mimic (LNA-MM-miR-Mimic) failed to alter the arrhythmia-
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promoting or Kir2.1 protein-upregulating effects of LNA-antimiR-26.  Second, we tested 
directly whether overexpression of miR-26 is still able to suppress AF if its repressive 
effect on KCNJ2 is specifically prevented, while its inhibitory effects on other target genes 
are maintained.  To achieve this goal, we used the miRNA-masking oligodeoxynucleotide 
(miR-Mask) strategy, or target-protection approach, that has been developed to produce 
target gene-specific protection against a miRNA (28).  Two miR-Masks (Online Figure 9) 
were designed to be fully complementary to the two binding sites for miR-26 at the 3’UTR 
of KCNJ2 without binding to any other functionally-identified targets, and were LNA-
modified for greater in vivo efficacy.  These miR-Masks are composed of single-stranded 
DNA, which is unable to incorporate into the RNA-induced silencing complex (RISC) that 
is essential for miRNA action.  Thus, the miR-Masks bind specifically and tightly to the 
miR-26 binding-sequence of KCNJ2 (preventing miR-26 binding) but do not bind to other 
miR-26 targets, and do not mimic miR-26 effects on KCNJ2 translation or mRNA stability.  
Consequently, the miR-Masks prevent the effect of miR-26 on KCNJ2 without preventing 
effects on other miR-26 targets.  As shown in Figure 4C, in mice pretreated with the LNA-
miR-Masks via tail vein injection, Adv-miR-26 failed to protect against AF induction and 
maintenance, in contrast to the clear protection produced by Adv-miR-26 in non-pretreated 
mice.  Moreover, administration of the LNA-miR-Masks alone increased AF inducibility 
and maintenance (Figure 4C), indicating that endogenous background miR-26 expression 
offers significant protection against AF.  The ability of the LNA-miR-Masks to prevent the 
repressive effect of miR-26 on Kir2.1 was verified in mice treated with the construct 
together with Adv-miR-26 (Figure 4D). 
Figure 4 shows the ability of miR-Mimic and miR-Mask to counteract the effects of 
antimiR-26a and Adv-miR-26a respectively.  The ability of the LNA-miR-Mimic alone 
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(Figure 5A) to downregulate, and the LNA-miR-Masks alone (Figure 5B) to upregulate, 
atrial Kir2.1 protein level in mice were also verified.  Further control experiments were 
conducted to confirm biologically the gene-specificity of LNA-miR-Mimic and LNA-miR-
Masks on KCNJ2, by verifying the lack of action on other miR-26 targets predicted 
bioinformatically not to interact (as described in Online Methods and Online Figure 9 
legend).  First, administration of LNA-miR-Mimic (Figures 5C and D) showed no effects 
on the expression of protein-products of two previously-validated target genes of miR-26, 
Cyclin D2 and Cyclin E2 (29).  Second, in contrast to Kir2.1, the repressive effects of Adv-
miR-26a on Cyclin D2 and Cyclin E2 protein-expression (Online Figures 8C and D) were 
not affected by co-application of the LNA-miR-Masks (Figures 5E and F), in agreement 
with the absence of recognition sites for the LNA-miR-Masks on these two genes.  
 
Potential mechanism of miR-26 downregulation in AF 
Having established the role of miR-26 in controlling AF through targeting KCNJ2, we went 
on to elucidate potential molecular mechanisms underlying the dysregulation of miR-26 in 
AF.  We suspected that the three members of the miR-26 family, miR-26a-1, miR-26a-2 
and miR-26b, might be transcriptionally regulated in man by a common transcription factor, 
since both miR-26a and miR-26b were significantly downregulated in AF (Figure 1B).  
Computational analysis using MatInspector V2.2 revealed a common feature of the 5’-
flanking regions of the human host genes for the miR-26 family members:  they all contain 
a cluster of putative cis-acting elements for NFAT (nuclear factor of activated T-cells) 
within 5 kb upstream of the transcriptional start sites across different species (Figure 6A; 
Online Table 4).  Intriguingly, enhanced NFAT activity has been frequently implicated in 
AF promotion and is believed to couple rapid atrial activity to atrial remodeling via Ca2+-
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sensitive signaling through calcineurin (30-32).  We therefore explored the role of NFAT in 
regulating expression of miR-26a/b. 
We first identified the transcription start sites (TSSs) of the host genes using 
5’RACE techniques:  CtdspI for miR-26a-1, Ctdsp2 for miR-26a-2, and Cdtsp1 for miR-
26b (Online Figures 10a-d).  We then subcloned the promoter fragments spanning the 
putative NFAT binding sites upstream of the TSSs (Online Figures 10b-d) into pGL3 
luciferase vector and conducted luciferase assays to assess the effects of a decoy 
oligodeoxyribonucleotide that contains the ideal binding site for NFAT (dODN-NFAT; for 
sequence, see Online Figure 11) to sequester NFAT and block its function, as well as to 
study the effects of siRNAs targeting NFATc3 and NFATc4 to knock down NFAT 
expression (Online Figure 12) and to analyze the actions of the cell-permeable NFAT 
inhibitor INCA6.  As depicted in Figure 6B, dODN-NFAT, NFAT-siRNAs or INCA6 
robustly increased luciferase activity of the miR-26 host-gene promoter constructs.  Next, 
we evaluated the effects of INCA6 on the expression levels of miR-26a and miR-26b in 
H9c2 cells.  As shown in Figure 6C, 24-hr incubation of cells with INCA6 produced 
concentration-dependent increases in both miR-26a and miR-26b expression.  Similar to 
INCA6, transfection of H9c2 cells with dODN-NFAT or NFAT-siRNAs caused around 2-
fold upregulation of both miR-26a and miR-26b (Figure 6C).  As expected, the host genes 
demonstrated parallel changes in their expression (Figure 6D).  In contrast to miR-26, miR-
1 expression, as a negative control, was not significantly affected by dODN-NFAT, 
siRNAs and INCA6 (Online Figure 13).  These results indicate that NFAT negatively 
regulates transcription of the miR-26 family members.  Negative-control scrambled dODN 
and siRNA did not affect miR-26 promoter activity or the expression level of miR-26 
(Figures 6B and C). 
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 To verify the physical interaction between NFAT and the cis-acting elements of 
miR-26, we first carried out EMSA in conjunction with supershift to assess the ability of 
NFAT to bind the putative cis-acting elements in the 5’-flanking regions of the miR-26a 
and miR-26b host genes.  We incubated each probe, a synthesized, digoxigenin-labeled 
putative NFAT cis-acting element (double-stranded oligodeoxynucleotides fragment) with 
nuclear extract from Hela cells.  As depicted in Figure 7A, a shifted band representing 
protein-DNA binding was identified, which was eliminated upon addition of excessive non-
labelled probes but was supershifted by the antibody to NFAT.  We then subsequently 
conducted ChIP to further verify the protein-DNA interactions that occur inside the nucleus 
of living cells.  Our results confirmed the binding of NFAT to each of the three cis-
elements in the 5’-flanking regions of the three miR-26 members (Figure 7B). 
We reasoned that if NFAT is indeed a negative regulator of miR-26, inhibition of 
NFAT activity should downregulate Kir2.1 protein by relieving the inhibitory effect on 
miR-26, provided that other regulatory factors are kept unchanged.  This hypothesis was 
supported by the data shown in Figure 7C: application of INCA6 significantly decreased 
Kir2.1 protein expression.  Finally, we confirmed NFAT-modulation in AF as evidenced by 
enhanced translocation of NFATc3 and NFATc4 from cytoplasm to nucleus in atrial 
samples of AF dogs and patients on immunohistochemical examination (Figure 7D).  The 
experiments shown in Figures 6 and 7 indicate that NFAT is a negative regulator of miR-26 
transcription and that, since NFAT is translocated to cardiomyocyte nuclei in AF, it is a 
strong candidate to underlie AF-induced miR-26 dysregulation. 
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DISCUSSION 
Taken together, our results identify miR-26 as a potentially important regulator of KCNJ2 
gene-expression and, via IK1, a determinant of AF-susceptibility.  In addition, our findings 
identify miR-26 as a novel potential mediator of the electrophysiological effects of Ca2+-
dependent NFAT signaling, believed to be an important player in AF perpetuation (30-32).  
Our study therefore reveals novel molecular control mechanisms for AF at the miRNA 
level, as summarized schematically in Figure 8.  
AF can be induced by a variety of factors, including atrial dilation, oxidative stress, 
atrial ischemia or hypoxia, and intracellular Ca2+ overload; all of these ultimately act by 
altering, directly or indirectly, atrial electrical activity, principally by modulating ion 
channel function and/or expression (9, 10, 33).  Many ion currents are altered by atrial 
electrical remodeling during AF (10).  IK1 is a particularly important mechanistic 
determinant of AF-supporting reentry because, in addition to accelerating repolarization, 
enhanced IK1 increases Na+-current availability, accelerating and stabilizing reentrant rotors 
(18).  IK1 enhancement is not only a potentially important contributor to AF associated with 
atrial remodeling (18, 33) but is also the causative factor in familial AF resulting from gain-
of-function mutations associated with Kir2.1 channelopathies (34-36).   
More generally, IK1 plays a central role in cardiac excitability and arrhythmogenesis 
(20, 37).  Although IK1-alterations are important in the failing heart, they are not explained 
by changes in candidate-subunit transcript-levels (38), suggesting post-transcriptional 
regulation.  Similarly, KCNJ2 protein-expression changes in patients with AF may exceed 
mRNA alterations (16), pointing to post-transcriptional mechanisms such as microRNA-
induced inhibition of translation.  Our findings indicate that miR-26 regulates this 
important K+-channel under specific disease conditions and provide insights into the 
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transcriptional control of miR-26.  Further studies of miR-26 dysregulation of IK1 in other 
pathological contexts are clearly of potential interest. 
Downregulation of L-type Ca2+-current is well-established as an important 
component of the ionic remodeling associated with AF (9, 33).  The Ca2+-calcineurin-
NFAT system plays a central role in detecting the rapid repetitive atrial activation that 
occurs during AF, and in coupling AF to L-type Ca2+-currrent downregulation (30-32).  
The contribution of IK1 upregulation has been established more recently (10), but is 
recognized to be of substantial importance to AF pathophysiology (18).  Our findings here 
suggest that the calcineurin-NFAT system engaged by AF might also induce IK1 changes 
via transcriptional regulation of miR-26, indicating that this Ca2+-dependent system may be 
a common pathway for at least 2 of the important changes in ion-channel function 
associated with AF. 
We found that adenoviral gene-transfer of miR-26 via tail-vein injection was able to 
upregulate cardiac miR-26 expression and suppress AF inducibility and maintenance.  
AF-therapy is presently quite inadequate, with conventional antiarrhythmic drugs having 
limited efficacy and potentially-significant toxicity (9, 39).  There is therefore great interest 
in novel therapeutic approaches to the arrhythmia, one of which in early development is 
gene therapy (39, 40).  Our findings suggest that miR-26 could conceivably be a candidate 
for AF-targeting gene-therapy in the future. 
The expression of miR-1, which is upregulated in myocardial infarction and 
established by a previous study to target KCNJ2/Kir2.1/IK1 (1), was unaltered in our 
samples from dogs and patients with AF (Figure 1A).  Girmatsion et al (4), however, 
reported that the expression of miR-1 was reduced by approximately 86% in left atrial 
samples of AF patients undergoing mitral valve repair or bypass grafting.  There was a 
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corresponding increase in Kir2.1-protein expression. Based on their data, the authors 
proposed that downregulation of miR-1 is responsible for upregulation of Kir2.1/IK1 in AF 
patients.  However, their study leaves a number of important unresolved issues.  First, no 
direct evidence for an AF-promoting role of miR-1 downregulation was presented.  Second, 
Kir2.1 was found to be upregulated by only 1.5-fold at the protein level but by 3-fold at the 
mRNA level in the Girmatsion study.  These results are inconsistent with the expected 
effect of miR-1, because miR-1 has been documented not to affect KCNJ2 transcript levels 
(1).  Third, the authors showed that the expression of connexin-43, another validated target 
of miR-1 (1), was unaltered.  Finally, whether the observed upregulation of Kir2.1 
expression in their preparations was caused by miR-1 downregulation was not tested.  The 
lack of miR-1 expression change in our patient and dog samples indicates that miR-1 
changes are unlikely to have been a major contributor to AF in our subjects.  
Although we identified miR-26 downregulation in AF as an important potential 
contributor to IK1 upregulation and AF-promotion, we are in no way claiming that miR-
26/IK1 changes are the only factor governing AF-development.  AF is clearly a complex 
condition that results from multiple potential etiological contributors that can interact with 
each other (36).  In addition to IK1 changes, the electrical disturbances in AF-related 
remodeling can stem from changes in ICaL, constitutive IKACh and alterations in connexin 
function (36).  Indeed, a comparison of the time-course of changes in AF-duration, miR-26 
expression and Kir2.1 protein-expression in our canine AF-model (Online Figure 14) 
shows that AF-vulnerability is significantly increased at one week of atrial tachypacing, 
before significant changes in miR-26 and Kir2.1 appear, indicating that other factors are 
certainly involved.  Nevertheless, further statistically-significant changes occur in AF-
vulnerability between weeks 1 and 6, concomitant with miR-26/Kir2.1 changes, consistent 
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with the profibrillatory properties of miR-26 downregulation/Kir2.1 upregulation seen in 
our mouse model.  Furthermore, structural alterations and changes in intracellular Ca2+ 
handling can also play a significant role, and the mechanistic contributors to AF vary, 
depending on underlying diseases and genetic factors (33, 36).  Nor is IK1 the only potential 
target for miR-26 in AF.  For example, we recently demonstrated that miR-26 also targets 
the nonselective cation-channel subunit TRPC3, through which it can alter fibroblast 
function and thereby contribute to AF-promotion (41).  However, the miR-26 interaction 
with the TRPC3 gene is not predicted to be mimicked by the KCNJ2-binding miR-Mimic, 
nor is it blocked by the miR-Masks, that we used in the present study.  Thus, the protective 
effects against KCNJ2 upregulation and AF-promotion that we observed in our mouse 
model with the miR-Mimic, and the opposite phenomena with the miR-Masks, are not 
mediated by TRPC3-changes.  Similarly, our miR-Mimic did not bind to any other 
functional transcripts in GenBank, and the miR-Mask interaction with the miR-26 binding 
sites on KCNJ2 did not apply to any other functional transcript in GenBank.  Therefore, our 
results strongly suggest that the effects of miR-26 alterations that we observed on AF in our 
in vivo mouse model were mediated through changes in KCNJ2/IK1.  Our observations of 
the AF-promoting effect of miR26-downregulation/IK1-upregulation are limited to changes 
in AF-vulnerability and AF-sustainability once induced.  We never saw spontaneously-
initiated AF in this study and thus our observations provide no information about the 
mechanisms of spontaneous AF-onset in man.  They rather relate to the factors determining 
the substrate for AF-initiation and persistence, upon induction by spontaneous atrial 
ectopy/tachyarrhythmia. 
We demonstrated in vitro that NFAT is a negative regulator of miR-26:  NFAT-
inhibition upregulated miR-26-transcription and reciprocally downregulated KCNJ2-
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expression.  However, we were unable to create an in vivo model to test whether we could 
mimic the effects on miR26/KCNJ2/AF-vulnerability seen with AF by enhancing NFAT-
signaling.  Until this is accomplished, the role of NFAT in AF-related miR26-regulation 
and associated AF-promotion remains to be fully established.  Another potential limitation 
to our findings is that the underlying heart diseases of patients from whom we obtained 
atrial-tissue samples (Online Table 1) could have influenced the results. 
In conclusion, we have discovered that miR-26 regulates the KCNJ2-gene and the IK1 
channel that it encodes.  The application of innovative miR-Mimic and miR-Mask methods 
allowed us to confirm that KCNJ2-changes are necessary and sufficient to explain 
AF-vulnerability increases that result from miR-26 upregulation and decreases caused by 
miR-26 downregulation in an in vivo mouse model.  MiR-26 is significantly decreased in 
AF-patients and an animal-model of AF, and AF-related miR-26 dysregulation is likely due 
to suppression of miR-26 transcription by the Ca2+-dependent transcription factor NFAT.  
These findings provide new insights into the molecular mechanisms underlying a common 
and important cardiac arrhythmia and may have implications for other arrhythmia 
conditions in which IK1 is dysregulated.
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METHODS 
AF induction in mice 
C57BL/6 mice were anesthetized with 1% sodium pentobarbital through tail vein injection 
(30 mg/kg).  Intracardiac pacing was performed in these animals by inserting an eight-
electrode catheter (1.1 F, octapolar EP catheter, Scisense) through the jugular vein and 
advancing it into the right atrium and ventricle with protocols similar to those reported in 
previous studies (5,42).  Inducibility of atrial arrhythmias was tested by applying 6-second 
tachypacing bursts through the catheter electrodes, using an automated stimulator 
interfaced with the data acquisition system (GY6000, HeNan HuaNan Medical Science & 
Technology Ltd, China).  The first 6-second burst had a cycle length of 40 ms, decreasing 
in each successive burst with a 2-ms decrement down to a cycle length of 20 ms.  
Successful induction of AF was defined as the creation of rapid irregular atrial rhythm 
lasting for ≥1 s, calculated from the direct atrial activation recordings. 
To study AF changes with miR-26 manipulation, adenovirus carrying pre-miR-26a 
(Adv-miR-26a) was injected into mice through a tail vein (100 μl; titer: 1010 pfu/ml) once 
daily for 3 consecutive days.  Manipulation of miR-26a was similarly achieved by tail vein 
injection of LNA-antimiR-26a and/or LNA-miR-Mimic or Adv-miR-26a and/or LNA-miR-
Mask at 5 mg/kg/day once a day for three days.  AF was measured and/or atrial-tissue 
samples for biochemical analysis were obtained three days after the last dose of the 
constructs.   
 
Human atrial samples from patients with atrial fibrillation 
Human tissues (right atrium appendage) were provided by the Second Affiliated Hospital of 
the Harbin Medical University under procedures approved by the Ethics Committee of 
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Harbin Medical University.  The tissues were obtained from 22 individuals undergoing 
heart surgery, ten in sinus rhythm and twelve with AF (Online Table 1).  These 
preparations were used to isolate total RNA for real-time RT-PCR quantification of 
miRNAs and to extract cytosolic proteins for measurement of Kir2.1. 
 
Dog AF model 
Mongrel dogs of either sex, weighing between 15 and 25 kg, were instrumented with right 
atrial pacemakers (Shanghai Fudan University, Shanghai, China) under sodium 
pentobarbital (30 mg/kg i.v.) anesthesia.  AF was induced by up to 6 weeks of atrial 
tachypacing at 400 bpm.  Dogs with spontaneously-persisting AF, defined as continuous 
spontaneous AF maintenance for at least 2 hours, were used in this study (5). 
 
Cell culture 
The H9c2 (rat embryonic ventricular) cell line used in this study was purchased from 
American Type Culture Collection (ATCC, Manassas, VA) and cultured in Dulbecco’s 
Modified Eagle Medium (DMEM). 
 
Cardiomyocyte isolation and primary cell culture 
The enzymatic dispersion techniques used to isolate single atrial myocytes from neonatal 
rats and adult mice have been previously described in detail (5).  Briefly, 1-3 day old rats 
were decapitated and their hearts were aseptically removed.  The atria were dissected, 
minced and trypsinized at 37°C for 10 min.  Dissociated cells were plated in 24-well plates 
in Dulbecco’s Modified Eagle Medium (DMEM, Ivitrogen) containing 10% FBS and 0.1 
mM bromodeoxyuridine (Sigma) and the non-adherent cardiomyocytes were removed.  The 
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cells (1×105/well) were seeded in a 24-well plate for further experiments.  This procedure 
yielded cultures with 90±5% myocytes, as assessed by microscopic observation of cell 
beating.  The cardiomyocytes were also verified by positive staining with an anti-α-actin 
monoclonal antibody through immunocytochemistry. 
For the isolation of adult mouse heart cells, mice that had been treated with varying 
constructs were anaesthetized with sodium pentobarbital (30 mg/kg ip).  The hearts were 
rapidly removed and retrogradely perfused through the aorta using a modified Langendorff 
apparatus.  The preparation was perfused with standard Tyrode’s solution (in mM: NaCl 
126, KCl 5.4, HEPES 10, NaH2PO4•2H2O 0.33, MgCl2•6H2O 1.0, CaCl2 1.8, and glucose 
10; pH adjusted to 7.4 with NaOH) for 5 min, then switched to Ca2+-free Tyrode’s solution 
until beating stopped, followed by perfusion with the same solution containing collagenase 
II (7 mg/50 ml) and BSA.  The freshly isolated atrial myocytes were gently centrifuged and 
resuspended in Kraftbruhe (KB) storage solution (in mM: glutamic acid 70, taurine 15, KCl 
30, KH2PO4 10, MgCl2 0.5, EGTA 0.5, HEPES 10, and glucose 10; pH adjusted to 7.35 
with KOH).  All solutions were aerated with 100% oxygen and warmed to 37±0.5°C.  Only 
single rod-shaped, Ca2+-tolerant, and quiescent cells with clear cross-striations were 
selected for patch clamp recording. 
 
Computational prediction of miRNA target genes and cis-acting elements for 
transcription factors 
We used seven established miRNA target prediction algorithms: DIANA-microT3.1, 
miRanada, MirTarget2, PicTar, PITA, microcosm, and TargetScan5.1.  Only the miRNAs 
that are predicted to target a given gene by at least four of the seven algorithms were 
considered as candidates for further analysis (43). 
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 The binding sites for various transcription factors in the promoter regions of the host 
genes of miR-26a-1, miR-26a-2 and miR-26b from different species (human, canine, rat 
and mouse) were analyzed with MatInspector V2.2 (Genomatix) (44).  Analyses were made 
to the 5’flanking regions 5 kb upstream of the transcriptional start sites of the host genes 
(Online Table 4). 
 
Synthesis of miRNAs and anti-miRNA antisense inhibitors 
miR-26a and miR-26b were synthesized by Integrated DNA Technologies Inc (IDT), and 
their respective antisense oligonucleotides, AMO-26a and AMO-26b, were synthesized by 
Exiqon (Denmark).  Five nucleotides or deoxynucleotides at both ends of the antisense 
molecules were locked (LNA; the ribose ring is constrained by a methylene bridge between 
the 2’-O- and the 4’-C atoms).  Additionally, a scrambled RNA was used as negative control.  
For in vivo experiments, LNA-modified constructs, LNA-antimiR-26a, LNA-miR-Mimic, 
and LNA-miR-Masks, were synthesized by Exiqon (Demark).  The LNA-antimiR-26a and 
LNA-miR-Masks are single-stranded DNA analogues complementary to mature miR-26 
(5’-uucaaguaauccaggauaggcu-3’) and the miR-26 binding sites on KCNJ2, respectively, 
which were chemically modified with 2’-OMe phosphoramidites and locked nucleic acids 
(the ribose ring is constrained by a methylene bridge between the 2’-O- and the 4’-C atoms) 
(28).  For negative control experiments, a mismatched miR-26 LNA-antimiR, MM-LNA-
antimiR-26 (5’-TCCTGGATactaTGt-3’), was also synthesized.  LNA-miR-Mimic is a 
double-stranded RNA fragment with locked nucleotides one at the 5’-end and two at the 3’-
end.  The LNA-antimiR-26, LNA-miR-Mimic, or LNA-miR-Masks was injected into mice 
through the tail vein at a dosage of 5 mg/kg/d in 0.2 ml saline once a day for three 
consecutive days. 
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Quantitative real-time RT-PCR analysis.  
The Taqman® MicroRNA RT kit and Taqman® MicroRNA Assay kit (Applied Biosystems) 
were used in conjunction with real-time PCR with TaqMan for quantification of miRNAs 
in our study, as previously described in detail (1).  Total RNA samples were isolated with 
Ambion’s mirVana miRNA Isolation Kit, from human right atrial appendages, canine left 
atrial preparations, cultured neonatal rat atrial myocytes, H9c2 cells, and mouse left atrium.  
Reactions contained Taqman® MicroRNA Assay qRT-PCR Primer sets specific for human, 
canine, rat and mouse miRNAs, and a scrambled miRNA as a negative control.  qRT-PCR 
was performed on a thermocycler (Mx3005PTM Realtime PCR System; Stratagene) for 40 
cycles.  Fold variations in miRNA expression between RNA samples were calculated after 
normalizing to the internal control, snU6.  The threshold cycle (CT) is defined as the 
fractional cycle number at which the fluorescence passes the fixed threshold. 
 For quantification of transcripts of the host genes of the miR-26 family members, 
quantitative real-time RT-PCR was carried out with total RNA samples treated with DNase 
I.  TaqMan quantitative assay of transcripts was performed with real-time two-step reverse 
transcription PCR, involving an initial reverse transcription with random primers and 
subsequent PCR amplification of the targets.  Expression level of b2m was used as an 
internal control. 
 
Western blot analysis 
Protein samples (membrane and cytosolic samples separately) were extracted from canine 
left atria, human right atrial appendages, cultured neonatal rat atrial myocytes, and murine 
atrial tissues of wild-type and transgenic mice for immunoblotting analysis, with 
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procedures essentially the same as described in detail elsewhere (1).  The protein content 
was determined by BCA Protein Assay Kit using bovine serum albumin as an internal 
standard.  Protein samples (~50 µg) were fractionated by SDS-PAGE (6-12% 
polyacrylamide gels) and transferred to PVDF membranes (Millipore, Bedford, MA).  The 
samples were then incubated overnight at 4°C with the primary antibodies in 1:200.  
Affinity purified mouse monoclonal anti-Kir2.1 antibody was purchased from UC 
Davis/NIH NeuroMab Facility (David, CA).  Rabbit polyclonal anti-HERG1 was 
purchased from Alomone Labs (Israel).  Goat polyclonal anti-KvLQT1 and anti-Kv4.3, 
mouse monoclonal anti-NFATc3 and rabbit polyclonal anti-NFATc4 were purchased from 
Santa Cruz Biotechnology (USA).  And rabbit polyclonal anti-cyclin D2 and anti-cyclin E2 
were purchased from Cell Signalling Technology (USA).  The next day after incubation 
with the primary antibody, the membrane was incubated with secondary antibody (Santa 
Cruz Biotech, Inc.) diluted in PBS for 2 h at room temperature.  Finally, the membrane was 
rinsed with PBS before scanning with an Infrared Imaging System (LI-COR Biosciences).  
GAPDH was used as an internal control for protein input, using anti-GAPDH monoclonal 
antibody (Fitzgerald Industries International Inc).  Western blot bands were quantified 
using QuantityOne software by measuring the band intensity (Area x OD) for each group 
and normalizing to GAPDH.  The final results are expressed as fold changes by 
normalizing the data to the control values. 
 
Construction of luciferase-miRNA-target site fusion plasmids 
To construct reporter vectors bearing miRNA-target sites, we synthesized fragments 
containing the exact target sites for miR-26a and miR-26b in the 3’UTR of KCNJ2, and the 
fragments carrying nucleotide replacement mutations at the seed sites (Online Figure 2), 
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through Invitrogen.  Each construct contains one of the two predicted binding sites for miR-
26a and miR-26b (Online Figure 2).  These inserts were ligated into HindIII and SpeI sites 
in the pMIR-REPORTTM luciferase miRNA expression reporter vector (Ambion) (1). 
 
Construction of promoter-luciferase fusion plasmids 
Fragments corresponding to the promoter regions spanning the putative NFAT binding sites 
upstream to the TSSs of Ctdspl (for miR-26a-1), Ctdsp2 (for miR-26a-2) and Ctdsp1 (for 
miR-26b) were synthesized by Invitrogen.  The fragments were subcloned into luciferase-
containing pGL3-promoter vector (Promega, Madison, WI) for studying the role of NFAT 
in regulating transcription of the miR-26 family members and their host genes, according to 
procedures described elsewhere (44, 45).  The sequences of the promoter fragments used 
are (the underlined, boldface letters indicate the NFAT binding sites):   
Ctdspl (for miR-26a-1): 5’-
ATTATTCAGTCTATCTTGAATGTGCTGTAAGGACTGGGATAAAGATATATTTTT
TCCTCATGGATAGGTACTTGTCCCAACAATTTTTGA 
Ctdsp2 (for miR-26a-2): 5’-
TGTTTCCAAATTGCCTCTTACCAACCATGCAGTCAGAGAGGCCAGAGGAAAGG
GGATACAGCAGGTAGGGAACCAAGTGAGAGTCAGTGG 
Ctdsp1 (for miR-26b): 5’-
AAGACCCATTTTACAGATGAGGTAGTGCTATCTCCAAGTCCTCAACGAGGAAA
CCGAGAAGCCTCTAGTCCCGGGTCTTCAGAAAACGCA. 
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Construction of adenovirus and infection 
The procedures were similar to the study reported by van Rooij et al (46) and our previous 
study (5).  Mouse miR-26a-1 precursor DNA (5'-
GGATCCgTTCCGGCACCGGAGCAAGTTCATT 
AGGTCCTATCCGACACGTCCAGGGTTCCCCGGATAAGAACCAATGAACGTGCC
CCTGCGCCCGGACttttttAAGCTT-3') was synthesized by GenScript (Nanjing, P.R. 
China).  The fragment was first inserted into adenovirus shuttle plasmid pDC316-EGFP-U6 
(Microbix Biosystems Inc, Canada).  pDC316-EGFP-U6 was then cotransfected with the 
infectious adenovirus genomic plasmid pBHGlox∆E1,3Cre into 293 cells by liposome 
reagent.  Following co-transfection of these two DNAs, homologous recombination 
occurred to generate a recombinant adenovirus in which the transgene (pre-miR-26) is 
incorporated into the viral genome, replacing the ∆E1 region (Online Figure 5). 
 
Preparation of decoy ODNs 
Single-stranded phosphorothioate decoy oligodeoxynucleotides (ODN) were synthesized 
by IDT incorporation (Coralville, IA; Online Figure 11).  The ODN was dried and 
dissolved in sterilized Tris-EDTA buffer (10 mM Tris + 1 mM EDTA) (44, 47).  The 
supernatant was purified using Micro Bio-spin30 columns (BioRad, Hercules, CA) and 
quantified by spectrophotometry.  The double-stranded decoy ODN was then prepared by 
annealing complementary single stranded ODN by heating to 95°C for 10 min followed by 
cooling to room temperature slowly over 2 h.  The decoy ODN was prepared at a 
concentration of 50 μM in saline.  For negative control, a scrambled decoy ODN was also 
used. 
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siRNAs to NFATc3 and NFATc4 
siRNAs (Online Figure 11 for sequences) and the scrambled negative control siRNA 
(StealthTM RNAi Negative Control Duplexes, Medium GC Duplex; Cat#: 12935-300) were 
synthesized by Invitrogen. 
 
Transfection procedures 
Neonatal rat atrial myocytes and H9c2 cells were transfected with 100 nM miRNA and/or 
10 nM AMOs, siRNAs, or negative control constructs with lipofectamine 2000 
(Invitrogen), according to the manufacturer’s instructions as in previous studies (1,48).  
Cells were used for luciferase assay 24 hours after the transfection or were collected for 
total RNA or protein purification 48 hours after the transfection. 
 For decoy oligodeoxynucleotides (ODN) studies, cells were washed with serum-free 
medium once and then incubated with 500 μl fresh fetal bovine serum (FBS)-free medium 
(39, 42).  Decoy ODNs and lipofectamine 2000 (0.25 μl, Invitrogen, Carlsbad, CA) were 
separately mixed with 25 μl of Opti-MEM ® I Reduced Serum Medium (Gibco, Grand 
Island, NY) for 5 min.  Then the two mixtures were combined and incubated for 20 min at 
RT.  The lipofectamine: ODN mixture was added dropwise to the cells and incubated at 
37°C for 5 h.  Subsequently, 25 μl fresh medium containing 30% FBS was added to the 
well and the cells were maintained in culture until use. 
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Luciferase activity assay 
For luciferase assay involving miRNA function, H9c2 cells were transfected with the 
pMIR-REPORTTM luciferase miRNA expression reporter vector carrying the 3’UTR of 
KCNJ2 or promoter-luciferase fusion plasmid pGL3, as previously described in detail (1, 
44, 45). 
 
Chromatin immunoprecipitation assay (ChIP) 
ChIP assays were conducted with the Millipore Magna ChIPTM kit according to the 
manufacturer’s instructions (Millipore, USA) as previously described (48).  Briefly, H9c2 
cells were grown to subconfluency, washed and fixed in 1% formaldehyde for 10 min to 
crosslink nucleoprotein complexes and scraped in phosphate buffered saline containing 
protease inhibitor cocktail.  Pelleted cells were then lysed and sonicated in detergent lysis 
buffer.  Sheared DNA-protein complexes were immunoprecipitated by incubating overnight 
the lysates with 2 μg antibodies against NFATc3 (Santa Cruz Biotechnology Inc., Santa 
Cruz, CA) or IgG (as a control).  Magnetic Protein G beads provided with Millipore Magna 
ChIPTM kit (Millipore, USA) were used, and after extensive washing, crosslinks were 
removed at 62°C for 2 hours while agitating in 100 µl ChIP elution buffer and 1 µl 
Proteinase K.  The DNA was isolated using the QIAquick PCR purification kit (Qiagen) 
and the presence of the miR-26 promoter was analyzed by PCR amplification using 10% of 
purified DNA.  The primers used for miR-26 promoter sequences containing NFAT cis-
acting elements are listed in Online Table 5.  The PCR products were analyzed by gel 
electrophoreses on an 1% agarose gel and subsequent with GelRed™ Nucleic Acid Gel 
Stain. 
 
136 
 
Electrophoresis mobility shift assay (EMSA) 
EMSA was performed with the DIG Gel Shift kit (Roche, Mannheim, Germany), as 
described previously (44, 48).  Varying amounts of nuclear protein extracts from Hela cells 
were incubated with digoxigenin (DIG)-labeled double-stranded oligonucleotides 
containing the putative NFAT cis-acting element.  For competition experiments, 100-fold 
excess of unlabeled double-stranded NF-AT consensus oligonucleotides, and for super-shift 
experiments, 1 µg of NFATc3 antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA), 
were added to the reaction.  The generated chemiluminescent signals were recorded on X-
ray film. 
 
Whole-cell patch-clamp recording 
Patch-clamp techniques were applied to isolated atrial myocytes from mice subjected to 
tail-vein injection of LNA-construct probes and/or adenovirus-transferred miRNA probes.  
We used procedures that have been described previously in detail (1, 5, 38).  Briefly, the 
pipettes of patch electrodes had tip resistances of 2-3 MΩ when filled with pipette solution.  
Isolated cells were placed in a 1-ml chamber mounted on an inverted microscope (IX-70, 
Olympus) and perfused with Tyrode solution.  Whole-cell recording was performed using 
an Axopatch 200B amplifier (Axon instrument, USA).  Signals were filtered at 1 kHz and 
data were acquired by A/D conversion (Digidata 1320, Axon Instrument).  Ion currents 
were recorded in the whole-cell voltage-clamp mode.  For recordings of inward rectifier K+ 
current (IK1), the pipette solution contained (in mM) 20 KCl, 110 K-aspartate, 1 MgCl2, 
5 MgATP, 0.1 GTP, 5 Na2 phosphocreatine, 10 EGTA, and 10 HEPES (pH 7.2 with KOH); 
the external Tyrode solution contained (in mM) 126 NaCl, 5.4 KCl, 2 CaCl2, 0.8 MgCl2, 10 
HEPES, and 10 dextrose (pH 7.4 with NaOH).  CdCl2 (250 μM) was included to inhibit 
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ICaL.  Experiments were conducted at 36±1°C.  Junction potentials were zeroed before 
formation of the membrane-pipette seal and were not corrected for data analyses.  Series 
resistance and capacitance were compensated and leak currents were subtracted.  Cells with 
significant leak currents were rejected for analysis.  The data were collected in an IBM-
compatible computer and analyzed with the use of pCLAMP 9.2.  
IK1 was recorded with 100-ms square-wave pulses to voltages ranging from -120 mV 
to +10 mV with a holding potential of -20 mV at a frequency of 0.1 Hz (1).  For all 
recordings, sodium current was inactivated with the use of a holding potential of -20 mV.  
Since our study was designed for group comparisons of the experimental results, the 
currents were all recorded immediately after membrane rupture and series resistance 
compensation in order to minimize time-dependent rundown of currents.  Individual 
currents were normalized to the membrane capacity to control for differences in cell size, 
and are expressed as current densities (pA/pF). 
 
Data analysis 
Group data are expressed as mean±SEM.  Two-group only comparisons were performed by 
unpaired Student’s t-test.  Multiple-group comparisons for real-time RT-PCR and Western 
blot experiments were analyzed with one-way ANOVA followed by Bonferroni post-hoc 
tests.  The statistical comparisons for AF incidence were performed with χ2-test.  To 
account for multiple testing, we selected for comparison only results of primary biological 
significance and applied a correction using the Holm-Bonferroni method (Online Figure 
6a).  The statistical significances for multiple-group comparisons of AF duration with all 
the groups shown in Figures 3A, 4A and 4C were evaluated in a single one-way ANOVA 
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with post-hoc Tukey’s tests (Online Figure 6b).  A P-value less than 0.05 was considered 
significant. 
Study Approval 
All animal handling and human tissue sample procurement procedures were approved prior 
to study onset by the Animal Care and Use and Human Research Ethics Committees at the 
Harbin Medical University and the Montreal Heart Institute.  
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Figure Legends 
Figure 1.  Downregulation of miR-26 and upregulation of KCNJ2/Kir2.1 in atrial 
fibrillation (AF).  A and B. Quantitative real-time RT-PCR (qPCR) for various microRNAs 
showing downregulation of miR-26 in atrial samples from a canine model (n=10 for Ctl 
and n=9 for AF) and from AF and sinus-rhythm patients (n=5 per group), respectively.  
*p<0.05, ***p<0.001 vs Ctl. (For description of patient population, see online 
Supplementary Table 1.)  C and D. Western blot analysis showing significant 
upregulation of Kir2.1 in atrial tissues from AF dogs (n=9/group) and AF patients (n=6 for 
Ctl and n=5 for AF). **p<0.01 vs Ctl. E and F. qPCR showing significant upregulation of 
KCNJ2 transcripts in atrial tissues from AF dogs (n=9/group) and AF patients (n=6 for Ctl 
and n=5 for AF). *p<0.05 vs Ctl.  Values are expressed as mean±SEM. 
Figure 2.  Regulation of Kir2.1-expression by miR-26.  A and B. Immunoblots showing 
effects of miR-26a (n=5) and antisense (AMO-26a; n=6) on Kir2.1 protein-expression in 
H9c2 rat ventricular cells. miR-26a (100 nM) and AMO-26a (10 nM) were transfected with 
lipofectamine.  Ctl: Mock-treated with lipofectamine; miR-NC:  negative-control miRNA; 
AMO-NC: negative-control AMO.  **p<0.01, ***p<0.001 vs Ctl; φφp<0.01 vs miR-26a 
alone.  C. qPCR showing effects on KCNJ2 transcript-levels in H9c2 cells.  *p<0.05, 
**p<0.01 vs Ctl; n=4 per group.  D. IK1 density in cultured neonatal rat ventricular 
cardiomyocytes.  IK1 was elicited by 100-ms pulses to voltages indicated.  *p<0.05 vs Ctl; 
n=11/group.  E. Luciferase reporter activities from H9c2 cells co-transfected with miR-26a 
(10 nM) or AMO-26a (10 nM) and chimeric vectors carrying luciferase gene and a 
fragment containing one of the binding motifs.  Ctl/WT: control with wild-type binding 
sites; MT: Mutated miR-26 binding sites in the 3’UTR of KCNJ2.  *p<0.05, **p<0.01, 
***p<0.001 vs Ctl; φφφp<0.001 vs miR-26a alone; δδ p<0.01 vs miR-26a + AMO26a; 
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n=3/group for mutated constructs and 4/group for other groups.  F. Verification of changes 
in miR-26 expression by qPCR. AMO-26a and AMO-26b target both miR-26a and miR-
26b.  **p<0.01, ***p<0.001 vs Ctl; φφp<0.01, φφφp<0.001 vs miR-26a alone; n=4/group.  
Values are mean±SEM. 
Figure 3.  A. Effects of miR-26 and its antisense on AF in mice.  Upper panels: 
representative atrial electrogram recordings.  WT: Control mice receiving vehicle injections.  
Adv-miR-Free:  Adenovirus vector without miR-26; MM LNA-antimiR-26a: mismatched 
LNA-antimiR-26a; as negative control constructs.  Burst pacing is highlighted by solid 
underlines, whereas dashed underlines indicate AF.  Lower panels:  Percentage of animals 
with successful AF induction (left: results are shown as (n/N), where n=number inducible 
into AF/total of N mice) and AF-duration in animals with successful AF-induction (right).  
*p<0.05, ***p<0.001 vs WT; φφφp<0.001 vs LNA-antimiR-26a.  Note: Here and in Figure 
4, related data-sets for AF incidence and AF duration, are shown separately for clarity in 
display.  However, statistical comparisons were performed between all animals with 
interventions simultaneously (see Online Figure 6 for all comparisons), with the statistical 
comparisons here reflecting the results of simultaneous comparisons of all data in Online 
Figure 6.  B. IK1 in atrial myocytes isolated from mice treated with various constructs.  Left 
panels: IK1 recordings.  Right panel: IK1 density-voltage relationships.  Results for Adv-
miR-26a and LNA-antimiR-26a are shown with solid lines and the symbols defined on the 
figure; results for their controls (Adv-miR-free and MM LNA-antimiR-26a) are shown with 
dashed lines.  *p<0.05 vs WT; n=12 cells/group.  C. qPCR verification of atrial miR-26 
expression-changes resulting from various constructs (NB. antimiR-26a is complementary 
to both miR-26a and miR-26b).  ***p<0.001 vs WT; n=8 mice/group.  Values are 
mean±SEM. 
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Figure 4.  A. Inhibitory effect of LNA-miR-Mimic on induction (left) and maintenance in 
inducible animals (right) of AF induced in mice also treated with LNA-antimiR-26a.  MM 
LNA-miR-Mimic: mismatched miR-Mimic (negative control).  Number inducible/total-
used is indicated by n/N values within brackets.  *p<0.05, ***p<0.001 vs WT; φφp<0.01, 
φφφp<0.001 vs LNA-antimiR-26a alone; §p<0.05 vs LNA-antimiR-26a + LNA-
miR-Mimic.  B. Western blot verifying ability of miR-Mimic to knock down Kir2.1.  
**p<0.01 vs WT; φφp<0.01 vs LNA-antimiR-26a alone; §§p<0.01 vs LNA-antimiR-26a + 
LNA-miR-Mimic; n=6 for each group.  C. LNA-miR-Mask abolishes the protective effect 
of Adv-miR-26a against AF induction (left) and maintenance (right).  +LNA-miR-Mask: 
mice injected with LNA-miR-Mask (5 mg/kg/day daily for 3 days before injection of Adv-
miR-26a); LNA-miR-Mask:  mice injected with LNA-miR-Mask alone.  MM miR-Mask: 
mismatched miR-Mask (negative control).  *p<0.05 vs WT; φp<0.05, φφp<0.01 vs Adv-
miR-26a alone; §§p<0.01 vs Adv-miR-26a + LNA-miR-Mask.  D. Western blot verifying 
ability of miR-Mask to protect against Kir2.1 knockdown by Adv-miR-26a.  ***p<0.001 vs 
WT; φφφp<0.001 vs Adv-miR-26a alone; §§§p<0.001 vs Adv-miR-26a + LNA-miR-Mask; 
n=6/group.  Values are mean±SEM.  Group definitions as in Figure 3.  Note: The 
experiments shown in Figures 3A, 4A and 4C were done contemporaneously.  Thus, the 
same WT group data serve as controls in each case, and the same LNA-antimiR-26a and 
Adv-miR26a data are shown in Figure 3 and Figure 4.  As in Figure 3, related data-sets for 
AF incidence and AF duration, are shown separately for clarity in display.  However, 
statistical comparisons were performed between all animals with interventions 
simultaneously (see Online Figure 6 for all comparisons), with the statistical comparisons 
here reflecting the results of simultaneous comparisons of all data in Online Figure 6. 
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Figure 5.  A. and B. Verification of the ability of the LNA-miR-Mimic alone to reduce (A) 
and the LNA-miR-Mask alone to increase (B) atrial Kir2.1 protein level, by Western blot 
on protein samples from atrial tissues.  The respective negative control constructs were also 
examined.  **p<0.01 vs WT; n=6 /group.  C. and D. Verification of the specificity of the 
LNA-miR-Mimic to repress Kir2.1 without affecting the other untargeted genes, Cyclin D2 
and Cyclin E2. **p<0.01 vs WT; n=5/group.  E. and F. Verification of the specificity of the 
LNA-miR-Masks to block action of miR-26 on Kir2.1 without altering its effects on two 
other proven target genes, Cyclin D2 and Cyclin E2 (27).  miR-26a: Adv-miR-26a; miR-
Masks:  LNA-miR-Masks; MM miR-Mask:  mismatched LNA-miR-Mask.  **p<0.01 vs 
WT; n=6/group.  Values are expressed as mean±SEM. 
Figure 6.  A. Schematic genomic maps of the 3 miR-26 family members showing human 
host genes, intronic locations of pre-miR-26a/b, and putative NFAT binding sites (indicated 
by arrows) in the 5’flanking regions.  TSS: transcription start site.  B. Effects of NFAT-
inhibition on promoter activities of the host genes of human miR-26 family members:  
Ctdspl/miR-26a-1, Ctdsp2/miR-26a-2, and Ctdsp1/miR-26b, determined by luciferase 
activity assay using pGL3 vector carrying the promoter regions containing NFAT binding 
sites.  NFAT was inhibited by INCA6 (100 nM), or sequestered by decoy 
oligodeoxyribonucletotide (dODN-NFAT; 10 nM), or silenced by siRNAs to NFATc3 and 
NFATc4 (10 nM).  Negative controls failed to affect luciferase activity (data not shown).  
*p<0.05, **p<0.01, ***p<0.001 vs Ctl; n=4/group.  C. Effects of NFAT inhibition by 
INCA6 (left panel; n=5/group), dODN-NFAT (10 nM; middle panel; n=6/group), and 
siRNA (10 nM; right panel; n=6/group) on miR-26a and miR-26b levels, determined by 
qPCR in H9c2 cells.  *p<0.05, **p<0.01 vs Ctl.  D. Effects of NFAT inhibition on 
expression of miR-26 host genes, determined by qPCR in H9c2 cells.  Note that NFAT 
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inhibition does not affect miR-1 levels (Supplementary Figure 13 online).  *p<0.05 vs 
Ctl; n=6/group.  Values are mean±SEM. 
Figure 7.  A. EMSA to test in vitro binding of NFATc3 to its cis-acting element in the 
promoter region of human host genes for miR-26a-1, miR-26a-2, and miR-26b.  Note 
shifted band representing protein-DNA binding (arrows), abolished with excess non-labeled 
probe.  Supershifted band (hollow arrows) represents NFATc3-cis-element binding in 
presence of anti-NFATc3 antibody.  B. Chromatin immunoprecipitation (ChIP) testing in 
vivo binding of NFAT to human host genes of miR-26a-1, miR-26a-2, and miR-26b.  Top: 
PCR products of 5’-flanking region encompassing NFAT binding sites following 
immunoprecipitation with anti-NFATc3 antibody.  Bottom: Host gene binding measured by 
qPCR following ChIP, expressed as fold-changes over IgG negative-control.  Input: 
genomic DNA without immunoprecipitation.  **p<0.01, ***p<0.001 vs IgG; n=3/group.  
C. Western blot showing Kir2.1 downregulation by INCA6 (100 nM).  **p<0.01 vs Ctl; 
n=5/group.  Values in B and C are mean±SEM.  D. Immunohistochemical images showing 
nuclear translocation of NFATc3 and NFATc4 in atrial samples from AF dogs (CA) and 
patients (HA).  Blue: nuclear staining (DAPI); Red: NFAT staining; Violet: NFAT nuclear 
localization in merged images.  Findings similar to those in D were obtained in 3 subjects 
per group. Scale bar: 25 um. 
Figure 8.  Molecular mechanism underlying the AF-promoting effect of miR-26 
downregulation (shown in blue).  AF activates NFAT, enhancing NFAT translocation into 
the nucleus, where it transcriptionally represses the expression of miR-26 genes.  Reduced 
miR-26 expression then derepresses its target gene KCNJ2 at both mRNA and protein 
levels, causing an augmentation of IK1.  The augmented IK1 favors the maintenance of AF.  
Note: The roles of components illustrated in darker blue were shown by manipulation both 
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in vivo and in vitro; those in lighter blue were demonstrated in vitro only.  In green are the 
underlying pathophysiological contributors to initial AF occurrence, which also contribute 
to the properties and probability of AF in the presence of enhanced IK1. 
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Supplementary Material 
 
Online Methods 
Computational prediction of miRNA target genes and cis-acting elements for 
transcription factors. 
We used seven established miRNA target prediction algorithms: 
DIANA-microT3.1, miRanada, MirTarget2, PicTar, PITA, microcosm, and 
TargetScan5.1.  Only the miRNAs that were predicted to target KCNJ2 gene by 
at least four of the seven algorithms were considered as candidates for further 
analysis (1). 
 The binding sites for various transcription factors in the promoter regions of 
the host genes of miR-26a-1, miR-26a-2 and miR-26b from different species 
(human, canine, rat and mouse) were analyzed with MatInspector V2.2 
(Genomatix) (2).  Analyses were made to the 5’flanking regions 5 kb upstream of 
the transcriptional start sites of the host genes (Online Table 4). 
 
Bioinformatic identification of miR-26 as a candidate KCNJ2-regulating microRNA 
of interest.   
We first performed an initial miRNA screening microarray analysis of AF samples 
(described in one of our previous publications (3)) followed by a bioinformatic search for 
miRNAs that target KCNJ2. Initially, we suspected miR-101 as the primary candidate 
miRNA for KCNJ2 regulation.  However, in followup experiments, we found that the 
expression-levels of miR-101 in the human heart are very low compared to miR-1 or 
miR-26a/b (Figure A below), which makes miR-101 unlikely to be the principal regulator 
of KCNJ2.  Therefore, we changed our strategy and measured the expression levels of all 
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the highly-conserved potential KCNJ2-targeting miRNAs in our atrial-tachypaced (ATP) 
dog samples, including miR-1, miR-16, miR-24, miR26a/b, miR-101 and miR-195, as 
shown in Figure B.  After this screening, we selected miR-26a/b for study, based on the 
fact that it is the only microRNA that both targets KCNJ2 and is highly expressed in the 
heart, with an expression-level that is downregulated in AF-models like the ATP dog. 
 
Figure A 
Relative expression of miR-26 and miR-101 in human LA
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Figure B 
Expression of KCNJ2-targeted miRNAs in atrium of ATP dogs
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Rapid amplification of cDNA ends (5’-RACE).  The transcription start sites 
(TSS) of the host genes CtdspI (for miR-26a-1), Ctdsp2 (for miR-26a-2) and 
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Ctdsp1 (for miR-26b) were determined with Marathon cDNA Amplification Kit, 
as previously described (2, 4).  Human RNA sample was purchased from 
Clontech (Mountain View, CA).  The gene-specific primers (GSPs) used for 
5’RACE are shown in Online Table 5. 
 
Verification of miR-Mask and miR-Mimic specificity.  Searches for 
complementarity of the sequences of miR-Mimic and miR-Masks to other 
functionally-known transcripts in the mouse genome were performed by BLAST 
to confirm the specificity for the KCNJ2 gene.  No significant complementarity 
was found to any other transcript with known function.  The effectiveness and 
specificity of miR-Mask and miR-Mimic constructs was tested by assessing their 
ability to prevent and mimic (respectively) the effects of miR-26 on 
Kir2.1-expression and AF-vulnerability, as well as a lack of effect on miR-26 
targets (cyclin D2 and E2) documented in the literature (5) as well as in the present 
study.  
 
Data analysis.  Group data are expressed as mean ± SEM. Two-group only comparisons 
were performed by unpaired Student’s t-test.  Multiple-group comparisons for real-time 
RT-PCT and western blot experiments were analyzed by one-way ANOVA with 
Bonferroni -adjusted post-hoc t-tests.  Differences in AF incidence were analyzed using 
χ2-test.  To account for multiple testing, we selected for comparison only results of 
primary biological significance and applied a correction using the Holm-Bonferroni 
method.  The statistical significances of multiple-group comparisons for AF duration were 
obtained with one-way ANOVA on all data, followed by post-hoc Tukey tests.  A 
two-tailed p<0.05 was taken to indicate a statistically significant difference. 
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Online Figure Legends 
Online Figure 1.  Alignment of sequences of mature miR-26 family miRNAs of 
different species.  The sequences of miR-26a-1 and miR-26a-2 are identical 
among species.  The seed sites (5’end 2-8 nucleotides) are highlighted in yellow.  
Note that the human sequences of miR-26a and miR-26b are identical to mouse 
(and other species as well), which justifies the use of these miRNAs in mouse 
experiments. 
Online Figure 2.  Sequences of miR-26a/b and their antisense molecules used in 
our study. (a) Alignment of the sequences of miR-26a/b (upper sequences) with 
their target sites in the 3’-UTRs of human KCNJ2 (lower sequences).  The 
complementarity is indicated by boldface letters highlighted in yellow and 
connected by “|”.  (b) Sequences of the negative control miRNA (miR-NC) and 
negative control miRNA antisense oligodeoxynucleotides (AMO-NC). 
Online Figure 3.  Western blot analysis of the effects of miR-26 on protein 
levels of several K+ channel pore-forming α-subunits. (a) Lack of effect of 
miR-26a on human ether-ago-go-related gene (HERG) K+ channel subunit 
responsible for the rapid delayed-rectifier K+ current (IKr). +AMO-26a: 
co-transfection of miR-26a and AMO-26a; miR-NC: negative control miRNA; 
AMO-NC: negative control AMO.  (b) Lack of effect of miR-26a on human 
voltage-gated long QT K+ channel subunit 1 (KvLQT1) responsible for the slow 
delayed-rectifier K+ current (IKs).  (c) Lack of effect of miR-26a on human 
voltage-gated shaker-type of K+ channel subunit (Kv4.3) responsible for the 
transient outward K+ current (Ito1). n=3/group. 
Online Figure 4. Sequences of the antisense to miR-26a (a) with locked 
nucleotides (LNA-antimiR-26a) and the mismatched LNA-antimiR-26a (MM 
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LNA-antimiR-26a) for negative control.  The complementarity between 
LNA-antimiR-26a or MM LNA-antimiR-26a and miR-26a/b is highlighted in 
yellow.  The boldface and underlined letters represent the LNA-modified 
nucleotides.  The lower case letters indicate the mismatched nucleotides.  Note 
that the miRNA sequence of miR-26a is 100% conserved among human, rat and 
mouse.  
Online Figure 5.  Schematic illustration of construction of adenovirus vector 
carrying mouse pre-miR-26a-1. Mouse miR-26a-1 precursor DNA (5'-GGATCCg 
TTCCGGCACCGGAGCAAGTTCATTAGGTCCTATCCGACACGTCCAGGGT
TCCCCGGATAAGAACCAATGAACGTGCCCCTGCGCCCGGACttttttAAGCT
T-3') was inserted into adenovirus shuttle plasmid pDC316-EGFP-U6. 
pDC316-EGFP-U6 was then co-transfected with the infectious adenovirus 
genomic plasmid pBHGlox∆E1,3Cre into 293 cells by lipofectamine.  Following 
co-transfection of these two DNAs, homologous recombination occurred to 
generate a recombinant adenovirus in which pre-miR-26a-1 is incorporated into the 
viral genome, replacing the ∆E1 region.  The control vector (Adv-miR-free) 
lacked the pre-miR-26a DNA unit. 
Online Figure 6.  One contemporaneous set of wild type controls was performed 
for all groups.  For clarity, results are shown separately for different sets of 
interventions in Figures 3 and 4 of the main manuscript.  However, statistical 
comparisons were performed considering all groups simultaneously, as shown in 
this figure.  AF incidence comparisons (a) were by χ2, with correction for 
multiple testing by the Holm-Bonferroni method.  AF durations (b) were 
compared by one-way ANOVA with post-hoc Tukey’s tests. 
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Online Figure 7.  Verification of cellular uptake of Adv-miR-26a-1 in mouse 
atrial tissues.  Adv-miR-26a-1 was administered by direct injection into tail veins.  
Three days after Adv-miR-26a-1 administration, the animals were scarified and 
atrial tissues were sliced for laser scanning confocal microscope examination.  
Cardiomyocytes stained in green (GFP incorporated in the viral vector) indicate 
successful Adv-miR-26a-1 uptake.  Control samples were obtained from 
sham-operated, age-matched mice.  The images shown are from three 
independent experiments from three separate animals from each group. 
Online Figure 8.  Verification of the ability of the LNA-antimiR-26a to 
upregulate (A), and adv-miR-26a to downregulate (B), atrial Kir2.1 protein level 
in mice, determined by Western blot analysis with protein samples from atrial 
tissues.  Their respective negative control constructs were also examined. 
*p<0.05, **p<0.01 vs Ctl; n=6 for each group. C and D. Verification of 
Adv-miR-26a on two proven targets of miR-26, Cyclin D2 and Cyclin E2 (5).  
**p<0.01 vs WT; n=5/group.  The LNA constructs were injected into mice via 
tail vein at a dosage of 5 mg/kg/day in 0.2 ml saline once a day for three 
consecutive days, and Adv constructs were injected through the tail vein at 1010 
pfu/ml in 100 μl.  The atrial tissues for the analyses were obtained 3 days after 
the last construct administration.   
Online Figure 9.  Sequences of the miR-Mimic (a) and miR-Mask (b) and their 
mismatched counterparts as negative control constructs used in our study.  The 
complementarity between the guide strand of the miR-Mimic or miR-Mask and 
the 3’UTR of KCNJ2 is highlighted in yellow and connected by “|”.  The 
boldface and underlined letters represent the LNA-modified nucleotides.  The 
lower case letters indicate the mismatched nucleotides to KCNJ2. GS: guide strand; 
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PS: passenger strand.  The two miR-Masks were designed to fully base pair the 
two binding sites for miR-26 in the 3’UTR of KCNJ2 so as to protect these sites 
from binding miR-26.  Searches for complementarity of the sequences of 
miR-Mimic and miR-Masks to other functionally-known transcripts in the mouse 
genome were performed by BLAST to confirm the specificity for the KCNJ2 gene. 
Online Figure 10.  Identification of transcription start sites (TSSs) and genomic 
characteristics of the host genes of the miR-26 family miRNAs using 5’RACE 
techniques.  (a) DNA gel image showing the single, discrete bands obtained by 
5’RACE, indicating a single TSS for each host gene (Ctdsp2, Ctdspl or Ctdsp1).  
(b)-(d) Genomic sequences of Ctdspl for miR-26a-1, Ctdsp2 for miR-26a-2, and 
Cdtsp1 for miR-26b.  TSSs are indicated; putative NFAT binding sites are shown 
in red letters; the fragments highlighted in green containing NFAT binding sites 
are those used for promoter activity analysis by luciferase assay.  The outer and 
inner (nested) primers for 5’RACE, and the forward and reverse primers for ChIP 
experiments, are indicated by lines above or below the sequences.  
Online Figure 11.  The constructs used to inhibit the function of nuclear factor 
of activated T-cells (NFAT). (a) Sequences of decoy oligodeoxynucleotide 
(dODN) fragments used to sequestrate NFAT (dODN-NFAT) and the negative 
control dODN (dODN-NC).  (b) Sequences of small interference RNA (siRNA) 
used to knock down the cardiac isoforms of NFAT: NFATc3 and NFATc4. 
Online Figure 12.  Verification of the efficacy of siRNAs in knocking down the 
cardiac isoforms of NFAT, NFATc3 and NFATc4, assessed by qPCR (a) and by 
Western blot analysis (b) in H9c2 rat ventricular cells.  siRNA to NFATc3 and 
siRNA to NFATc4 were co-transfected into cells. NC: negative control siRNA.  
**p<0.01, ***p<0.001 vs Ctl; n=4 for each group. 
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Online Figure 13.  Effects of NFAT inhibition on expression of miR-1, 
determined by qPCR in H9c2 rat ventricular cells.  Control cells were 
mock-treated with lipofectamine 2000 for experiments involving transfection of 
dODN-NFAT or siRNAs. Note that NFAT does not affect miR-1 level.  n=3 for 
INCA group and n=4 for the other groups. 
Online Figure 14. A. AF incidence in 1-week and 6-week atrial tachypacing (ATP) canine 
model.  B. AF duration in ATP canine model.  C. Quantitative RT-PCR measurement of 
miR-26a in atrium and ventricle of 1-wk and 6-wk ATP dogs.  D. Western blot analysis of 
Kir2.1 protein in atrium and ventricle of 1-wk and 6-wk ATP dogs. n=5/group; *p<0.05, 
**p<0.01, ***p<0.001. 
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Online Figures 
 
Online Figure 1 
 
 
 
 
             miR-26a-1/miR-26a-2                 miR-26b 
Human  UUCAAGUAAUCCAGGAUAGGCU-3’  UUCAAGUAAUUCAGGAUAGGU-3’ 
Canine  UUCAAGUAAUCCAGGAUAGGCU-3’  UUCAAGUAAUUCAGGAUAGGUU-3’ 
Rat   UUCAAGUAAUCCAGGAUAGGCU-3’  UUCAAGUAAUUCAGGAUAGGU-3’ 
Mouse  UUCAAGUAAUCCAGGAUAGGCU-3’  UUCAAGUAAUUCAGGAUAGGU-3’ 
 
 
 
 
 
Online Figure 1.  Alignment of sequences of mature miR-26 family miRNAs of 
different species.  The sequences of miR-26a-1 and miR-26a-2 are identical 
among species.  The seed sites (5’end 2-8 nucleotides) are highlighted in yellow.  
Note that the human sequences of miR-26a and miR-26b are identical to mouse 
(and other species as well), which justifies the use of these miRNAs in mouse 
experiments. 
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Online Figure 2 
a.  miR-26:KCNJ2 Complementarity 
miR-26a 
-3'-UCGGAUAGGACCUAAUGAACUU-5’  miR-26a  
-----|::|-|||---|--||||||| 
254-UGUUUUUCC---AAAACUUGAA-272  3’UTR of KCNJ2 (Binding Site 1) 
254-UGUUUUUCC---AAActgctgA-272  Mutant 3’UTR of KCNJ2 
 
--3'-UCGGAUAGGACCUAAUGAACUU-5’  miR-26a 
-------|||-|----|--|||||||| 
3132-UCCCUCUAAGAGUAUACUUGAA-3153 3’UTR of KCNJ2 (Binding Site 2) 
3132-UCCCUCUAAGAGUAUctgctgA-3153 Mutant 3’UTR of KCNJ2 
 
 
miR-26b 
-3'-UGGAUAGGACUUAAUGAACUU-5’   miR-26b 
----:::|-|||---|--||||||| 
255-GUUUUUCC---AAAACUUGAA-272  3’UTR of KCNJ2 (Binding Site 1) 
255-GUUUUUCC---AAActgctgA-272  Mutant 3’UTR of KCNJ2 
 
 
--3'-UGGAUAGGACUUAAUGAACUU-5’  miR-26b 
------|||-|-------|||||||| 
3133-CCCUCUAAGAGUAUACUUGAA-3153  3’UTR of KCNJ2 (Binding Site 2) 
3133-CCCUCUAAGAGUAUctgctgA-3153  Mutant 3’UTR of KCNJ2 
 
 
b.  Negative Control miRNA and AMO miR-NC 
 
miR-NC 
5’-UCAUAAAGCUGAUAACCUCUAGAU-3’         
3’-UAAGUAUUUCGACUAUUGGAGAUC-5’ 
 
 
AMO-NC 
5’-TCATACAGCTAGATAACCAAAGA-3’ 
 
Online Figure 2.  Sequences of miR-26a/b and their antisense molecules used in our 
study. (a) Alignment of the sequences of miR-26a/b (upper sequences) with their target 
sites in the 3’-UTRs of human KCNJ2 (lower sequences).  The complementarity is 
indicated by boldface letters highlighted in yellow and connected by “|”.  (b) Sequences 
of the negative control miRNA (miR-NC) and negative control miRNA antisense 
oligodeoxynucleotides (AMO-NC). 
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Online Figure 3 
 
 
Online Figure 3.  
Western blot analysis of the 
effects of miR-26 on protein 
levels of several K+ channel 
pore-forming α-subunits. (a) 
Lack of effect of miR-26a on 
human ether-ago-go-related 
gene responsible for the 
rapid delayed-rectifier K+ 
current (IKr). +AMO-26a: 
co-transfection of miR-26a 
and AMO-26a; miR-NC: 
negative control miRNA; 
AMO-NC: negative control 
AMO.  (b) Lack of effect of 
miR-26a on human 
voltage-gated long QT K+ 
channel subunit 1 (KvLQT1) 
responsible for the slow 
delayed-rectifier K+ current 
(IKs).  (c) Lack of effect of 
miR-26a on human 
voltage-gated shaker-type of 
K+ channel subunit (Kv4.3) 
responsible for the transient 
outward K+ current (Ito1). 
n=3/group. 
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Online Figure 4 
 
 
-------5’-TCCTGGATTACTTGA-3’  LNA-antimiR-26a 
----------||||||||||||||| 
-3’-UCGGAUAGGACCUAAUGAACUU-5’ miR-26a 
-3'-U•GGAUAGGACUUAAUGAACUU-5’ miR-26b 
----------||||||||----|| 
-------5’-TCCTGGATactaTGt-3’  MM-LNA-antimiR-26a 
 
 
-------5’-TCCTGAATTACTTGA-3’  LNA-antimiR-26b 
----------||||||||||||||| 
-3'-U•GGAUAGGACUUAAUGAACUU-5’ miR-26b 
-3’-UCGGAUAGGACCUAAUGAACUU-5’ miR-26a 
          
 
 
Online Figure 4. Sequences of the antisense to miR-26a (a) with locked 
nucleotides (LNA-antimiR-26a) and the mismatched LNA-antimiR-26a (MM 
LNA-antimiR-26a) for negative control.  The complementarity between 
LNA-antimiR-26a or MM LNA-antimiR-26a and miR-26a/b is highlighted in 
yellow.  The boldface and underlined letters represent the LNA-modified 
nucleotides.  The lower case letters indicate the mismatched nucleotides.  Note 
that the miRNA sequence of miR-26a is 100% conserved among human, rat and 
mouse.  
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Online Figure 5 
 
Online Figure 5.  Schematic illustration of construction of adenovirus vector carrying 
mouse pre-miR-26a-1. Mouse miR-26a-1 precursor DNA (5'-GGATCCg 
TTCCGGCACCGGAGCAAGTTCATTAGGTCCTATCCGACACGTCCAGGGTTCCC
CGGATAAGAACCAATGAACGTGCCCCTGCGCCCGGACttttttAAGCTT-3') was 
inserted into adenovirus shuttle plasmid pDC316-EGFP-U6. pDC316-EGFP-U6 was then 
co-transfected with the infectious adenovirus genomic plasmid pBHGlox∆E1,3Cre into 
293 cells by lipofectamine.  Following co-transfection of these two DNAs, homologous 
recombination occurred to generate a recombinant adenovirus in which pre-miR-26a-1 is 
incorporated into the viral genome, replacing the ∆E1 region.  The control vector 
(Adv-miR-free) lacked the pre-miR-26a DNA unit. 
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Online Figure 6 
 
 
 
Online Figure 6.  One contemporaneous set of wild type controls was performed 
for all groups.  For clarity, results are shown separately for different sets of 
interventions in Figures 3 and 4 of the main manuscript.  However, statistical 
comparisons were performed considering all groups simultaneously, as shown in 
this figure.  AF incidence comparisons (a) were by χ2, with correction for 
multiple testing by the Holm-Bonferroni method.  AF durations (b) were 
compared by one-way ANOVA with post-hoc Tukey’s tests.
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Online Figure 7 
 
 
Online Figure 7.  Verification of cellular uptake of Adv-miR-26a-1 in mouse 
atrial tissues.  Adv-miR-26a-1 was administered by direct injection into tail veins.  
Three days after Adv-miR-26a-1 administration, the animals were sacrificed and 
atrial tissues were sliced for laser scanning confocal microscope examination.  
Cardiomyocytes stained in green (GFP incorporated in the viral vector) indicate 
successful Adv-miR-26a-1 uptake. Control samples were obtained from 
sham-operated, age-matched mice. The images shown are from three independent 
experiments from three separate animals from each group. 
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Online Figure 8 
 
 
 
Online Figure 8.  Verification of the ability of the LNA-antimiR-26a to 
upregulate (A), and adv-miR-26a to downregulate (B), atrial Kir2.1 protein level in 
mice, determined by Western blot analysis with protein samples from atrial tissues.  
Their respective negative control constructs were also examined. *p<0.05, 
**p<0.01 vs Ctl; n=6 for each group. C and D. Verification of Adv-miR-26a on 
two proven targets of miR-26, Cyclin D2 and Cyclin E2 (5). **p<0.01 vs WT; 
n=5/group.  The LNA constructs were injected into mice via tail vein at a dosage 
of 5 mg/kg/day in 0.2 ml saline once a day for three consecutive days, and Adv 
constructs were injected through the tail vein at 1010 pfu/ml in 100 μl.  The atrial 
tissues for the analyses were obtained 3 days after construct administration.  
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Online Figure 9 
 
a. miR-Mimic 
 --5’-UUUUAGCCUUCGUUAAGACGTT-3’  LNA-miR-Mimic/PS 
-3’-AGAAAAUCGGAAGCAAUUCUGC-5’  LNA-miR-Mimic/GS 
----||||||| ----|||||||||| 
449-UCUUUUACAUAACGUUAAGACG-470  3’UTR of KCNJ2 
 
 
 --5’-UUUUAGCCUUCcccuAcugGTT-3’  LNA-MM-miR-Mimic/PS 
-3’-AGAAAAUCGGAAGgggaUgacC-5’  LNA-MM-miR-Mimic/GS 
----||||||| ----|----|---| 
449-UCUUUUACAUAACGUUAAGACG-470  3’UTR of KCNJ2 
 
 
 
b. miR-Mask 
---------3’-AAATGTTTTGAACTT-5’  LNA-miR-26-Mask1 
------------||||||||||||||| 
----260-UGUUUUUACAAAACUUGAA-278  3’UTR of KCNJ2 
 
---------3’-TTCTCATATGAACTT-5’  LNA-miR-26-Mask2 
------------||||||||||||||| 
3100-UCCCUCUAAGAGUAUACUUGAA-3121 3’UTR of KCNJ2 
 
 
---------3’-TTGCATATACTTGAT-5’  LNA-MM-miR-Mask 
 
 
Online Figure 9.  Sequences of the miR-Mimic (a) and miR-Mask (b) and their mismatched 
counterparts as negative control constructs used in our study.  The complementarity between the 
guide strand of the miR-Mimic or miR-Mask and the 3’UTR of KCNJ2 is highlighted in yellow and 
connected by “|”.  The boldface and underlined letters represent the LNA-modified nucleotides.  
The lower case letters indicate the mismatched nucleotides to KCNJ2. GS: guide strand; PS: 
passenger strand.  The two miR-Masks were designed to fully base pair the two binding sites for 
miR-26 in the 3’UTR of KCNJ2 so as to protect these sites from binding miR-26.  Searches for 
complementarity of the sequences of miR-Mimic and miR-Masks to other functionally-known 
transcripts in the mouse genome were performed by BLAST to confirm the specificity for the 
KCNJ2 gene.  
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Online Figure 10 
a. DNA gel 
 
 
 
Online Figure 10.  Identification of transcription start sites (TSSs) and genomic 
characteristics of the human host genes of the miR-26 family miRNAs using 
5’RACE techniques. (a) DNA gel image showing the single, discrete bands 
obtained by 5’RACE, indicating a single TSS for each host gene (Ctdsp2, Ctdspl 
or Ctdsp1).  (b)-(d) See below.  Genomic sequences of Ctdspl for miR-26a-1, 
Ctdsp2 for miR-26a-2, and Cdtsp1 for miR-26b.  TSSs are indicated; putative 
NFAT binding sites are shown in red letters; the fragments highlighted in green 
containing NFAT binding sites are those used for promoter activity analysis by 
luciferase assay.  The outer and inner (nested) primers for 5’RACE, and the 
forward and reverse primers for ChIP experiments, are indicated by lines above or 
below the sequences.  
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Online Figure 10 
b. Ctdspl/miR-26a-1 
 -3626 CAACTCCCTA CTTGTCATTT TAGATAACTC TGAGATCCCC AGTGTCTAGA 
 -3576 GCAGAACCTT GCATATAGAA TATGCACTCA ATAAATGTTT GTTGAATGAA 
 
               Forward Primer 
 -3526 TATAGCCAAA TTTATCAGTC TTATCCTGGC AATTTCTTAA GTTTTTGTCA 
 
 /ChIP    
 -3476 CTCTCAGGCC TTTCCCATCC AAGATCAAAA AGCACTTACC CATTTGTTCT 
 -3426 GGTTTATGTT AATTTTTTAT ATTTAATTAT TCAGTCTATC TTGAATGTGC 
 
            Reverse Primer/ChIP   
 -3376 TGTAAGGACT GGGATAAAGA TATATTTTTT CCTCATGGAT AGGTACTTGT 
                                   NFAT Binding Site            
 
 -3326 CCCAACAATT TTTGAATCTT TCTTTCATGT GTAAAACCAA AATACTGTGT 
 -3276 TATCTAAGAC TGTTTCAGTA AGGTATTATG CAATCACTTA TAATAGTAGT 
 -3226 AACAGCAATT ATGTCACCAC ATAAGAAAAT GCTAACCTTA TAATTTTAAA 
 -3176 CATGGCTTTT TTATAGCTAC ATAAAATTAT GTCAGCATAT AGGCAAGGAC 
          ……………………………………………………………………………………………………………………………………………… 
          ……………………………………………………………………………………………………………………………………………… 
          ……………………………………………………………………………………………………………………………………………… 
  -676 TGCCTCAGAC TCCTCCCCAC ATCTCTCACA CCCCAGGCCT CTCACCTCAC 
  -626 TCATTCTGCC AGGCCCCCCT GACACCCCTC ACTTCTAACC CCCCGAGCCC     
  -576 CTCTGCCGTC CGCTACACCC CGAGCCCCTC ACCCCACTCA ACTGCCCCGG 
 -526 GCCCCCGCGC GCGCGGCCGC CCCCTCCCGC CCTCCACTCA CCCTGTGTCG 
  ……………………………………………………………………………………………………………………………………………… 
                                            TSS (+1) 
 -26   GGGGGGCCGG GCCTGCGGGC GGCCGCCGCG CCGCGCACCC ATGGACGGCC 
   +25 CGGCCATCAT CACCCAGGTG ACCAACCCCA ATGGACGGCC CGGCCATCAT 
              Translation Start Site 
 
      Inner Primer/5’RACE    
   +75 CACCCAGGTG ACCAACCCCA AGGAGGACGA GGGCCGGTTG C 
                                   Outer Primer/5’RACE 
 
Online Figure 10b.  Identification of transcription start sites (TSSs) and genomic characteristics 
of the host genes of the miR-26 family miRNAs using 5’RACE techniques.  Genomic sequences 
of Ctdspl for miR-26a-1. TSSs are indicated; putative NFAT binding sites are shown in red letters; 
the fragments highlighted in green containing NFAT binding sites are those used for promoter 
activity analysis by luciferase assay.  The outer and inner (nested) primers for 5’RACE, and the 
forward and reverse primers for ChIP experiments, are indicated by lines above or below the 
sequences.  
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Online Figure 10 
c. Ctdsp2/miR-26a-2 
 -3792 GGACACCCAG TCCGACTTCA GTAGCCACAG CAGGAGACAG ACAGGGACAG 
 
                Forward 
 -3742 CCACTCCATG TTTGCCCCAC ATAGCCCCCC ATTCTAGCAT TTGGGGGTAA 
 
 Primer/ChIP     
 -3692 TGGGGACACT GCTGTTGTTT CCAAATTGCC TCTTACCAAC CATGCAGTCA 
 -3642 GAGAGGCCAG AGGAAAGGGG ATACAGCAGG TAGGGAACCA AGTGAGAGTC 
                   NFAT Binding Site 
 
                           Reverse Primer/ChIP    
 -3592  AGTGGGCTTT CTCCTGGGAG AGTTGTTAGA CCTGGCTTCA GCTATCTCCC 
 -3542 TTGAACCACC TAAAATGAAC CACCTAAAGT TACACAACCA GCAACTGGCC 
         …………………………………………………………………………………………………………………………………………………………… 
          …………………………………………………………………………………………………………………………………………………………… 
          …………………………………………………………………………………………………………………………………………………………… 
          …………………………………………………………………………………………………………………………………………………………… 
                                                                TSS (+1) 
    -42  TCGATTACTC ACTATAGGGC TCGAGCGGCC GCCCGGGCAG GTCGCTTTTT 
   +8  CCGTAACAAA ATAGCAAAGC TCCCGACTGT CCGCAGCCCC GGCCGCTCAC 
 +58  AGATGGAGGG TCCCAGGGCC TAGGACGCAG CCCCCAGCGG GAAGCTCCAG 
  
 
 Inner Primer/5’RACE 
 +108 CTGGCCGTGA AGAGGCCGAG TCGAGAGCCG GGAGGCGCGC GGGGGTGGGC 
        Outer Primer/5’RACE 
 
 
 
 
Online Figure 10c.  Identification of transcription start sites (TSSs) Genomic sequence of Ctdsp2 
for miR-26a-2.  TSSs are indicated; putative NFAT binding sites are shown in red letters; the 
fragments highlighted in green containing NFAT binding sites are those used for promoter activity 
analysis by luciferase assay.  The outer and inner (nested) primers for 5’RACE, and the forward 
and reverse primers for ChIP experiments, are indicated by lines above or below the sequences.  
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Online Figure 10 
d. Ctdsp1/miR-26b 
-542   ATTCAAGAGC GTGATTCTGA GGTTTGCACA GCTGTTTCGG GCCAGCAGAG 
 
     Forward Primer/ChIP  
 -492 CCTTCGCTGG CTCTTGACGT CCTTGCGAGG TGATCTCTGC GACCACCAGA 
-442 CAGGAGAGAA GACCCATTTT ACAGATGAGG TAGTGCTATC TCCAAGTCCT 
 -392 CAACGAGGAA ACCGAGAAGC CTCTAGTCCC GGGTCTTCAG AAAACGCAGA 
            NFAT Binding Site                           Reverse Primer 
  
 -342 GGTGGAGCCG CGCCGCACTC GGGCACTCCC CGGCGTGGGC GCTCCCGGCG 
 /ChIP   
             
 -292 GGCGGGCCTT GGCCGAGGGC GCTCGGCGGC CTGGAACGGT GAGCCGGGTG 
 -242 CCGGGCCTGC CACGCAGCCG CAGAGACTCA GCCCCGCCGG CGGGCGGCAG 
 -192 GAAGGGAGGC GACGCCCCCT GGAGCGCGGC AGGAACCCGG CCCGGCCCGC 
 -142 CTCCCAGTCC CGCCTAGCCG CGCCGGTCCC AGAAGTGGCG AAAGCCGCAG  
 -92 CCGAGTCCAG GTCACGCCGA AGCCGTTGCC CTTTTAAGGG GGAGCCTTGA 
 
                                                      TSS (+1)   
 -42    AACGGCGCCT GGGTTCCATG TTTGCATCCG CCTCGCGGGA AGGAAACTCC 
 
                    Inner Primer/5’RACE 
 +9      ATGTTGTAAC AAAGTTTCCT CCGCGCCCCC TCCCTCCCCC TCCCCCCTAG                          
                               Outer Primer/5’RACE 
  
 +59  AACCTGGCTC CCCTCCCCTC CGGAGCTCGC GGGGATCCCT CCCTCCCACC  
 +109    CCTCCCCTCC CCCCCGCGCC CCGATTCCGG CCCCAGCCGG GGGGGAGGCC  
 +159    GGGCGCCCGG GCCAGAGTCC GGCCGGAGCG GAGCGCGCCC GGCCCCATGG 
                                                           
                                                             Translation Start Site 
 +209    ACAGCTCGGC CGTCATTACT CAGATCAGCA AGGAGGAGGC TCGGGGCCCG 
                
 
Online Figure 10d.  Identification of transcription start sites (TSSs) and genomic characteristics 
of the host genes of the miR-26 family miRNAs using 5’RACE techniques.  (d) Genomic 
sequence of Cdtsp1 for miR-26b.  TSSs are indicated; putative NFAT binding sites are shown in 
red letters; the fragments highlighted in green containing NFAT binding sites are those used for 
promoter activity analysis by luciferase assay.  The outer and inner (nested) primers for 5’RACE, 
and the forward and reverse primers for ChIP experiments, are indicated by lines above or below 
the sequences.  
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Online Figure 11 
 
a.  Decoy Oligodeoxynucleotides (dODN) 
dODN-NFAT 
5’-CGCCCAAAGAGGAAAATTTGTTTCATA-3’ 
3’-GCGGGTTTCTCCTTTTAAACAAAGTAT-5’ 
 
dODN-NC 
5’-TAGTTATGCATCACGACCTGAT-3’  
3’-ATCAATACGTAGTGCTGGACTA-5’ 
 
 
 
b.  Small Interfering RNA (siRNA) 
siRNA-NFATc3 
5’-UUAUCUUCCCUUCUACCUCCCACUG-3’ 
3’-AAUAGAAGGGAAGAUGGAGGGUGAC-5’ 
 
siRNA-NFATc4 
5’-ACCGAGUCACGAAUCUCCCAUCUAA-3’ 
3’-UGGCUCAGUGCUUAGAGGGUAGAUU-5’ 
 
 
 
 
Online Figure 11.  The constructs used to inhibit the function of nuclear factor of 
activated T-cells (NFAT). (a) Sequences of decoy oligodeoxynucleotide (dODN) 
fragments used to sequestrate NFAT (dODN-NFAT) and the negative control 
dODN (dODN-NC).  (b) Sequences of small interference RNA (siRNA) used to 
knock down the cardiac isoforms of NFAT: NFATc3 and NFATc4. 
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Online Figure 12 
 
Online Figure 12.  Verification of the efficacy of siRNAs in knocking down the 
cardiac isoforms of NFAT, NFATc3 and NFATc4, assessed by qPCR (a) and by 
Western blot analysis (b) in H9c2 rat ventricular cells.  siRNA to NFATc3 and 
siRNA to NFATc4 were co-transfected into cells.  NC: negative control siRNA.  
**p<0.01, ***p<0.001 vs Ctl; n=4 for each group. 
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Online Figure 13 
 
 
 
 
 
Online Figure 13.  Effects of NFAT inhibition on expression of miR-1, 
determined by qPCR in H9c2 rat ventricular cells.  Control cells were 
mock-treated with lipofectamine 2000 for experiments involving transfection of 
dODN-NFAT or siRNAs. Note that NFAT does not affect miR-1 level.  n=3 for 
INCA group and n=4 for the other groups. 
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Online Figure 14 
 
 
Online Figure 14. A.  AF incidence in 1-week and 6-week atrial tachypacing (ATP) 
canine model.  B. AF duration in ATP canine model.  C. Quantitative RT-PCR 
measurement of miR-26a in atrium and ventricle of 1-wk and 6-wk ATP dogs. D. Western 
blot analysis of Kir2.1 protein in atrium and ventricle of 1-wk and 6-wk ATP dogs.  
n=5/group; *p<0.05, **p<0.01, ***p<0.001.
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Online Tables 
 
 Online Table 1. Clinical characteristics of the patients used* in our study  
Patient 
No. 
Gende
r Age Diagnosis Surgery 
Non-AF (NAF) Patients  
NAF 1 male 43 Left atrial myxoma (SR)  Resection operation 
NAF 2 male 52 CAD, Tricuspid incompetence. 
(SR)
TVP 
NAF 3 female 46 RHD, MVS (SR) MVR 
NAF 4 female 22 CHD (SR) CHD repair. 
NAF 5 female 37 CAD, Tricuspid incompetence, 
Cardiac hypertrophy (SR) 
TVP 
NAF 6 male 55 Hypertension, MVP (SR) MVR 
NAF 7 male 44 Infective endocarditis (SR) MVR 
NAF 8 female 23 CHD (SR)   CHD repair. 
NAF 9 male 30 Tricuspid incompetence (SR) TVP 
NAF 10 female 36 ASD (SR) ASD closure. 
AF Patients 
AF 1 male 39 RHD (AF) AVR 
AF 2 female 68 RHD, MVS (AF) MVR, RFA 
AF 3 male 55 MVD, AF MVR, RFA 
AF 4 female 56 CAD, AVS (AF) AVR 
AF 5 male 52 RHD (AF) MVR, RFA 
AF 6 female 56 RHD (AF) MVR  
AF 7 female 55 RHD, MVS (AF) MVR, RFA 
AF 8 female 66 RHD, MVS (AF) MVR, RFA 
AF 9 female 50 RHD, MVD (AF)  MVR, RFA 
AF 10 female 59 RHD, MVD (AF)  MVR, RFA 
AF 11 male 57 RHD, MVD (AF)  MVR, RFA 
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AF 12 female 54 RHD, MVD (AF)  MVR, RFA 
*Samples from a total of 22 patients were obtained (10 SR, 12 AF). Of these, 10 (NAF 1-5 
and AF 1-5) were used for miRNA expression characterization; 11 (NAF 2-5, 6 and 7; AF 4, 
6-9) were used for KCNJ2 mRNA/protein expression measurement; 6 (NAF 8-10; AF 10-12) 
were used for immunohistochemical analyses of NFAT translocation.  
Abbreviations: AF, atrial fibrillation; ASD, atrial septal defect; AVR, aortic valve 
replacement; AVS, aortic valve stenosis; CAD, coronary artery disease; CHD, congenital heart 
disease; MVP, mitral valve prolapse; MVR, mitral valve replacement; MVD, mitral valve 
disease; MVS, mitral valve stenosis; RFA, radiofrequency ablation; RHD, rheumatic heart 
disease; SR, sinus rhythm; TVP, tricuspid valvuloplasty.  
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Online Table 2. Echocardiographic data for mice subjected to miR-26a overexpression 
or knockdown 
 
 
BW(g): Body Weight; HW(g): Heart Weight; LAID(cm): Left Atrial Internal Diameter; 
IVSd(cm): Interventricular Septum thickness at end-diastole; IVSs(cm): Interventricular 
Septum thickness at end-systolic; LVIDd(cm): Left Ventricular Internal Diameter at 
end-diastole; LVIDs(cm): Left Ventricular Internal Diameter at end-systolic; LVPWd(cm): 
LV Posterior Wall thickness in diastole; LVPWs(cm): LV Posterior Wall thickness in systolic; 
EDV(ml): End Diastolic Volume; ESV(ml): End Systolic Volume; EF(%): Ejection Fraction; 
SV (ml): Stroke Volume; FS(%): Fractional Shortening. n=5 per group; Data are mean ± 
SEM. 
 WT Adv-miR-26a Adv-miR-Free LNA-antimiR-26a MM LNA-antimiR-26a
BW (g) 29.87±0.81 29.66±1.11 29.18±0.69 29.87±0.81 28.42±0.44 
HW (g) 0.13±0.01 0.13±0.01 0.13±0.002 0.12±0.004 0.12±0.003 
HW/BW 
(mg/g) 4.21±0.18 4.37±0.17 4.40±0.10 4.15±0.12 4.29±0.10 
LAID 
(cm) 0.20±0.01 0.20±0.02 0.21±0.01 0.20±0.01 0.21±0.01 
IVSd 
(cm) 0.10±0.01 0.09±0.01 0.10±0.01 0.10±0.003 0.11±0.003 
IVSs 
(cm) 0.12±0.003 0.13±0.01 0.14±0.01 0.13±0.01 0.12±0.005 
LVIDd 
(cm) 0.33±0.01 0.32±0.02 0.37±0.02 0.35±0.02 0.30±0.01 
LVIDs 
(cm) 0.21±0.01 0.21±0.03 0.24±0.02 0.22±0.01 0.20±0.01 
LVPWd 
(cm) 0.11±0.01 0.09±0.01 0.09±0.005 0.11±0.01 0.11±0.01 
LVPWs 
(cm) 0.11±0.01 0.09±0.01 0.11±0.01 0.12±0.01 0.13±0.01 
EDV 
(ml) 0.09±0.01 0.09±0.01 0.14±0.02 0.11±0.02 0.08±0.01 
ESV 
(ml) 0.03±0.01 0.03±0.01 0.04±0.01 0.03±0.03 0.02±0.003 
EF (%) 70.0±6.0 68.9±7.5 70.5±3.0 71.3±1.9 68.9±4.6 
SV (ml) 0.07±0.01 0.06±0.01 0.09±0.01 0.08±0.01 0.05±0.01 
FS (%) 35.4±4.4 35.4±5.7 34.8±2.1 35.2±1.5 34.0±3.6 
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Online Table 3. Effects of miR-26a manipulation on electrophysiological parameters of 
mice 
 QTc Interval (ms) 
QRS Duration 
(ms) 
P-R Interval 
(ms) 
Control/WT 49.4±1.5 9.3±0.5 45.7±2.2 
Adv-miR-26a 56.3±2.1* 10.8±0.7 49.1±1.1 
Adv-miR-Free 47.8±1.7 9.8±0.5 46.9±1.8 
LNA-antimiR-26a 42.8±1.4* 9.8±0.6 45.4±1.2 
MM LNA-antimiR-26a 49.2±2.2 9.4±0.5 47.5±1.5 
Adv-miR-26a 
+ miR-Mask 48.2±1.9† 9.4±0.5 47.1±2.1 
LNA-antimiR-26a 
+ miR-Mimic 48.5±1.4¶ 9.5±0.4 46.8±1.9 
Adv-miR-26a: adenovirus vector carrying pre-miR-26a; Adv-miR-Free: empty adenovirus 
vector; MM LNA-antimiR-26a: mismatched LNA-antimiR-26a; MM LNA-antimiR-1: mismatched 
LNA-antimiR-1; P-R interval: indicating atrioventricular conduction, mainly determined by 
L-type Ca2+ current; QRS complex: indicating the excitation conduction time in ventricular 
tissues, mainly determined by Na+ current; QTc: heart rate-corrected QT interval; Ctl/WT: 
control (wild-type) mice without gene-transfer.. *p<0.05 vs Control/WT; †p<0.05 vs 
Adv-miR-26a; ¶p<0.05 vs LNA-antimiR-26a; Student t-test; n=12 mice per group. 
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Online Table 4.  Predicted NFAT binding motifs in the promoter regions of the host 
genes for the miR-26 family miRNAs of various species 
miRNA Human Canine Rat Mouse 
Host gene 
 
miR-26a-1 
 
NFAT Binding Sites 
 
 
Ctdspl; Chr3 
 
4430-GTGATGGAAACAT
TTGGAG (1/0.97) 
†4040-ATGGAGGAAATT
AGAGATG (1/1)‡ 
3992-CAGGTGGAAAGGC
ACTCCA (1/0.95) 
3340-CATGAGGAAAAAA
TATATC (1/0.96) 
 
Ctdspl; Chr23 
 
2922-GCGGAGGAAAAAG
TAGCTG (1/0.99) 
1590-GCTGAGGAAATAA
ACTAGG (1/1) 
1479-CCTCAGGAAACAG
TGGTCA (1/0.95) 
1173-CACGGAAATTCAC
ATGAAA 
(1/0.88) 
Ctdspl; Chr8 
 
2651-TATGGAAAGCTTA
ACTCTG (1/0.89) 
2466-TTTGGAAACAGGC
CCACTC (1/0.87) 
2285-AGAGGAAAGAGAA
TGGCTG (1/0.87) 
2283-GGAGAGGAAAGAG
AATGGC (1/0.99) 
 
Ctdspl; Chr9 
 
2480-GTTGGAAATATCA
CCTGTT (1/0.89) 
1293-GTTGGAAAGAAAC
TTCCAG (1/0.88) 
1213-CGTGGAAAAGTAA
GGAAGT (1/0.92) 
59-AAGGAGGAAAGCGAG
GAGG (1/0.97) 
 
Host Gene 
 
miR-26a-2 
 
NFAT Binding Sites 
 
 
 
Ctdsp2; Chr12 
 
4480-TTGGAGGAAAGGA
GAATGA (1/0.97) 
3618-CCAGAGGAAAGGG
GATACA (1/0.97) 
3385-CTATAGGAAAGAG
GCCCAC (1/0.96) 
3361-TCTGGAAAGCTCT
GTAGGG (1/0.92) 
 
Ctdsp2; Chr10 
 
2529-GTTGGAAACAGGG
AAGCCT (1/0.99) 
 
 
 
 
 
 Ctdsp2; Chr10 
 
2507-GGGGGAAAAAGAC
AGGGTG (1/0.85) 
1535-GAAGAGGAAATGA
ACAGGA (1/0.97) 
1177-AGGGGAAAAAAGA
GCAGTG (1/0.83) 
304-GTCGGAAACACAAA
CACCC (1/0.83) 
 
Host Gene 
 
miR-26b 
 
NFAT Binding Sites 
 
 
Ctdsp1; Chr2 
 
1134-GGAGAGGAAAGCG
CGCCAC (1/0.97) 
373-AACGAGGAAAAAGA
CCAAC (1/0.99) 
371-AACGAGGAAACCGA
GAAGC (1/0.84) 
 
 
Ctdsp1; Chr37 
 
209-GGGGAGGAAACTCC
ATGTT (1/0.97) 
190-GCGGAGGAAACTTT
GTTAC (1/0.97) 
 
 
 
Ctdsp1; Chr9 
 
2999-TTTAAGGAAAGAG
GCCCAC (1/0.98) 
2557-TGTGAGGAAACAA
ACAAAC (1/1) 
107-GGGGAGGAAACTCC
ATGTT (1/0.97) 
88-GCGGAGGAAACTTTG
TTAC (1/0.97) 
 
Ctdsp1; Chr1 
 
2751-TTTAAGGAAAGAG
GCCTAC (1/0.98) 
2271-TGCAAGGAAACAA
ACAAAC (1/0.96) 
1454-ACAGGAAAAATAA
AAAATA (1/0.88) 
434-GCTGGAAAAATGGC
TCAGG (1/0.92) 
 
Ctdsp: carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase; Chr: 
chromosome; †The numbers before the sequences indicate the relative positions of the 
putative NFAT binding sites in the genome. ‡The numbers in the brackets indicate the scores 
for similarity of the putative NFAT cis-acting elements in the promoter regions of the host 
genes for the miR-26 family miRNAs to the canonical core binding sites and overall matrix 
for NFAT action, respectively; the sequences highlighted in yellow with boldface are the ones 
used for EMSA experiments.
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Online Table 5. The primers used for PCR-amplification of miR-26 promoter sequences 
spanning NFAT cis-elements for chromatin immunoprecipitation assay (ChIP) 
 
Host Gene 
/miRNA Forward Primer Reverse Primer 
Ctdspl/miR-26a-1 5’-AAGTTTTTGTCACTCTCAGG-3’ 5’-GTACCTATCCATGAGGAAAA-3’ 
Ctdsp2/miR-26a-2 5’-GGGGTAATGGGGACACTGCT-3’ 5’-GGAGATAGCTGAAGCCAGGT-3’ 
Ctdsp1/miR-26b 5’-GCTCTTGACGTCCTTGCGAG-3’ 5’-GGCTCCACCTCTGCGTTTTC-3’ 
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Online Table 6. The gene-specific primers (GSP) used for 5’RACE to identify the 
transcription start sites of the host genes for miR-26 miRNA family members 
Host Gene 
/miRNA 
GSP1 
(Outer) 
GSP2  
(Nested) 
Ctdspl/miR-26a-1 
5’-GCAACCGGCCCTCGTCCTCCT-3
’ 
(40 bp downstream of ATG) 
5’-CTCGTCCTCCTTGGGGTTGGTC-3’ 
(30 bp downstream of ATG) 
Ctdsp1/miR-26b 5’-GAGGGAGGGGGCGCGGAGGA-3’ (161 bp upstream to ATG) 
5’-GGCGCGGAGGAAACTTTG-3’ 
(170 bp upstream to ATG) 
Ctdsp2/miR-26a-2 5’-CCTCCCGGCTCTCGACTC-3’ (387 bp upstream to ATG) 
5’-TCTCGACTCGGCCTCTTCAC-3’ 
(396 bp upstream to ATG)  
“ATG” indicates translational start site of the host genes. 
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CHAPTER 4.   The Control of Adverse Structural 
Remodeling by MiRNAs in AF 
As noted in Sections 1.3.2 and 1.5.4 of the Introduction, atrial fibrosis is a key component of 
AF-associated adverse atrial structural remodeling and is critically determined by fibroblast 
activation, which requires cellular Ca2+ entry. TRP channels are well known to be 
responsible for Ca2+ entry in various cell types; thus, they may likely contribute to atrial 
fibrotic remodeling. Emerging evidence from a recent study has indicated an important role 
of TRPM7 channels in AF-associated fibrotic remodeling [168]. However, whether other 
TRP channels are also involved in this remodeling process remain unclear. This is a 
potentially-important question, given the fact that many TRP channels including TRPM7 are 
known to be abundantly expressed in cardiac fibroblasts with similar functions and structure 
[164, 168]. Notably, a recent study showed that, unlike other TRP members, TRPC3 is 
mainly enriched in freshly-isolated atrial fibroblasts and this enrichment diminishes upon 
fibroblast differentiation to myofibroblasts, suggesting a potentially-important role of 
TRPC3 in determining fibroblast function [237].  Hence, in this Chapter, we carried out 
studies to determine whether TRPC3 plays a role in AF-induced fibrosis by promoting 
fibroblast activation and whether miRNAs are also involved in this process. 
 
This work has been accepted for publication in Circulation. 
 
Harada M, Luo X, Qi X, Tadevosyan A, Maguy A, Ordog B, Ledoux J, Kato T, Naud P, 
Voigt N, Shi Y, Kamiya K, Murohara T, Kodama I, Tardif J, Schotten U, Van Wagoner D, 
Dobrev D, Nattel S. TRPC3-dependent Fibroblast Regulation in Atrial Fibrillation. 
Circulation. 2012 (in press). 
 
194 
 
4.1 TRPC3-dependent Fibroblast Regulation in Atrial Fibrillation 
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Abstract 
Background: Fibroblast proliferation and differentiation are central in atrial fibrillation 
(AF)-promoting remodeling. Here, we investigated fibroblast regulation by Ca2+-permeable 
transient receptor potential canonical-3 (TRPC3) channels. Methods and Results: 
Freshly-isolated rat cardiac-fibroblasts abundantly expressed TRPC3 and had appreciable 
non-selective cation currents (INSC) sensitive to a selective TPRC3-channel blocker, 
pyrazole-3 (3-µmol/L). Pyrazole-3 suppressed angiotensin-II-induced Ca2+-influx, 
proliferation and α-smooth-muscle actin (αSMA) protein-expression in fibroblasts. 
Ca2+-removal and TRPC3-blockade suppressed extracellular-signal regulated kinase 
(ERK)-phosphorylation, and ERK-phosphorylation inhibition reduced 
fibroblast-proliferation. TRPC3-expression was upregulated in atria from AF-patients, 
goats with electrically-maintained AF and tachypacing-induced heart-failure dogs. 
TRPC3-knockdown (shRNA-based) decreased canine atrial-fibroblast proliferation. In 
left-atrial (LA) fibroblasts freshly isolated from dogs kept in AF for 1 week by 
atrial-tachypacing, TRPC3 protein-expression, currents, ERK-phosphorylation and 
extracellular-matrix gene-expression were all significantly increased. In cultured 
LA-fibroblasts from AF-dogs, proliferation-rates, αSMA-expression and 
ERK-phosphorylation were increased, and suppressed by pyrazole-3. MicroRNA-26 was 
downregulated in canine AF-atria; experimental micro-RNA-26 knockdown reproduced 
AF-induced TRPC3-upregulation and fibroblast-activation.  MicroRNA-26 has Nuclear 
Factor of Activated T-cells (NFAT) binding-sites in the 5’-promoter-region.  
NFAT-activation increased in AF-fibroblasts and NFAT negatively regulated microRNA-26 
transcription. In vivo pyrazole-3 administration suppressed AF while decreasing fibroblast 
proliferation and extracellular-matrix gene-expression.  
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Conclusions: TRPC3-channels regulate cardiac fibroblast proliferation and differentiation, 
likely by controlling Ca2+-influx that activates ERK-signaling. AF increases 
TRPC3-channel expression by causing NFAT-mediated downregulation of microRNA-26 
and causes TRPC3-dependent enhancement of fibroblast proliferation and differentiation. 
In vivo TRPC3-block prevents AF-substrate development in a dog model of 
electrically-maintained AF. TRPC3 likely plays an important role in AF-promoting 
fibroblast pathophysiology and is a novel potential therapeutic target. 
 
Keywords:  arrhythmia – calcium – ion channels – fibrillation – remodeling 
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Introduction 
Atrial fibrillation (AF) is the most common arrhythmia in clinical practice, increasing both 
morbidity and mortality.1,2  As the utility of conventional anti-arrhythmic agents targeting 
cardiac ion-channels is limited by inefficacy and side effects, new treatment strategies are 
required.1-3  An improved understanding of underlying mechanisms may help in designing 
novel therapies.2  Under pathological conditions, cardiac fibroblasts first proliferate and 
then differentiate into myofibroblasts that secrete profibrotic extracellular-matrix.3,4  Atrial 
fibrotic remodeling causes conduction abnormalities and may promote 
fibroblast-cardiomyocyte electrical interactions that favor AF occurrence and 
maintenance.5,6  Therefore, fibroblast control mechanisms could constitute novel 
antiarrhythmic targets.  While it is known that cellular Ca2+-homeostasis regulates 
fibroblast-function,6 the precise regulatory mechanisms remain unclear.  
 Transient receptor potential (TRP)-channels, activated by cell-stretch and other 
pathological stimuli, regulate cellular Ca2+entry.6  TRP-channels modulate fundamental 
cell-functions like cell proliferation and death.6-8  Mechanical stretch and related stimuli 
contribute to arrhythmic substrates;3 TRP-channels are candidates to link 
arrhythmic-remodeling stimuli to arrhythmia-promoting cardiac-fibroblast responses.  In 
preliminary studies (Supplemental Figure 1), we noted cell-selective expression of TRPC3 
in freshly-isolated fibroblasts, along with TRPC3-downregulation upon 
fibroblast-differentiation to myofibroblasts, identifying TRPC3 as a potential modulator of 
fibroblast function.  We undertook the present study to test the following hypotheses:  (1) 
TRPC3-subunits play a role in fibroblast function in normal hearts and in an AF-model; (2) 
fibroblast TRPC3-expression is upregulated in AF under the control of discrete 
microRNA-related molecular mechanisms; and (3) in vivo TRPC3-inhibition can suppress 
AF-associated remodeling.
198 
 
Methods 
A detailed description of methods used in this study is available in the online Data 
Supplement. 
 
Cardiac fibroblast isolation and culture 
Fibroblasts were isolated from adult rat or dog hearts as previously described.9  Tissues 
were digested with collagenase-II and cardiomyocytes removed by low-speed 
centrifugation and passage through a 20-µm nylon filter.  Fibroblasts were concentrated 
by high-speed centrifugation (2,000 rpm, 10 min).  Freshly-isolated fibroblasts or cells in 
primary culture within 3 days of isolation (Supplemental Figure 2A) were used in most 
experiments.  Long-term cultured first-passage cells (2-3 weeks), which express 
alpha-smooth muscle actin (αSMA) and show actin-fiber organization (Supplemental 
Figure 2B) were used in rat-myofibroblast studies. 
 
Atrial tissue-samples from humans, goats, and dogs 
Right-atrial appendage biopsies were obtained from patients in sinus rhythm and with 
chronic AF during coronary-artery bypass-graft surgery following informed consent as 
approved by the ethical-review committee of Dresden University of Technology.  AF was 
induced in chronically-instrumented goats using repetitive burst-pacing for 10 days.10  
Congestive heart failure (CHF) dogs with an AF substrate were created by ventricular 
tachypacing (240 bpm, 2 weeks).11  Normal goats and dogs were used as controls. 
Right-atrial tissue samples were collected and fast-frozen in liquid-N2. 
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AF-dogs 
A total of 48 mongrel dogs (20-36 kg) were divided into control and atrial-tachypacing 
groups.  Animal-care procedures followed National Institutes of Health guidelines and 
were approved by the Animal Research Ethics Committee of the Montreal Heart Institute.  
Dogs were anesthetized with ketamine (5.3 mg/kg i.v.)/diazepam (0.25 mg/kg, 
i.v.)/isoflurane (1.5%), intubated, and ventilated.  A unipolar pacing lead was inserted into 
the right-atrial appendage under fluoroscopic guidance and connected to a pacemaker in the 
neck.  Bipolar electrodes were inserted into the right-ventricular apex and right-atrial (RA) 
appendage for electrogram-recording.  Atrioventricular-block/ventricular-pacing 
(employed in many studies of atrial-tachycardia remodeling12) were not performed, to more 
closely mimic spontaneous clinical AF-episodes.  The atrial pacemaker was programmed 
to stimulate the RA at 600-bpm for 1 week, with fibrillatory atrial activity maintained during 
pacing as assessed by daily ECG and intracardiac recordings.  Echocardiography was 
performed on Day 0 (baseline) and Day 7 to assess left-atrial (LA) dimension, LA systolic 
function and left-ventricular diastolic volume. 
 For in vivo pyrazole-3-treatment of AF-dogs, Alzet osmotic pumps were 
implanted subcutaneously in the back to continuously-administer intravenous pyrazole-3 
(0.1-mg/kg/day in DMSO and polyethylene glycol) or vehicle during atrial-tachypacing 
(Supplemental Figure 3).   
 
Electrophysiological studies 
A terminal open-chest electrophysiological study (EPS) was performed on Day 7.  Dogs 
were anesthetized with morphine (2 mg/kg, s.c.) and α-chloralose (120 mg/kg, i.v., followed 
by 29.25 mg/kg/h), and ventilated.  After median sternotomy, atrial effective refractory 
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period (ERP) and mean AF-duration induced by burst pacing were measured as previously 
described.12  
 
TaqMan low-density arrays  
RNA was extracted using TRIzol. RNA-integrity was assessed via Agilent Bioanalyzer. 
(RIN>7.5 required).  cDNA was synthesized with High-Capacity cDNA Reverse 
Transcription Kit and random-hexamer primers.  TaqMan low-density arrays (TLDAs) 
were used in two-step RT-PCR.13  Real-time PCR was performed on the 7900HT Fast 
Real-Time PCR System.  TRP-subunit genes were investigated using inventoried Taqman 
assays.  The mean expression of genes with a Ct-value <30 was used as the reference.14  
 
Whole-cell patch clamping 
Whole-cell voltage-clamp was performed to record non-selective cation-current (INSC) at 
37°C.  The pipette-solution contained (mmol/L): 135 CsCl, 0.1 CaCl2, 10 EGTA, 4.0 
MgATP, 1.0 MgCl2, 10 HEPES, 6.6 sodium-phosphocreatine, 0.3 Na-GTP (pH 7.4/CsOH).  
The bath-solution contained (mmol/L):  140 NaCl, 5.4 TEA-Cl, 2.0 CaCl2, 1.0 MgCl2, 10 
HEPES, 10.0 glucose (pH 7.4/CsOH).  Nifedipine (5-μmol/L) was used to block any 
L-type Ca2+-current.  Na+-current was inactivated with a holding-potential of 0 mV.  
Currents were elicited with 3-s voltage-ramp protocols (1 mV/ms, from -110 mV to 100 
mV, 0.1 Hz), at a holding potential of 0 mV.15 
 
Cell-proliferation and cell-cycle analysis 
Cardiac fibroblasts were cultured in T25 culture-flasks (2.0×105 cells/flask, 25 cm2 
growth-area) for each treatment-group.  After incubation, cells were harvested following 
trypsinization, and then fixed with ice-cold 75% ethanol.  Samples were stored at -20°C 
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until analysis.  Pelleted cells were re-suspended and incubated (4°C, 30 minutes) in 
staining solution containing propidium-iodide.  Cell-numbers and DNA content-frequency 
histograms were obtained via FACScan (constant flow-rate, 60 µl/min, 5-min acquisition 
time).  
 
Western blots  
Protein was extracted, quantified, and processed.12,16  Cytoplasmic and nuclear 
protein-fractions were extracted from fresh fibroblasts with ProteoExtract Subcellular 
Proteome Extraction Kit (Calbiochem, Darmstadt, Germany).  Protein-samples were 
separated by gel-electrophoresis and transferred to polyvinylidene-difluoride membranes.  
Membranes were blocked and incubated with mouse anti-α smooth-muscle actin, 
anti-phospho-p44/42-MAP-kinase, anti-TRPM7, anti-NFATc3, anti-HSP70, anti-Lamin 
A/C and anti-vimentin, rabbit anti-TRPC3, anti-TRPC1 (1/200, Alomone), 
anti-calsequestrin and anti-NFATc4antibodies.  Secondary antibodies conjugated to 
horseradish-peroxidase were used for detection via chemiluminescence.  
 
Confocal-imaging 
Cultured/freshly-isolated fibroblasts or left atrial tissue cryosections were fixed with 
2%-paraformaldehyde, washed with PBS, and incubated with mouse anti-alpha SMA, goat 
anti-vimentin, mouse anti-NFATc3, rabbit anti-NFATc4, followed by donkey anti-mouse 
IgG-Alexa Fluor-555, donkey anti-rabbit IgG-Alexa Fluor-488, donkey anti-goat 
IgG-Alexa Fluor-488, and/or TOPRO-3 iodide.  Apoptosis was assessed by TUNEL-assay 
with ApopTag. Fluorescent-images were obtained via Zeiss LSM-710 or OLYMPUS 
Fluoview FV1000 inverted confocal microscope. 
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Ca2+-imaging 
Primary cultured rat-fibroblasts (1-day culture) were loaded with Fluo-4 (10-µmol/L) in 
phenol-free M199-medium in the presence of pluronic acid (2.5 µg/ml) for 50 min.  
Ca2+-imaging was obtained with an Andor Revolution confocal system and a Xion camera 
(Andor Technologies) mounted on an upright Nikon FN-1 microscope.  Fluo-4 was 
excited at 488-nm; emitted fluorescence collected at 495 nm. Images (512×512 pixels) 
were acquired at 15 frames/sec.  FO was determined by averaging fluorescence from 10 
consecutive baseline images.17  
 
qPCR 
To study microRNA, RNA/microRNA were extracted with TRIzol/mirVana miRNA 
Extraction Kit (Ambion).  Real-time RT-PCR was performed with 6-carboxy-fluorescein 
(FAM)-labeled fluorogenic Taq-Man primers.  Fluorescence-signals were detected in 
duplicate, normalized to β2-microglobulin RNA for total RNA and to U6 snRNA for 
microRNA, and quantified with MxPro qPCR-software (Stratagene).16  
 
TRPC3-knockdown 
TRPC3-knockdown lentivirus-vector plasmid was obtained from Open Biosystems (Oligo 
ID: V2LMM_11490).  A scrambled shRNAmir over-expressing virus was used as a 
negative control.  For lentivirus-infection, 3-day cultured fibroblasts were plated in T25 
culture flasks at 4×103 cells/cm2, infected at 50 m.o.i. and incubated for 3 days before 
experiments. 
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microRNA (miR) overexpression/knockdown 
For overexpression, sense and antisense oligoribonucleotides were synthesized by 
Invitrogen and the double-stranded RNA was created by annealing.  A scrambled RNA 
was the negative control.  For knockdown, antisense anti-miR oligonucleotides (AMO26a) 
with locked nucleic acid (LNA)-technology were synthesized by Exiqon (Woburn, MA).  
Scrambled oligonucleotides with methylene bridges were used as negative controls.  Dog 
LA-fibroblasts in primary culture were transfected with miR-26a duplex (100-nmol/L), 
AMO26a (10-nmol/L), and/or control-sequences with lipofectamine-2000 (Invitrogen).18 
 
Dual luciferase-reporter assay 
A fragment containing the miR target-sequence was synthesized by Invitrogen and was 
used as a template for PCR amplification.  The PCR product was subcloned in the 
pMIR-REPORT luciferase miR-expression reporter vector.  HEK293 cells were 
transfected with 50-ng pMIR-REPORT, 0.5ng pRL-TK (for internal control) and miR-26a 
duplex (10-nmol/L) and/or AMO26a (3-nmol/L) with lipofectamine-2000.  
 
Statistical analysis 
Data are presented as mean±SEM. Two-way ANOVA with multiple-group comparisons 
(Bonferroni-corrected t-test) was applied to data with two or more main-effect factors. 
One-way ANOVA was applied for single main-effect factor experiments. Repeated-measure 
analyses were used when the same set of subjects/materials were exposed to multiple 
interventions. Students’ t-tests were used for comparisons involving only two groups. For 
multiple comparisons with Bonferroni correction, adjusted P-values were calculated by 
multiplying original P-values by the number of comparisons (N) performed; values shown 
are adjusted values (N×P). Two-tailed P<0.05 was considered statistically significant. For 
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additional details, see Online Supplement. 
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Results 
TRPC3-mediated INSC and Ca2+ entry 
INSC-recordings from freshly-isolated rat fibroblasts are shown in Figure 1A and 
Supplemental Figure 2C.  INSC was substantially suppressed by superfusion with the 
TRPC3-selective blocker pyrazole-3 (Figure 1B)19 and by the general TRP-channel blocker, 
gadolinium (Gd3+, 100-μmol/L, Supplemental Figure 2C).  Passage-cultured 
myofibroblasts (Supplemental Figure 2B) showed larger membrane-capacitance than 
fibroblasts (16.8±1.4 pF vs. 6.4±0.4 pF, P<0.01) but had much smaller Gd3+- and 
Pyr3-sensitive INSC, consistent with qPCR-data (Supplemental Figure 2D-F).  
 We then tested whether TRPC3-channels contribute to Ca2+-entry in cardiac 
fibroblasts.  Because diacylglycerol (DAG) has been suggested to be a physiological 
activator of TRPC3,20 we examined the effect of TRPC3-blockade on Ca2+-entry induced 
by 1-oleoyl-2-acetyl-sn-glycerol (OAG) and angiotensin-II, which activate DAG-receptors 
directly and indirectly respectively.  Both angiotensin-II (Figures 1C-D) and OAG 
(Supplemental Figures 4A-B) induced fibroblast Ca2+-entry, which was prevented by Pyr3, 
suggesting that TRPC3-channels are needed for OAG- and angiotensin-II-induced 
Ca2+-entry.  
 
Role in fibroblast proliferation and differentiation 
We next examined whether TRPC3-channel block affects cardiac fibroblast proliferation.  
Rat cardiac fibroblasts were maintained in the presence or absence of Gd3+, Pyr3 or 
control-vehicle for up to 1 day in primary culture.  After 24-hour culture in 
vehicle-medium (CTL), the number of fibroblasts increased substantially (Figure 1E).  
After 1-hour and 24-hour treatment, fibroblasts were collected for proliferation-analysis 
using flow cytometry.  Representative DNA-content histograms showing the G2/M-phase 
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cell-content, an index of DNA-duplication, are provided in Supplemental Figures 5A-B.  
Pyr3 significantly slowed the increase in fibroblast-number and G2/M-phase cell-content 
(Figures 1E-F), as did Gd3+ (Supplemental Figures 5C-D).  Pyr3 also significantly 
increased the percentage of TUNEL-positive fibroblasts versus control (Supplemental 
Figure 6).  These data suggest that TRPC3-channels regulate cardiac fibroblast survival 
and proliferation.  
 After fibroblasts proliferate, they differentiate into extracellular-matrix 
(ECM)-secreting myofibroblasts characterized by altered morphology and increased 
αSMA-expression.  Supplemental Figure 7A shows confocal images of rat fibroblasts, 
cultured with or without Pyr3, stained with anti-αSMA-antibodies.  The spindle-shaped 
expansion and αSMA-enhanced expression associated with myofibroblast-differentiation 
was inhibited by 3-µmol/L Pyr3.  Figure 1G shows representative α-SMA-immunoblots 
on cultured rat-fibroblasts:  αSMA protein-expression was significantly decreased by Pyr3 
(Figure 1H).  Thus, TRPC3-channels participate in fibroblast differentiation into 
myofibroblasts.  We also examined the effect of TRPC3-blockade on 
already-differentiated myofibroblasts. Consistent with downregulation of TRPC3 in 
myofibroblasts, their cell-number, G2/M-phase cell-content and αSMA-expression were 
unchanged by Pyr3 (Supplemental Figures 7B-D).  Thus, once fibroblasts differentiate 
into myofibroblasts, TRPC3-channels appear no longer to be involved their regulation. 
 
TRPC3-mediated Ca2+-entry, ERK-1/2 phosphorylation and fibroblast activation 
We then examined whether TRPC3-mediated Ca2+-entry acts by modulating 
Ca2+-dependent ERK-1/2-activation, which affects cell-survival and 
fibroblast-activation.21,22  Fibroblasts were cultured for 24 hours in three conditioned 
media: 1) 0.4-mmol/L Ca2+, 2) 2.4-mmol/L Ca2+, and 3) 2.4-mmol/L Ca2+ with Pyr3.  
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ERK-1/2-phosphorylation was significantly decreased in low-[Ca2+] medium and with 
exposure to Pyr3 (Figure 2A).  Next, we examined the effect of extracellular 
Ca2+-concentration on fibroblast proliferation.  The increase in cell-number of cultured 
fibroblasts and the G2/M-phase cell-content were significantly smaller with lower [Ca2+] in 
the culture-medium (Figures 2B-C).  A selective ERK-pathway inhibitor, PD98058 
(50-µmol/L), also significantly reduced the number of fibroblasts and the G2/M-phase 
cell-content after 24-hour culture (Figures 2D-E).  The data in Figure 2 suggest that 
TRPC3-mediated Ca2+-influx contributes to ERK-1/2-activation that regulates fibroblast 
proliferation. 
 
TRPC3-knockdown suppresses atrial-fibroblast proliferation  
We were unable to study TRPC3-knockdown in rat-fibroblasts because spontaneous 
TRPC3-downregulation in culture was almost complete over the time-period needed for 
lentiviral-mediated knockdown.  However, we noted that TRPC3-downregulation was 
slower in cultured dog-atrial fibroblasts, which were used to study the effects of 
TRPC-knockdown.  TRPC3-subunit mRNA and protein expression significantly 
decreased in TRPC3-shRNA-infected fibroblasts; TRPC6 mRNA remained unchanged 
(Supplemental Figures 8A-B).  The fold-increase in cultured-fibroblast cell-number was 
significantly attenuated in TRPC3-shRNA-infected fibroblasts (Supplemental Figure 8C), 
as was the G2/M-phase cell-content (Supplemental Figure 8D), indicating that 
TRPC3-channels are involved in canine atrial-fibroblast proliferation.  
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Atrial TRPC3-expression in large animal/human AF-substrates 
To assess a potential role in the AF-substrate, we examined the protein-expression of 
TRPC1, TRPC3, and TRPM7-subunits in RA tissue-samples from AF-patients, AF-goats, 
and CHF-dogs with an AF-substrate.  Atrial TRPC3-expression significantly increased in 
all groups with AF-substrates (Supplemental Figures 9A-C) whereas TRPC1 and TRPM7 
remained unchanged (Supplemental Figures 9D-I).  
 
Atrial remodeling in dogs with electrically-maintained AF 
To examine further the potential role of TRPC3 in AF, we used a canine model of 
electrically-maintained AF.  Representative surface and intracardiac day-7 
ECG-recordings showing irregular/rapid atrial activity and irregular ventricular responses 
typical of AF are shown in Figure 3A.  Spontaneous AF was maintained after 
pacing-cessation.  Fibrillatory electrical activity and spontaneous post-pacing AF were 
consistently observed during the 1-week pacing period (Supplemental Figure 10).  
Immediately following tachypacing-onset (recordings at 6.0±0.2 mins post-onset), 
ventricular activation rate increased by 55%, but ventricular rate then returned to control 
values by Day 3 (Supplemental Figure 11A).  At end-study, atrial and ventricular-filling 
pressures were slightly but significantly increased in AF-dogs (Supplemental Table 1).  
Supplemental Figure 11B illustrates atrial structural remodeling in AF-dogs, with 
significant changes in LA diastolic area and fractional area-change (Supplemental Figures 
11C-D).  
AF-dogs showed electrical remodeling manifested by reduced ERPs (Figure 3B) 
and increased duration of burst-pacing induced AF (Figure 3C).  LA fibrosis and 
vimentin-staining (index of fibroblast-density) were assessed by histomorphometry (Figure 
3D).  Fibrous-tissue content was unchanged (Figure 3E), but vimentin-positive area 
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(Figure 3F) and protein-expression (immunoblots, Figure 3G) increased significantly in 
AF-dogs.  
 
TRPC3-regulation of atrial-fibroblast activation in AF-dogs 
Figure 4A shows INSC before and after 3-μmol/L Pyr3 in freshly-isolated LA-fibroblasts.  
Pyr3-sensitive current increased significantly in LA-fibroblasts of AF-dogs (Figure 4B), 
corresponding to increased TRPC3-subunit protein-expression in freshly-isolated 
LA-fibroblasts (Figure 4C).  ERK-phosphorylation (Figure 4D) and ECM gene-expression 
(Figure 4E) were also significantly increased in LA-fibroblasts of AF-dogs.  
The cell-number increase-rate, G2/M-phase cell-content and αSMA 
protein-expression all increased in LA-fibroblasts of AF-dogs (Figure 5A-C), indicating 
increased fibroblast proliferation and differentiation.  In vitro treatment of AF-fibroblasts 
with Pyr3 significantly decreased these fibroblast-activation indices (Figures 5D-F).  
ERK-activation was significantly increased in AF (Figure 5G).  ERK-phosphorylation in 
AF-dogs was significantly reduced after 24-hour treatment with Pyr3 (Figure 5H).  These 
data suggest that TRPC3-channels are an important contributor to fibroblast-activation in 
AF. 
 
MiR-26 regulation of TRPC3 channels 
MicroRNAs post-transcriptionally regulate protein-expression in many pathological 
conditions.1  MiR-target prediction (Target scan) suggested that miR-26 targets the 
TRPC3-gene (Supplemental Figure 12A).  Expression of the 2 miR-26 isoforms, miR-26a 
and b, which have identical seed-sequences, was significantly decreased in freshly-isolated 
LA-fibroblasts from AF-dogs (Figure 6A).  Other miRs involved in cardiac remodeling1 
were studied and miR-133 was also downregulated; however, miR-26 was particularly 
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strongly-expressed in fibroblasts (Figure 6B) whereas miR-133 expression was 
cardiomyocyte-selective (Figure 6C).  Neither miR-1 nor miR-133 target TRPC3.  
 We then examined post-transcriptional regulation of TRPC3 by miR-26a with dual 
luciferase reporter assay.  Luciferase vectors carrying the miR-26a target gene-sequence of 
TRPC3 were cotransfected along with miR-26a duplex and/or antisense anti-miR-26a 
oligonucleotides (AMO26a, Supplemental Figure 12B) into HEK-293 cells.  MiR-26a 
overexpression significantly decreased luciferase-readout whereas knockdown of 
endogenous miR-26a by AMO26a significantly increased luciferase-fluorescence (Figure 
6D), indicating that miR-26a regulates TRPC3 translation. 
 Using immunoblotting, we further validated the effect of miR-26a on TRPC3 
protein-expression in cultured canine LA- fibroblasts.  MiR-26a overexpression 
significantly decreased TRPC3 protein-expression whereas miR-26a knockdown to mimic 
AF-related miR-26 downregulation increased TRPC3-protein (Figure 6E).  We then 
assessed the regulation of fibroblast proliferation by miR-26a. MiR-26a overexpression 
significantly decreased fibroblast-number (Figure 6F) as well as G2/M-cell percentage 
(Figure 6G) whereas miR-26a knockdown increased these fibroblast-proliferation indices.  
These data indicate that miR-26a controls TRPC3-expression by downregulating TRPC3 
protein, producing parallel changes in fibroblast proliferation-indices. 
 
NFATc3 regulation of miR-26a 
We next looked for the potential mechanism of fibroblast miR-26 control in AF.  
Nuclear-translocation of the Nuclear Factor of Activated T-cells (NFAT), subsequent to 
dephosphorylation by Ca2+/calmodulin-dependent calcineurin activation, is important in 
AF-related cardiomyocyte-remodeling.1  The promoter regions of the host genes for 
miR-26a/b in humans and dogs are predicted to have multiple binding motifs for NFAT 
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(Supplemental Figure 12D).  We therefore evaluated cellular localization of NFAT in 
fibroblasts from AF and control dogs.  Figure 7A shows representative confocal images of 
freshly-isolated LA-fibroblasts stained with vimentin, TOPRO3 (nuclear stain) and 
NFATc3/c4-antibodies.  Nuclear localization of NFATc3 increased significantly in AF 
(Figure 7B).  We also quantified nuclear NFAT-localization by immunoblotting on isolated 
canine fibroblast-nuclei.  AF significantly reduced the cytosolic and increased the nuclear 
protein fraction of NFATc3 (Figure 7C).  To assess NFAT-regulation of miR26 
gene-expression, we examined the effect of incubation with a selective 
membrane-permeable NFATc3/c4 blocker, INCA6 (2.5-µmol/L), on miR-26 and TRPC3 
expression in canine atrial fibroblasts.  INCA6 significantly increased miR-26a/b 
expression (Figure 7D) and decreased TRPC3 protein-expression (Figure 7E), consistent 
with an inhibitory effect of NFAT on miR-26 transcription.  These data suggest that 
AF-induced NFATc3-translocation suppresses miR-26a-transcription, thereby reducing 
miR-26a inhibition of TRPC3-translation and resulting in TRPC3 protein-upregulation.  
 
Effects of in vivo TRPC3 blockade on the AF-substrate 
To more directly assess the role of TRPC3 in the AF-promoting remodeling of our AF-dogs, 
additional AF-dogs were treated with Pyr3 (0.1-mg/kg/day by continuous intravenous 
infusion) or vehicle for the entire period of atrial tachypacing (Supplemental Figure 3).  At 
the terminal electrophysiological study, Pyr3-treated dogs showed significantly-reduced 
AF-duration (Figure 8A).  They also had slightly but significantly greater ERP-values at 
short cycle-lengths (Figure 8B).  Consistent with in vivo TRPC3-control of fibroblast 
function, Pyr3 significantly decreased LA vimentin-expression (Figure 8C), as well as 
fibroblast-number on Day 3 (Figure 8D) and G2/M-cell content on Day 2 (Figure 8E) in 
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LA-fibroblasts cultured from AF-dogs.  Pyr3 also decreased ECM gene-expression in 
LA-fibroblasts freshly-isolated from AF-dogs (Figure 8F). 
 
Discussion 
This study shows that TRPC3-channels control fibroblast-function via Ca2+-dependent 
ERK-phosphorylation resulting from Ca2+-entry through INSC.  In addition, atrial 
TRPC3-expression is upregulated in AF, inducing fibroblast proliferation, differentiation 
and activation.  TRPC3-upregulation in AF is due to downregulation of its regulatory 
microRNA, miR-26, under the control of NFATc3.  Infusion of a highly-selective 
TRPC3-inhibitor, Pyr3, suppresses development of the AF-substrate in a canine model. 
 
Comparison with Previous Studies on TRP Channel-dependent Regulation of 
Fibroblast Function 
TRPC3 is a Ca2+-permeable ion channel that shows 75% homology with TRPC6 and 7.20  
These channels show substantial Ca2+-permeability and mediate receptor-activated 
extracellular Ca2+-entry.20,23,24  TRPC3/6/7-channels are directly activated by DAG 
liberation into the plasma-membrane, triggered by agonist-binding to G protein-coupled 
receptors like angiotensin-II and endothelin-1 (ET-1) receptors.20,23 TRPC-channels are 
widely expressed and are involved in diverse biological functions, such as neuronal cell 
survival,24 blood vessel constriction,25 immune cell maturation,26 and cardiac 
hypertrophy.27,28  However, the regulatory role of TRPC3-channels in cardiac fibroblast 
function has not been previously reported. 
   Rose et al. demonstrated that a TRP channel-like INSC is elicited by C-type 
natriuretic peptide in freshly-isolated rat ventricular fibroblasts.15  Transcripts encoding 
TRPC3-subunits were highly expressed in the fresh fibroblasts and INSC was activated by 
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phorbol esters.  However, the role of INSC in fibroblast function was not examined.  
   Nishida et al. reported thatTRPC1, 3, 6, and 7 mRNAs are detected in neonatal rat 
fibroblasts and TRPC6-channels contribute to the regulation of ET-1-induced myofibroblast 
formation through JNK and NFAT signaling.29  However, in contrast to our observations 
regarding TRPC3 channels, ERK1/2-phosphorylation was not affected by ET-1-activated 
TRPC6 currents.  Of note, the Nishida study was performed in neonatal cells and 
TRP-channel dependent regulation of fibroblast function may change during development 
from neonatal to adult conditions.  
   Du et al. demonstrated that current corresponding to TRP melastatin-related 7 
(TRPM7), a Ca2+/Mg2+-permeable channel, is strongly expressed in fibroblasts isolated 
from right-atrial samples of AF patients and likely plays an important role in AF 
pathophysiology.30  shRNA-based TRPM7 knockdown decreased TRPM7-mediated 
Ca2+-influx in cultured atrial fibroblasts and suppressed fibroblast differentiation induced 
by TGFβ-stimulation.  Our results showed substantial TPRC3-subunit expression and 
associated current, as well as significant physiological function, in fibroblasts that were 
freshly-isolated or kept under conditions limiting differentiation.  Furthermore, 
TRPC3-dependent current and fibroblast-regulation were enhanced in AF-dog fibroblasts.  
The expression and function of TRPC3-channels disappeared following differentiation to 
myofibroblasts under culture conditions.  In contrast, mRNA-expression of 
TRPM7-subunits remained high in myofibroblasts, similar to the findings of Du et al, who 
also showed strong mRNA expression of TRPM7 but not TRPC3 subunits in cultured 
human atrial fibroblasts.  Cardiac fibroblast phenotype dynamically changes during 
proliferation and differentiation.  Our findings suggest that TRPC3 controls proliferation 
and differentiation of fibroblasts, but is downregulated in the end-cell myofibroblast.  This 
negative-feedback system may prevent excessive ECM-remodeling.  In contrast, TRPM7 
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is likely the dominant TRP-channel in differentiated myofibroblasts. 
 Du et al. found increased TRPM7-current in fibroblasts isolated from atrial 
samples of AF-patients but did not have sufficient tissue to perform Western-blot studies.  
We found increased protein-expression of TRPC3, but not TRPC1 or TRPM7, by 
immunoblotting of atrial samples in AF-patients, AF-goats and CHF-dogs.  This 
observation suggests that the increased TRPM7-function noted by Du et al. in fibroblasts 
from AF-patients may have been due to increased membrane-trafficking of 
TRPM7-subunits or altered regulation rather than increased channel-expression per se. 
 
Potential mechanisms 
Mio et al. established the 3-dimensional structure of TRPC3-channels with cryo-electron 
microscopy.31  TRPC3-channels have both a pore-forming transmembrane domain and a 
large intracellular domain representing a “nested-box” structure.  The latter structure may 
act as a molecular anchor for signaling complexes.  TRPC3-mediated Ca2+-influx and an 
increase in local Ca2+-concentration may trigger protein-protein interactions that activate 
downstream signaling pathways that regulate fibroblast function.  A recent study using 
B-lymphocytes demonstrated that TRPC3 channels act as a platform for protein kinase C 
(PKC), and that the sustained scaffolding of PKC at the plasma membrane is associated 
with the activation of the ERK1/2 signaling pathway.32  
 ERK1/2 is a protein kinase and intracellular signaling molecule involved in 
various biological functions, including cell growth and survival.21,22  In the present study, 
selective inhibition of ERK1/2 signaling attenuated rat fibroblast proliferation, suggesting 
that ERK1/2 signaling contributes to fibroblast function.  Olson et al. demonstrated that 
angiotensin-induced intracellular Ca2+-increases and PKC activation in adult rat cardiac 
fibroblasts synergistically contribute to ERK1/2 activation and fibroblast proliferation.33  
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TRPC3-channels may be particularly important in this situation because angiotensin-II 
increases cellular production of DAG, which activates TRPC3-channels.  Our data showed 
that TRPC3 blockade suppresses Ca2+-entry caused by angiotensin-II, a well-known 
profibrotic agent, in rat cardiac fibroblasts. 
 
Novelty and potential significance 
This is the first study to show a role of TRPC3-channels in controlling fibroblast-function 
and the first to indicate that AF activates fibroblasts via TRPC3-related mechanisms.  
Furthermore, we were able to identify the mechanism of TRPC3-upregulation in AF 
(reduced miR-26 negative control of TRPC3-translation, due to enhanced NFATc3 
nuclear-translocation in AF-fibroblasts which causes enhanced inhibitory 
NFATC3-regulation of miR-26), and found that a TRPC3-inhibitor suppresses 
AF-promoting remodeling.  An emerging body of evidence indicates that TRP-channels 
act as important mediators for a wide variety of physiological functions and are a potential 
target for drug discovery.  There is a need to develop novel approaches to AF treatment, 
and therapies that prevent fibroblast activation are of potentially-great interest.6  Our 
findings point to TRPC3 as a candidate target for AF-prevention. 
Although it is well-recognized that AF promotes atrial fibrosis, little information is 
available about how this happens.  In our dog model, AF upregulated TRPC3 and caused 
fibroblast activation that depended on TRPC3-related Ca2+-entry, which activated 
ERK-phosphorylation.  Similar TRPC3-upregulation was observed in atrial samples from 
AF-patients, AF-goats and AF-prone CHF-dogs.  TRPC3-channels acted primarily in 
non-differentiated fibroblasts, enhancing their ability to proliferate and differentiate into 
myofibroblasts.  Once myofibroblasts were formed, TRPC3-channels downregulated.  
This behavior of TRPC3-channels has not been described previously:  TRPC3-channels 
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promote fibrosis by causing fibroblasts to proliferate and activate, but are then 
downregulated in activated myofibroblasts to prevent a positive-feedback process.  The 
effects of in vivo Pyr3-infusion to prevent enhanced proliferation and ECM-expression of 
fibroblasts from AF-dogs, along with the associated suppression of AF-promotion, are 
consistent with an important role for TRPC3 in fibroblast-mediated AF-promoting 
remodeling. 
Although NFAT nuclear-translocation has previously been shown to occur in 
AF-cardiomyocytes and to be involved in cardiomyocyte-remodeling,1,34 our study 
constitutes the first demonstration of AF-associated NFAT-changes in fibroblasts and their 
involvement in AF-related fibroblast-remodeling. 
 
Potential limitations 
We cannot exclude the possibility that fibroblast properties were affected by cell isolation 
and culture.  Considering that fibroblasts lose their original properties after lengthy 
culture-intervals, we used cells in short-term primary culture (maximum of 3 days after 
isolation) in most experiments.  However, this approach cannot completely reproduce the 
complex in vivo milieu.  Any extrapolation of these results to human disease should be 
made cautiously.  
Our patch-clamp recording conditions differed from those used by Du et al30 in 
that they used pipette solutions that were virtually Mg2+-free, whereas our pipettes 
contained Mg2+ at concentrations typically used for cardiac cell patch-clamp recording. 
TRPM7-currents are strongly suppressed by intracellular Mg2+,35,36 which likely explains 
why most of the gadolinium-sensitive current we observed was also sensitive to Pyr3.  
Under our conditions, INSC would not be expected to contain substantial TRPM7-current 
and was strongly downregulated in myofibroblasts.  Thus, TRPM7-channels play a much 
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larger role than other TRP-channels, including TRPC3, in regulating Ca2+-influx in 
differentiated myofibroblasts. 
Our AF-dogs showed increased atrial fibroblast density and signs of fibroblast 
activation like enhanced α-SMA expression (Figure 8C) and ECM-gene upregulation 
(Figure 7E).  However, we did not see increased fibrous-tissue content in AF-dogs.  We 
suspect that the lack of fibrosis was due to the relatively short time (7 days) that the dogs 
were kept in AF, with longer intervals necessary for fibrosis-development.  When AF is 
maintained for longer periods (>3 months), clear fibrosis develops, even when excessive 
ventricular rates and left-ventricular dysfunction are prevented.37  It is important to 
emphasize that fibroblast-proliferation and differentiation can promote AF by a range of 
mechanisms that does not require enhanced fibrous-tissue content, particularly 
fibroblast-cardiomyocyte electrical interactions.3  The small atrial ERP-increases we noted 
in Pyr3-treated AF-dogs may reflect enhanced fibroblast effects on the electrophysiology of 
coupled cardiomyocytes.3  Alternatively, a direct role in cardiomyocytes cannot be 
excluded and should be assessed in follow-up work.  Our findings raise many interesting 
additional questions that need to be answered, but are outside the scope of the present 
study. 
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Figure Legends 
Figure 1. A, Representative INSC-recordings with or without pyrazole3 (Pyr3, 3-µmol/L).  
B, Mean±SEM Gd3+- and Pyr3-sensitive INSC-density (n=7 cells in Gd3+ and 9 cells 
in Pyr3).  C, Recordings of angiotensin-II induced intracellular Ca2+-response in 
presence or absence of Pyr3.  D, Mean±SEM angiotensin-II (AngII)-induced Ca2+ 
fluorescence (F/F0), normalized to baseline in 0-mmol/L Ca2+ (n=18, 20 cells in 
AngII and AngII with Pyr3, *P<0.05 vs. 0-mmol/L Ca2+, #P<0.05 vs. 2-mmol/L 
Ca2+ in AngII).  E, Mean±SEM fibroblast count after 1-hour or 24-hour culture 
with vehicle-control, or 0.3 or 3-µmol/L Pyr3 (n=9/group, *P<0.05 vs. CTL, 
#P<0.05 vs. 1-hour treatment).  F, Mean±SEM percentage of cells in G2/M-phase 
after Pyr3-treatment (n=9, *P<0.05 vs CTL, #P<0.05 vs. 1-hour treatment).  G, 
Representative immunoblots for αSMA and GAPDH in rat fibroblasts cultured 
with or without Pyr3 (3-µmol/L) and H, mean±SEM αSMA/GAPDH expression 
ratio (n=8/group, *P<0.05 vs. CTL). 
Figure 2. A, Top: Representative immunoblots of phosphorylated-ERK-1/2 (p-ERK), total 
ERK-1/2 (t-ERK) and GAPDH in rat fibroblasts cultured with 0.4-mmol/L Ca2+, 
2.0-mmol/L Ca2+ and 2.0-mmol/L Ca2+ medium containing 3-µmol/L Pyr3.  
Bottom: Mean±SEM (p-ERK)/GAPDH, (t-ERK)/GAPDH and (p-ERK)/(t-ERK) 
(n=8/group, *P<0.05 vs. CTL, #P<0.05 vs. Pyr3).  B, Mean±SEM fibroblast 
cell-count after culture in M199-medium containing 0.4 to 4.4 mmol/L Ca2+ 
(n=8/group, *P<0.05 vs. 0.4-mmol/L Ca2+, #P<0.05 vs. 1-hour treatment).  C, 
Mean±SEM percentage of cells in G2/M-phase (n=8/group-, *P<0.05 vs. 
0.4-mmol/L Ca2+, #P<0.05 vs. 1-hour treatment).  D, Mean±SEM fibroblast 
cell-count after 1-hour and 24-hour treatment with 50-µmol/L PD98059 
(n=6/group, *P<0.05 vs. CTL, #P<0.05 vs. 1-hour treatment).  E, Mean±SEM 
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percentage of cells in G2/M phase after 50-µmol/L PD98059-treatment 
(n=6/group, *P<0.05 vs. CTL). 
Figure 3. A, Representative surface ECG (left) and intracardiac electrograms (right) in an 
awake AF-dog on Day 7.  B, Mean±SEM atrial ERP in CTL (n=11) and AF dogs 
(n=12) on Day 7 (*P<0.05).  C, Mean±SEM duration of induced AF (*P<0.05 vs. 
CTL).  D, Top, Representative Masson’s trichrome-stained left-atrial images from 
CTL (left) and AF (right) dogs.  Bottom, Representative immunofluorescent 
images of LA free-wall tissues stained with vimentin.  E, Mean±SEM 
fibrous-tissue content in left-atrial free-wall tissues (n=5 CTL, 5 AF dogs).  F, 
Mean±SEM vimentin-positive area (n=5 CTL, 5 AF dogs, *P<0.05 vs. CTL).  G, 
Representative immunoblots (top) and mean±SEM vimentin band-intensity 
normalized to GAPDH (bottom) in left-atrial samples from CTL (n=5) and AF 
dogs (n=5, *P<0.05 vs CTL).  
Figure 4. A, Representative INSC-recordings before and after Pyr3 (3-µmol/L) in 
freshly-isolated left-atrial fibroblasts from CTL and AF dogs.  B, Mean±SEM 
Pyr3-sensitive INSC-density in CTL (n=6 dogs, 8 cells) and AF dogs (n=6 dogs, 9 
cells; P<0.05 vs. CTL).  C, Representative immunoblots (top) and mean±SEM 
TRPC3-subunit band-intensity relative to GAPDH (bottom) in freshly-isolated 
left-atrial fibroblasts from CTL (n=6) and AF dogs (n=6, *P<0.05 vs. CTL).  D, 
Representative immunoblots (top) and mean±SEM data (bottom) for 
phosphorylated (p-)ERK-1/2 and total (t-)ERK-1/2 relative to GAPDH.  E, 
Mean±SEM extracellular matrix-gene mRNA-expression in freshly-isolated 
left-atrial fibroblasts (n=6 CTL and 6 AF, *P<0.05 vs. CTL). 
Figure 5. A, Mean±SEM cell-count of left-atrial fibroblasts after 2-day and 3-day culture in 
CTL (n=7) and AF dogs (n=7, *P<0.05 vs. CTL).  B, Mean±SEM percentage of 
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cells in G2/M phase (n=7 dogs/group, *P<0.05 vs. CTL).  C, Representative 
immunoblots (top) and mean±SEM αSMA/GAPDH (bottom) in cultured left-atrial 
fibroblasts from CTL (n=6) and AF dogs (n=7, *P<0.05 vs. CTL).  D, 
Mean±SEM cell-count of left-atrial fibroblasts after 1-hour or 24-hour culture with 
vehicle-control or Pyr3 (3-µmol/L) in AF dogs (n=6/group, *P<0.05 vs. DMSO).  
E, Mean±SEM percentage of cells in G2/M-phase (n=6/group, *P<0.05 vs. 
DMSO).  F, Representative immunoblots (top) and mean±SEM αSMA/GAPDH 
expression-ratios (bottom) in cultured left-atrial fibroblasts from AF dogs (n=7) in 
the presence of vehicle (DMSO) or Pyr3 (*P<0.05 vs. DMSO).  
G, Representative immunoblots (top) and mean±SEM phosphorylated (p-)ERK-1/2 
and total (t-)ERK-1/2 relative to GAPDH (bottom) in cultured left-atrial fibroblasts 
of CTL and AF dogs (n=6/group, *P<0.05 vs. CTL).  G, Representative 
immunoblots (top) and mean±SEM ERK in left-atrial fibroblasts from AF-dogs 
cultured with vehicle (DMSO) or Pyr3 (3-µmol/L, n=6/group; *P<0.05 vs. 
DMSO). 
Figure 6. A, Mean±SEM microRNA expression in freshly-isolated left-atrial fibroblasts in 
AF (n=7) and CTL dogs (n=7, *P<0.05 vs. CTL).  B, Mean±SEM relative 
microRNA expression in freshly-isolated left-atrial fibroblasts in CTL (n=5, 
*P<0.05 vs. miR-26a).  C, Mean±SEM relative microRNA expression in 
freshly-isolated left-atrial cardiomyocytes in CTL (n=5, *P<0.05 vs. miR-26a).  
D, Mean±SEM relative luciferase activitiy in HEK293 cells transfected with 
miR-26a overexpression (miR-26a duplex)/knockdown (antisense anti-mi26a 
oligonucleotides, AMO26a) probes (n=7/group, P<0.05 vs. cells transfected 
without the miR-26a probes).  E, Representative immunoblots (top) and 
mean±SEM TRPC3/GAPDH protein expression (bottom) in dog left-atrial 
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fibroblasts transfected with the miR-26a duplex/AMO26a (n=7, P<0.05 vs. cells 
without miR-26a probes).  F, Mean±SEM fibroblast count in dog left-atrial 
fibroblasts transfected with miR-26a duplex/AMO26a (n=7/group, *P<0.05 vs. 
cells transfected without the miR-26a probes).  G, Mean±SEM percentage of cells 
in G2/M-phase (n=7/group, *P<0.05 vs. cells transfected without the miR-26a 
probes).  
Figure 7. A, Representative immunofluorescent images of freshly-isolated left-atrial 
fibroblasts stained with NFATc3/NFATc4, vimentin (fibroblast marker) and 
TOPRO-3 (nuclear marker) antibodies in AF and CTL dogs.  B, Mean±SEM 
nuclear/cytoplasmic signal intensity ratio of NFATc3 (top) and NFATc4 (bottom, 
n=5, *P<0.05 vs. CTL).  C, Top: Representative immunoblots of cytosolic and 
nuclear protein fractions of HSP70 (cytosolic marker), Lamin A/C (nuclear 
marker), NFATc3 and NFATc4 in freshly-isolated left-atrial fibroblasts in AF and 
CTL dogs.  Bottom: Mean±SEM cytoplasmic NFATc3/NFATc4 relative to HSP70 
and nuclear NFATc3/NFATc4 relative to Lamin A/C (n=4/group, *P<0.05 vs. 
CTL).  D, Mean±SEM miR-26a and b expression in control-dog left-atrial 
fibroblasts treated with INCA6 (2.5-µmol/L) for 24 hours. (n=5/group, P<0.05 vs. 
DMSO).  E, Representative immunoblots (top) and mean±SEM TRPC3/GAPDH 
(bottom) in control-dog left-atrial fibroblasts treated with INCA6 (2.5-µmol/L) for 
24 hours (n=5, P<0.05 vs. DMSO). 
Figure 8. A, Mean±SEM duration of induced AF on Day 7 in AF-dogs treated throughout 
the AF-pacing period with intravenous Pyr3 (n=6, 0.1 mg/kg/day) or vehicle (n=6, 
*P<0.05 vs. vehicle). B, Mean±SEM atrial ERP (*P<0.05 vs. vehicle).  C, 
Representative immunoblots (top) and mean±SEM vimentin band-intensity 
normalized to GAPDH (bottom) in left-atrial tissue samples from Pyr3- (n=5) or 
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vehicle-treated AF dogs (n=5, *P<0.05 vs. vehicle).  D, Mean±SEM cell-count of 
left-atrial fibroblasts after 2-day and 3-day culture in Pyr3- (n=6) or vehicle-treated 
AF dogs (n=6, *P<0.05 vs. vehicle).  E, Mean±SEM percentage of cells in G2/M 
phase (n=6/group, *P<0.05 vs. vehicle).  F, Mean±SEM extracellular matrix-gene 
mRNA-expression in freshly-isolated left-atrial fibroblasts in Pyr3- (n= 5) or 
vehicle-treated AF dogs (n=5, *P<0.05 vs. vehicle). 
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Supplementary Material 
 
TRPC3-dependent Fibroblast Regulation in Atrial Fibrillation 
Supplemental Methods 
Rat fibroblast isolation and culture 
Adult male Sprague-Dawley rats weighing 200-250 g were anesthetized with ketamine (50 
mg/kg, i.p.) and xylazine (10 mg/kg, i.p.).  Hearts were quickly excised via thoracotomy 
into ice-cold Tyrode solution containing (mol/L) 140 NaCl, 5.4 KCL, 2.0 CaCl2, 1.0 
MgCl2, 10 HEPES, and 5.5 glucose (pH 7.35 with NaOH) and Langendorff-perfused at 
37°C with 1) Tyrode solution for 5 min; 2) Ca2+-free Tyrode solution for 5 min; 3) Ca2+-
free Tyrode solution containing 0.04 mg/ml collagenase-II for 30 min.  They were then 
removed, minced, and homogenized in Ca2+-free Tyrode solution.  Isolated cells were 
centrifuged (550 rpm, 3 min), separating cardiomyocytes (primarily in the pellets) from 
fibroblasts (in the supernatant).  Cardiomyocytes were further removed by passing the 
supernatant through a 20-µm nylon filter; fibroblasts were then further concentrated via 
centrifugation (2000 rpm, 10 min).  Pellets were resuspended and washed twice in M199-
medium supplemented with 10% fetal bovine serum for primary culture.  
Atrial tissue-samples from humans, goats, and dogs 
Human right-atrial appendage biopsies were obtained from patients in sinus rhythm and 
with chronic AF during coronary artery bypass graft surgery.  The study was approved by 
the ethical review committee of Dresden University of Technology.  All subjects gave 
informed consent.  AF was induced in chronically-instrumented goats using repetitive 
burst-pacing for 10 days.  Congestive heart failure (CHF) dogs with AF substrates were 
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created by rapid ventricular pacing (240-bpm, 2 weeks).  Normal goats and dogs were used 
as controls. Right-atrial tissue samples were collected and fast-frozen in liquid-N2. 
AF-Dogs 
A total of 48 mongrel dogs (20-36 kg) were divided into control and atrial-tachypacing 
groups.  Animal-care procedures followed National Institutes of Health guidelines (NIH 
Publication No. 85-23, revised 1996) and were approved by the Animal Research Ethics 
Committee of the Montreal Heart Institute.  Dogs were anesthetized with ketamine (5.3 
mg/kg i.v.), diazepam (0.25 mg/kg, i.v.), and isoflurane (1.5%), intubated, and ventilated.  
A unipolar pacing lead was inserted into the right-atrial appendage under fluoroscopic 
guidance.  The lead was connected to a pacemaker (Star Medical, Tokyo, Japan) implanted 
in the neck.  Two bipolar electrodes were inserted into the right-ventricular apex and 
right-atrial appendage for internal electrocardiogram (ECG) recording.  Atrioventricular-
block and ventricular pacing as employed in many studies of atrial-tachycardia remodeling1 
was not performed, to more closely mimic spontaneous clinical AF-episodes.  The atrial 
pacemaker was programmed to stimulate the right-atria at 600-bpm for 1 week, with 
fibrillatory atrial activity maintained during pacing as assessed by daily ECG and 
intracardiac recordings.  Echocardiography was performed on Day 0 (before atrial pacing, 
baseline) and Day 7 to assess changes in LA dimension, LA systolic function and LV 
diastolic volume. 
 For in vivo treatment of the AF dogs, an Alzet osmotic pump (model 2ML1) was 
implanted subcutaneously in the back and a selective TRPC3 blocker, pyrazole3 (0.1 
mg/kg/day, dissolved in DMSO and polyethylene glycol), or vehicle (DMSO and 
polyethylene glycol) was continuously administrated for the entire period of atrial 
tachypacing (Supplemental Figure 3).   
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Dog atrial fibroblast isolation and culture 
After the open chest study, the left-atrial tissues were immersed in oxygen-saturated, Ca2+-
containing Tyrode solution at room temperature.  The left circumflex coronary artery was 
cannulated and perfused with Ca2+-containing Tyrode-solution (37°C, 10 min), then 
perfused with Ca2+-free Tyrode-solution (15 min), followed by 50-minute perfusion with 
Tyrode-solution containing collagenase (Worthington, type II) and 1% bovine serum 
albumin (Sigma).  Digested left-atrial tissue was then removed, minced, and homogenized 
in M199 media. Isolated cells were centrifuged (800 rpm, 3 min) to separate 
cardiomyocytes (primarily in the pellets) from fibroblasts (in supernatant).  
Cardiomyocytes were further removed by filtration of the supernatant through a 20-µm 
nylon filter; fibroblasts were then further concentrated via centrifugation (2000 rpm, 10 
min).  Pellets were resuspended and washed twice in M199-medium supplemented with 
10% fetal bovine serum for primary culture.  
Terminal Open-chest Electrophysiological Study 
Dogs were anesthetized with morphine (2 mg/kg, s.c.) and α-chloralose (120 mg/kg, i.v., 
followed by 29.25 mg/kg/h), and mechanically ventilated.  Body temperature was 
maintained at 37°C.  A median sternotomy was performed, and bipolar electrodes were 
hooked into the RA appendages for recording and stimulation.  Right-atrial effective 
refractory period (ERP) was measured at basic cycle lengths of 150, 200, 250, 300, and 360 
ms with 10 basic (S1) stimuli, followed by an S2 with 5-ms decrements (all pulses twice-
threshold, 2-ms).  AF (irregular atrial rhythm > 400 bpm) was induced with 1-10 s atrial 
burst-pacing (10-20 Hz, 4×threshold, 2-ms pulses).  Mean AF-duration was determined in 
each dog based on 10 AF-inductions for AF<5 min and 5 inductions for 5-30 min AF.  
AF>30 min was considered sustained: cardioversion was not performed, and 
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electrophysiological assessment was terminated.  Haemodynamic data were obtained with 
fluid-filled catheters and transducers. 
qPCR 
Total RNA and microRNA were extracted with TRIzol (Invitrogen) and mirVana miRNA 
Extraction Kit (Ambion) from freshly isolated fibroblasts, respectively.  Real-time RT-PCR 
was performed with 6-carboxy-fluorescein (FAM)-labeled fluorogenic Taq-Man primers 
and probes (Applied Biosystem).  Fluorescence-signals were detected in duplicate, 
normalized to β2-microglobulin RNA for total RNA and to U6 snRNA for microRNA, and 
quantified with MxPro qPCR-software (Stratagene).  
TaqMan low-density arrays  
Total RNA was extracted using TRIzol. RNA-integrity was assessed via Agilent 
Bioanalyzer.  (RIN>7.5 required).  cDNA was synthesized using the High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems) with random hexamer primers.  TaqMan 
low-density arrays (TLDA, Applied Biosystems) were used in two-step RT-PCR as 
previously reported.2  Real-time RT-PCR was performed on the 7900HT Fast Real-Time 
PCR System.  Data were collected with SDS2.3 software and grouped with RQ Manager 
software.  TRP-subunit genes were investigated using inventoried Taqman assays.  
Ct-methodology was applied to determine mRNA expression-levels.  The mean expression 
of the genes with a Ct value below 30 (Ct<30) was selected as the reference.3   
Cell-Proliferation and Cell-Cycle Analysis 
Isolated cardiac fibroblasts were counted with hematocytometer and placed into T25 
culture-flasks (2.0×105 cells/flask, 25 cm2 growth-area) for each treatment group.  
Treatment was performed on Day 2 or Day 3 unless otherwise specified.  After 1-hour and 
24-hour incubation, cultured fibroblasts were totally harvested from each flask following 
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trypsinization, then washed in ice-cold PBS and fixed in 1.0 ml of ice-cold 75% ethanol.  
Samples were stored at -20°C until analysis.  Once pelleted, fibroblasts were re-suspended 
and incubated (4°C, 30 minutes) in 250 µl of staining solution containing propridium iodide 
(PI, Sigma) with RNAase and then 750 µl of PBS was added; the final volume in each 
sample was 1000 µl.  In each preparation, the numbers of cells and PI fluorescence were 
measured with a FACScan (constant flow-rate, 60 µl/min, 5-min acquisition time, BD 
Bioscience) at 617-nm emission-wavelength to create a DNA content-frequency histogram.  
Samples were gated on fibroblast population using forward scatter vs. side scatter plot (cell 
size vs. granularity) and doublet discrimination gating.  The percentage of cells in each 
phase of the cell cycle, G0/G1, S and G2/M phases, was analyzed using Flowjo software 
Dean-Jett-Fox model that fits G1 and G2 with Gaussian curves automatically (Tree Star 
Inc.).4 
 In order to confirm the accuracy of cell-counting with flowcytometry, 3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) cell proliferation assay was 
also performed with using Cell Proliferation Kit I (Roche).  Two-day cultured fibroblasts 
were resuspended and transferred into a 96-well plate (5.0×103 cells/well, 0.32 cm2 growth-
area).  The cells were incubated with the same treatment protocol for the flowcytometry 
experiment.  The assay was triplicated in each treatment group.  The absorbance (550 nm-
690 nm) was quantified using a scanning multiwell spectrophotometer (Synergy2, BioTek).  
The cell-counting with flowcytometry described above was also performed in parallel with 
the same passage fibroblast samples.  Both proliferation assays showed similar results 
(Figure A and B below).  
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A, Cultured rat fibroblast proliferation estimated by MTT assay after 1-hour and 24-hour 
treatment with vehicle-control, or 0.3 or 3-μmol/L Pyr3.  Mean±SEM spectrophotometrical 
absorbance (550 nm-690 nm) (n=6, P<0.05 vs. CTL).  B. Mean±SEM cell-count of rat 
fibroblast with flowcytometry after 1-hour and 24-hour treatment with vehicle-control, or 
0.3 or 3-μmol/L Pyr3. (n=6, P<0.05 vs. CTL). 
Western Blots  
Total protein was extracted from freshly-isolated/cultured fibroblasts or atrial tissues, 
quantified, and processed as previously described.  Cytoplasmic and nuclear protein 
fractions were extracted from fresh fibroblasts with ProteoExtract Subcellular Proteome 
Extraction Kit (Calbiochem, Darmstadt, Germany).  Protein-samples (20 µg/lane for total 
protein and 30 µg/lane for fractionated protein) were separated by 8% SDS-PAGE 
electrophoresis and then transferred to polyvinylidene-difluoride membranes.  Membranes 
were blocked and incubated with mouse anti-α smooth-muscle actin (αSMA, 1/2000, 
Sigma), mouse anti-phospho p44/42-MAP-kinase (1/2000, Cell signaling), mouse anti-
vimentin (1/1000, Santa Cruz), rabbit anti-TRPC3 (1/1000, Alomone), rabbit anti-TRPC1 
(1/200, Alomone), mouse anti-TRPM7 (1/1000, Neuromab), mouse anti-NFATc3 (1/1000, 
Santa Cruz), rabbit anti-NFATc4 (1/1000, Santa Cruz), mouse anti-HSP70 (1/1000, 
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Stressgen), mouse anti-Lamin A/C (1/1000, Abcam), anti-GAPDH (1/10000, Fitzgerald), 
and rabbit anti-calsequestrin (1/2500, Dianova).  Corresponding secondary antibodies 
conjugated to horseradish-peroxidase were used for detection. Staining was detected using 
chemiluminescence and quantified by video densitometry.  All expression data are provided 
relative to GAPDH or calsequestrin staining for the same samples on the same gels. 
Confocal Imaging 
Cultured/freshly-isolated fibroblasts or left atrial tissue cryosections were fixed with 
2%-paraformaldehyde, washed with PBS, and incubated with mouse anti-alpha SMA 
(1/400, Sigma), goat anti-vimentin (1/200, Santa Cruz), mouse anti-NFATc3 (1/200, Santa 
Cruz), rabbit anti-NFATc4 (1/200, Santa Cruz), followed by donkey anti-mouse IgG-Alexa 
Fluor 555 (1/600, Invitrogen), donkey anti-rabbit IgG-Alexa Fluor 488 (1/600, Invitrogen), 
donkey anti-goat IgG-Alexa Fluor 488 (1/600, Invitrogen), and TOPRO-3 iodide (1/500, 
Invitrogen).  Apoptosis was assessed using TUNEL-assay with ApopTag plus fluorescein 
in situ apoptosis detection kits (Millipore).  Fluorescent images were obtained via Zeiss 
LSM-710 or OLYMPUS Fluoview FV1000 inverted confocal microscope. 
Fluorescent Ca2+-Imaging 
Primary cultured fibroblasts (1-day culture as described above) were loaded with Fluo-4 
(10 µmol/L) in phenol-free M199-medium in the presence of pluronic acid (2.5 µg/ml) for 
50 min at 37°C. Ca2+-imaging was recorded with an Andor Revolution confocal system and 
a Xion camera (Andor Technologies) mounted on an upright Nikon FN-1 microscope with 
a 60× water-immersion objective (1.0 NA).  Fluo-4 was excited with a 488-nm solid-state 
laser; emitted fluorescence was collected at 495 nm.  Images (512×512 pixels) were 
acquired at 15 frames/sec for 5 min using iQ software (Andor Technologies).  Ca2+-
associated fluorescence was analyzed with custom-designed software (A. Bonev, 
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University of Vermont).  Regions of interest (ROIs) were determined by cell-outlines. FO 
was determined by averaging fluorescence of ROIs from 10 consecutive baseline images.5  
At the end of experiments, ATP (100-µmol/L) was applied to verify cell-viability.  One-day 
cultured fibroblasts were incubated in 2-mmol/L Ca2+-containing Tyrode solution followed 
by Ca2+-free solution to induce Ca2+-store depletion and store-dependent Ca2+-entry.  Under 
OAG (25-µmol/L)- or angiotensin-II (100-nmol/L)-stimulation, cell-Ca2+ was recorded 
with confocal microscopy 5 minutes before and after re-administration of 2-mmol/L Ca2+ 
into the extracellular solution. 
TRPC3-knockdown 
Plasmid constructs 
The TRPC3-specific shRNAmir over-expressing pGIPZ-based lentivirus vector plasmid 
was obtained from Open Biosystems (Oligo ID: V2LMM_11490). 
 The scrambled shRNAmir over-expressing plasmid was generated as follows.  The 
empty pGIPZ lentivirus vector plasmid carrying the mRNA-context sequence but no 
shRNA was obtained from Open Biosystems.  The EcoRI site of pGIPZ located at position 
5394 was removed by partial EcoRI digestion and Klenow fill-in, resulting in 
pGIPZΔEcoRI.  This modification allowed the direct cloning of the scrambled shRNAmir 
construct in pGIPZ between XhoI, 2654 and EcoRI, 2678 sites.  In the design of the 
scrambled shRNAmir and during the rest of the cloning procedure, we followed the 
methods by Paddison et al.6 Briefly, a 97bp long synthetic oligonucleotide 
( 5`TGCTGTTGACAGTGAGCGCCGATATCAGCAGATAATGAAATAGTGAAGCCACA
GATGTA TTTCATTATCTGCTGATATCGTTGCCTACTGCCTCGGA 3`, passanger 
strand, loop, guide strand) was PCR amplified by 
5`CAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG sense and 5` 
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CTAAAGTAGCCCCTTGAATTCCGAGGCAGTAGGCA antisense primers, carrying 
XhoI and EcoRI restriction sites, respectively.  PCR product was cloned in pGIPZΔEcoRI 
at XhoI, EcoRI sites. Sequence identity of the resulting clone was verified by sequencing. 
 The psPAX2 and pMD2.G lentivirus packaging plasmids were obtained from Didier 
Trono`s laboratory (http://tronolab.epfl.ch/, Ecole Polytechnique Federale de Lausanne, 
Lausanne, Switzerland) through Addgene (Addgene plasmid 12260 and 12259). 
 All plasmids were amplified in E. coli DH5α and purified by Nucleobond anion 
exchange columns (Macherey-Nagel) following the manufacturer’s instructions. 
 
Lentivirus production 
The Hek293T/17 cell line we used for producing lentivirus production was obtained from 
ATCC (Manassas, VA, USA) and were grown in DMEM (Invitrogen) supplemented with 
10% FCS (Gibco).  Lentiviruses were produced by following the protocols available from 
Didier Trono`s laboratory (http://tronolab.epfl.ch) with minor modifications.  A 
subconfluent monolayer of Hek293T/17 cells (ATCC) kept in DMEM (Invitrogen) 
supplemented with 10% FBS (Gibco) were transfected with a mixture of plasmids 
containing one of the vector plasmids and the psPAX2 and pMD2.G packaging plasmids in 
2:2:1 weight ratio by the calcium-phosphate precipitation method.  Eight hours after 
transfection, the culture medium was replaced by fresh culture medium.  The supernatant 
containing the lentivector particles was harvested two times 32 and 56 hours post-
transfection.  The harvested medium was clarified from cell debris by low-speed 
centrifugation and by filtration through a 0.45 μm pore size syringe-attached filter.  Virus 
particles were concentrated by ultracentrifugation at 47000 g (RCF average) for 2 hours in 
a swinging bucket rotor, re-dissolved in sterile PBS containing 1% BSA and stored at -80°C 
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in aliquots.  Virus preparations were titrated on Hek293T/17 cells. 
miR-26a-Overexpression/Knockdown 
For the miR-26a overexpression, the sense (5` UUCAAGUAAUCCAGGAUAGGCU 3`) 
and antisense (5` CCUAUUCUUGGUUACUUGCACG 3`) oligoribonucleotides were 
synthesized by Invitrogen.  The both strands were annealed by mixing the same volume of 
each oligoribonucleotides dissolved in annealing buffer (IDT, Coralville, IA) at a 
concentration of 200 µmol/L and then incubated at 95°C for 10 min, 70°C for 10 min and 
then 50°C for 10 min.  A scrambled RNA was used as negative control (sense: 5` 
UCAUAAAGCUGAUAACCUCUAGAU 3`, antisense: 5` CUAGAGGUUAU 
CAGCUUUAUGAAU  3`).  
 For the miR-26a knockdown, the antisense anti-miRNA oligonucleotides (AMO26a: 
5` AGCCTATCCTGGATTACTTGAA 3`) was synthesized by Exiqon (Exiqon, Woburn, 
MA).  Five oligonucleotides on 5`-end of the antisense molecules and four oligonucleotides 
on 3`-end were locked by a methylene bridge connecting the 2’-O atom and 4’ -C atom 
(Locked Nucleic Acid, LNA).  A scrambled oligonucleotides with the same methylene 
bridge were used as negative control (5` ACTCAGAAGGACAAGTAGAGTCT 3`).  
 Dog left-atrial fibroblasts in primary culture were transfected with miR-26a (final 
concentration of 100 nmol/L) and/or AMO26a (final concentration of 10 nmol/L), and 
negative control miRNAs or AMOs with lipofectamine 2000 (Invitrogen).7  After 48-hour 
transfection, cells were collected for total RNA/protein purification or proliferation analysis 
with a FACScan.  The efficacy of miR-26a overexpression/knockdown by the miR-26a 
probes was confirmed by qPCR before experiments (Supplemental Figure 12C). 
Dual Luciferase Reporter Assay 
A fragment (5` 
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TGACTATAGCACAAATGTGGGCAATAATATTTCTAAGTATAAAATACTT 
GAAATGGTGTAAATTTTTAGTATTAACTACCTTTATCATGTGAATCTTTAA 3` miR-
26a target site) containing miR-26a target gene of TRPC3 was synthesized by Invitrogen 
and was used as a template for PCR amplification with 5` GACTAGTTGACTATAGCA 
CAAATGT 3` and 5` CCCAAGCTTTTAAAGATTCACATGATA 3`as forward and reverse 
primers, respectively.  The PCR product was ligated into HindIII and SpeI sites (3` UTR 
region of luciferase gene) in the pMIR-REPORT luciferase miRNA expression reporter 
vector (CMV promoter-driven Firefly luciferase expression vector, Applied Biosystems) 
and was subcloned. 
 For luciferase assay, HEK293 cells were simultaneously transfected with 50 ng of 
pMIR-REPORT, 0.5 ng pRL-TK (TK promoter-driven Renilla luciferase expression vector, 
Promega, Madison, WI) and miR-26a (final concentration of 10 nmol/L) and/or AMO26a 
(final concentration of 3 nmol/L) with lipofectamine 2000 (Invitrogen).  After 48-hour 
transfection, luciferase activities were measured with a dual luciferase reporter assay kit 
(Promega) on a luminometer (Lumat LB9507, Berthold, Bad Wildbad, Germany).7  The 
pMIR-REPORT firefly luciferase signals were normalized to the pRL-TK renilla luciferase 
signals as an internal control. 
Statistical Analyses  
Data are presented as mean±SEM. Two-way ANOVA with multiple-group comparisons 
(Bonferroni-corrected t-test) was data with two or more main-effect factors like flow-
cytometry with varying culture-times (treatment and time as main-effect factors) and ERP 
(basic cycle length and dog-group main factors). One-way ANOVA was applied for single 
main-effect factor experiments like Western blots, qPCR, and luciferase assay. Repeated-
measure analyses were used when the same set of subjects/materials were exposed to 
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multiple interventions. Students’ t-tests were used for comparisons involving only two 
groups. For multiple comparisons with Bonferroni correction, adjusted P-values were 
calculated as multiplying original P values for each pairwise comparison by the number of 
comparisons (N) performed; values shown are adjusted values (N×P). Two-tailed P<0.05 
was considered to be statistically significant. All analyses were performed with SPSS 16.0. 
Specific Analyses for individual figures and tables: 
Two-way ANOVA with multiple comparison (Bonferroni-adjusted t-tests) was used for data 
with two or more factors as main effects and repeated measures (Figures 1D, 1E and 1F, 
Figures 2B-2E, Figure 3B, Figure 4B, Figure 5A, 5B, 5D, 5E, Figure 8B, 8D and 8E, 
Supplemental Figure 4B, Supplemental Figure 5C and 5D, Supplemental Figure 7B and 7C, 
Supplemental Fig 8C and 8D).  
One-way ANOVA was applied for data with a single main-effects factor as obtained 
in studies of heart rate and echocardiographic data over time, with one main factor and 3 
levels (groups) or more (Supplemental Fig 11A, 11C-11E). Repeated-measure analyses 
were used when the same set of subjects/materials were exposed to multiple interventions 
(Figure 2A, Figure 6B-6G, Supplemental Fig 12C). 
Paired t-tests were used for Figures 1H, Figure 5F Figures 7D and 7E, and 
Supplemental Figures 6B, 7D, 8A and 8B.  
Non-paired t-tests were used for Figures 3C, 3E-G, Figure 4CE, Figure 5C, 5G, 
Figure 7B, 7C, Figures 8A, 8C, and 8F, and Figures 9A-I as well as Supplemental Table 1. 
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Supplemental Table 1.  Hemodynamic Data 
 
 
Control 
(n=11) 
AF 
(n=12) 
Body weight, kg 26.8±0.3 28.2±0.2 
Systolic BP, mmHg 127±2 120±2 
Diastolic BP, mmHg 73±2 76±2 
RAP, mmHg 1.3±0.1 2.5±0.1* 
LAP, mmHg 2.6±0.1 6.5±0.3* 
RVP, mmHg 22±0.4 23±0.5 
RVEDP ,mmHg 1.5±0.1 4.2±0.3* 
LVP, mmHg 116±1.4 101±1.9 
LVEDP, mmHg 3.9±0.2 8.0±0.5* 
*P<0.05 vs control. 
BP indicates blood pressure; RAP and LAP, RA and LA mean pressure; RVP and LVP, RV 
and LV mean pressure; RVEDP and LVEDP, RV and LV end diastolic pressure. 
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Supplemental Figure Legends 
Supplemental Figure 1.  A, mRNA expression of TRP channels measured by Taqman 
Low-density array.  B, mRNA expression of TRPC3 channel on enlarged scale. 
Supplemental Figure 2.  A, Representative immunofluorescent images of freshly-isolated 
rat cardiac fibroblasts.  Red indicates α-smooth muscle actin (αSMA); green, 
vimentin; blue, TOPRO-3 (nuclear staining).  B, Representative immunofluorescent 
images of passage-cultured myofibroblasts.  C, Representative INSC-recordings with or 
without gadolinium (Gd3+, 100-µmol/L) in freshly-isolated rat cardiac fibroblasts.  
Voltage-clamp protocol is shown in the inset.  D and E, Representative Gd3+- and 
Pyr3-sensitive INSC in passage-cultured myofibroblasts.  F, Mean±SEM Gd3+- and 
Pyr3-sensitive INSC density (n=10 cells in Gd3+ and 8 cells in Pyr3).  
Supplemental Figure 3.  Protocol for in vivo TRPC3-blocker (pyrazole-3) treatment study 
in AF dogs. 
Supplemental Figure 4.  A, Recordings of OAG-induced intracellular Ca2+-response in 
presence or absence of Pyr3.  B, Mean±SEM OAG-induced Ca2+ fluorescence (F/F0), 
normalized to baseline intensity under 0-mmol/L and 2-mmol/L Ca2+ (n=14 cells in 
each condition, *P<0.05 vs. 0-mmol/L Ca2+, #P<0.05 vs. 2-mmol/L Ca2+ in OAG-
only).  
Supplemental Figure 5.  A and B, Representative DNA-content histograms and Dean-Jett-
Fox model fitting of rat cultured fibroblasts with or without 24-hour treatment of Gd3+ 
(100-µmol/L) or Pyr3 (3-µmol/L).  C, Mean±SEM cell-count of rat fibroblasts after 1-
hour and 24-hour culture with vehicle-control, or 10 or 100-μmol/L Gd3+ (n=8/group, 
*P<0.05 vs. CTL, #P<0.05 vs. 1-h treatment).  D, Mean±SEM percentage of cells in 
G2/M-phase after Gd3+ treatment (n=8/group, *P<0.05 vs. CTL, #P<0.05 vs. 1-h 
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treatment).   
Supplemental Figure 6.  A, Representative images of TUNEL staining in cardiac rat 
fibroblasts with or without Pyr3 treatment (3-µmol/L).  Red indicates TOPRO-3 
(nuclear staining); yellow, TUNEL-positive cells.  B, Mean±SEM percentage of 
TUNEL-positive cells. (n=5/group, *P<0.05 vs. CTL).  
Supplemental Figure 7.  A, Representative immunofluorescent images of rat cardiac 
fibroblasts cultured  with or without Pyr3 (3-µmol/L).  Red indicates α-smooth 
muscle actin (αSMA); blue, TOPRO-3 (nuclear staining).  B, Mean±SEM cell-count 
of culture-passaged fibroblasts after 1-hour and 24-hour treatment with 3-µmol/L 
Pyr3 or vehicle DMSO (n=6/group).  C, Mean±SEM percentage of culture-passaged 
fibroblast cells in G2/M-phase after Pyr3 treatment or vehicle DMSO (n=6/group).  
D, Representative immunoblots (left) and mean±SEM αSMA-expression in culture-
passaged fibroblasts (right, normalized to GAPDH) (n=6). 
Supplemental Figure 8.  A, Mean±SEM TRPC3 and TRPC6 mRNA-expression in 
scrambled (Scr)-shRNA- and TRPC3-shRNA-infected dog atrial fibroblasts 
(n=6/group, *P<0.05 vs. scrambled shRNA).  B, Top: Immunoblots for TRPC3 
subunits and GAPDH.  Bottom: Mean±SEM TRPC3/GAPDH protein-expression 
(n=6, *P<0.05 vs. scramble shRNA).  C, Mean±SEM fold-change over time in the 
number of fibroblasts, following infection with shRNA or scrambled-probe virus 
(n=6/group, *P<0.05 vs. scrambled shRNA).  D, Mean±SEM percentage of virus-
infected fibroblast cells in G2/M-phase (n=6/group, *P<0.05 vs. scrambled-shRNA). 
Supplemental Figure 9.  A, through C, Representative immunoblots (top) and mean±SEM 
(bottom) TRPC3 subunit protein-expression (normalized to calsequestrin, CSQ) in 
right-atrial samples from patients with AF (n=8) and in sinus rhythm (n=10), AF 
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model goats (n=8) and normal goats (n=5) and congestive heart failure dogs with AF 
substrates (n=8) and normal dogs (n=8) (*P<0.05 vs. control).  D through F, TRPC1 
subunit expression.  G through I, TRPM7 subunit expression. 
Supplemental Figure 10.  A-E, Representative surface ECGs (left) and intracardiac 
electrograms (right) in an AF dog on Day 0 through Day 7. 
Supplemental Figure 11.  A, Mean±SEM heart rate over time during atrial tachypacing, 
ATP (n=7 CTL and 12 AF, *P<0.05 vs. CTL).  B, Representative apical 4 chamber 
views of echocardiography on Day 0 (baseline, before pacing, left) and Day 7 (right) 
in an AF dog.  C, Mean±SEM atrial diastolic area (n=10 CTL and 11 AF, P<0.05 vs. 
CTL).  D, atrial fractional area change. E, ventricular diastolic volume.  
Supplemental Figure 12.  A, miR-26 and its complementary sequence on TRPC3 3’-UTR 
region.  Sequences highlighted in yellow represent the seed region of miR-26a.  B, 
Antisense anti-miR-26a oligonucleotide (AMO26a) sequence and its complementarity 
to miR-26.  Sequences highlighted in yellow represent the seed region of miR-26.  
Bold characters in the AMO26a sequence indicate locked nucleic acids (LNAs).  C, 
Results of miR-26a overexpression/knockdown by miR-26a duplex/AMO26a in dog 
left-atrial fibroblasts.  Lipo; lipofectamine transfection without the miR-26a probes. 
(n=4, P<0.05 vs. Lipo).  D, Multiple putative NFAT binding motifs in the promoter 
regions of the host gene for miR-26a and miR-26b in human and canine genomes.  
Ctdsp: Carboxy-Terminal Domain RNA polymerase II polypeptide A Small 
Phosphatase.  The numbers before the sequences represent the relative positions of 
predicted NFAT binding motifs to the transcription start site (TSS) of the host gene.  
The numbers in the brackets stand for the scores given by Genomatix 
(http://www.genomatix.de) for the similarity between the putative NFAT cis-acting 
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elements in the promoter regions of the host genes for miR-26a/b and the perfect 
NFAT binding sequence; Two scores are given as core sequence similarity and 
overall sequence similarity.  Only those with overall matrix similarity >0.95 are 
shown. 5000 bp upstream to the predicted TSS for miR-26a/b host genes in human 
and canine was analyzed. 
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CHAPTER 5.   GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
268 
 
5.1 Summary of the Novel Findings in this Thesis 
In Chapter 2, we have conducted the first systematic analysis of all the cardiac-expressed 
miRNAs, and demonstrated that there is only a subset of these cardiac-expressed miRNAs 
that have the potential to target human cardiac ion channel genes. Based on this analysis, 
we further demonstrated that most of the deregulated expression of ion channel genes as 
seen in three cardiac disease states (e.g. cardiac hypertrophy/cardiac failure, myocardial 
ischemia, and atrial fibrillation) can be explained by the expression changes of the 
corresponding miRNAs. This highlights the potential significance of miRNA regulation of 
cardiac ion channels in arrhythmogenesis under these cardiac conditions.   
In Chapter 3, we have performed the first detailed characterization of the role of miRNAs 
in IK1-related atrial electrical remodeling in AF. We first identified miR-26 as a key 
regulator of IK1 via controlling the expression of its underlying subunit Kir2.1. Moreover, 
our study demonstrated that downregulation of miR-26 due to enhanced NFATc3/c4 
activities accounts for the AF-induced IK1 enhancement. Furthermore, we observed that in 
vivo interference of miR-26 is able to control the AF susceptibility via regulation of IK1.  
In Chapter 4, we have presented the first study to characterize the function of TRPC3 
channels in AF, and to investigate the potential role of miRNAs in regulation of this 
channel under the same disease paradigm. We found that TRPC3 channels regulate 
fibroblast function via mediating Ca2+-entry, which results in activation of Ca2+-dependent 
ERK-signaling. Moreover, we provided evidence showing that TRPC3 is upregulated in AF 
and this upregulation is likely due to the reduced expression of miR-26 resulting from 
enhanced NFATc3/c4 activities in atrial cardiac fibroblasts. Furthermore, we observed that 
in vivo TRPC3 channel blockade suppresses the development of the AF-promoting 
substrate. 
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5.2 Significance of the Major Findings in this Thesis 
In general, the findings presented in this thesis provide a novel insight into how 
arrhythmias are generated. Specifically, they highlight the important contribution of 
miRNA to the AF pathogenesis and help to better understand the mechanisms underlying 
the remodeling processes associated with this common arrhythmic disorder. In the 
following section, the major findings and their potential significance will be addressed. 
 
5.2.1 Discovery of miR-26 as a novel molecular and signaling mechanism 
for AF vulnerability and a novel therapeutic target for AF 
treatment  
  
5.2.1.1   MiR-26 controls AF by inhibiting IK1-related adverse atrial electrical 
remodeling in atrial myocytes 
IK1 enhancement is a common observation in AF, representing one of the most important 
steps of ionic remodeling during AF [20, 376]. Enhanced IK1 has been well established to 
play a significant role in AF pathophysiology, particularly in determining the AF-
supporting reentry [20, 73]. In addition, it is also known to be a causative determinant in 
familial AF resulting from gain-of-function mutations associated with Kir2.1 
channelopathies [95, 377]. As noted in the Introduction, numerous studies have been done 
to understand the molecular mechanisms for this ionic remodeling. The results strongly 
suggest that the functional enhancement of IK1 in AF is likely ascribed to the increased 
expression of its underlying subunit Kir2.1 at protein and/or mRNA levels [83, 85]. What 
determines the altered expression of Kir2.1 in AF, however, remained puzzling. In this 
context, our study in Chapter 3 has provided a possible answer with the compelling 
evidence for the involvement of miRNAs. We found that miR-26 is consistently 
downregulated in AF dogs and AF patients, and this downregulation is accompanied by the 
coincided increase of Kir2.1 mRNA and protein. In addition, we experimentally validated 
KCNJ2 as a cognate target of miR-26, which mechanistically accounts for the inverse 
changes of expression between miR-26 and Kir2.1 as seen in AF. Furthermore, we 
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demonstrated that in vivo interference of endogenous miR-26 is able to affect AF 
vulnerability and this effect is attributed to the repression of KCNJ2/Kir2.1/IK1 by miR-26. 
Together, these findings demonstrate that miR-26 downregulation is responsible for the 
upregulation of Kir2.1/IK1 in AF, revealing a novel molecular mechanism for the AF-
induced electrical remodeling. Moreover, our findings also suggest that miR-26 controls 
AF by inhibiting the underlying adverse electrical remodeling. In addition to a previous 
study showing the important role of miR-328 in AF-induced ICaL downregulation [113], our 
study is the second demonstration of a crucial contribution of miRNAs to the adverse atrial 
electrical remodeling in AF. Given that ICaL downregulation and IK1 enhancement are the 
two most important ionic alterations underlying AF-induced electrical remodeling [20, 62], 
our findings together with those from the previous study have highlighted a central role of 
miRNAs in the AF-associated electrical remodeling. Moreover, our data also indicates that 
the miRNA-mediated electrical remodeling in AF seems to be a complex process which 
might require the synergistic regulation of multiple miRNAs. It should be noted that 
downregulation of miR-26 has also been reported in cardiac hypertrophy [350, 378], 
whether miR-26 may also contribute to electrical abnormalities associated with cardiac 
hypertrophy through a similar mechanism will be of interest for further study.     
 
While our results point to the direct involvement of miR-26 in AF-induced IK1 
augmentation, a previous study by Girmatsion et al. suggested the potential contribution of 
miR-1 to this adverse remodeling process [96]. The authors reported that expression of 
miR-1 was significantly reduced in the left atrial samples of AF patients with mitral valve 
diseases, along with a corresponding increase in Kir2.1-protein expression [96]. Since miR-
1 was established by a previous study to target Kir2.1 [204], the authors thus proposed that 
reduced expression of miR-1 is responsible for upregulation of Kir2.1/IK1 in AF patients 
[96]. Our studies in Chapter 3, however, found that the expression of miR-1 was unaltered 
in our samples from dogs and patients with AF (Chapter 3).  The reason for the discrepancy 
in miR-1 expression in AF patients between our study and the study by Girmatsion et al. 
remained unclear. Various confounding factors of the patient samples such as ethnic group, 
age, and gender may have likely contributed to this difference. In addition, the causative 
role of miR-1 downregulation in AF initiation and maintenance was not established in this 
study, which makes the role of miR-1 in AF questionable. Further evidence against the 
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contribution of miR-1 downregulation to AF came from a recent study showing that 
downregulation of miR-1 actually improves calcium handling [374], a condition which is 
beneficial for AF. Nonetheless, further experiments related to the possible role of miR-1 in 
AF are needed to clarify the issue. 
     
5.2.1.2   MiR-26 controls AF by inhibiting TRPC3-mediated adverse atrial structural 
remodeling in atrial fibroblasts 
Another major finding in our study is that miR-26 is abundantly expressed in atrial 
fibroblasts and AF-induced downregulation of miR-26 can result in upregulation of TRPC3 
in atrial fibroblasts. This finding together with the finding that TRPC3 channels positively 
regulate atrial fibroblast proliferation and differentiation suggest that miR-26 likely 
contributes to atrial fibrosis via regulation of TRPC3 in AF. Our findings are in agreement 
with the previous studies showing the fibrogenic potential of miRNAs in the heart under 
different pathological conditions including AF. For example, the profibrotic effect of miR-
21 and anti-fibrotic effect of miR-29 were reported in cardiac hypertrophy/heart failure and 
myocardial ischemia [284, 347, 354, 370]; downregulation of miR-133 and miR-590 were 
found to promote atrial fibrosis in experimental AF [375]. However, unlike these studies in 
which the fibrogenic effects of the miRNAs are primarily ascribed to the direct targeting of 
various ECM proteins and/or profibrotic factors, such as TGF-β1, sprouty-1, collagen, 
fibrillins, and elastin [284, 347, 375], our study (Chapter 4) suggests a novel mechanism: 
miR-26 contributes to AF-induced fibrotic remodeling by regulating fibroblast function 
through its targeting on TRPC3 channels. Notably, this potential mechanism may also be 
implicated in other cardiac pathological conditions. For example, reduced miR-26 [350, 
378] and enhanced TRPC3 [222, 379] expression have been consistently reported in cardiac 
hypertrophy, it is conceivable that our proposed mechanism may at least partially account 
for the fibrotic remodeling manifested in this pathological condition.      
 
Although, in Chapter 3, we have demonstrated a significant downregulation of miR-26 in 
atrial tissues obtained from AF dogs induced by atrial tachypacing as well as AF patients 
undergoing mitral valve disease, the cellular contribution of this miR-26 downregulation 
was not clearly defined. For example, the reduction of miR-26 could have resulted from its 
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expression changes in cardiomyocytes and/or cardiac fibroblasts, given that miR-26 is 
ubiquitously expressed in the heart [281]. In this regard, the study in Chapter 4 has 
provided direct evidence to clarify this issue. We first demonstrated that miR-26 is 
abundantly expressed at comparable levels in both atrial myocytes and atrial fibroblasts 
isolated from normal dogs (Chapter 4). Moreover, in atrial tachypacing (ATP) -induced AF 
dog model, we observed that miR-26 is significantly downregulated to a similar extent in 
both isolated atrial myocytes (unpublished data in Chapter 4) and atrial fibroblasts (Chapter 
4). These findings suggest that the observed miR-26 reduction in Chapter 3 is likely the 
contribution from two cell types. More importantly, our findings here also suggest that 
miR-26 downregulation is a common phenomenon in AF, accounting for IK1 enhancement 
in atrial myocytes and TRPC3 upregulation in atrial fibroblasts, and thereby contributing to 
AF-related electrical and structural remodeling. 
      
5.2.1.3   MiR-26 mediates the AF-promoting action of NFAT and is a key factor of two 
signaling pathways leading to AF 
It is well known that Ca2+-calcineurin-NFAT signaling plays a central role in detecting the 
rapid repetitive atrial activation that occurs during AF, and in coupling AF to L-type Ca2+-
current downregulation [109, 380, 381]. NFAT is activated upon dephosphorylation by 
calcineurin, a calcium/calmodulin-dependent protein phosphatase [382]. Activated NFAT is 
then translocated into nucleus where it functions as a transcription factor to control gene 
expression [382]. NFATc3 and NFATc4 are the two dominant isoforms expressed in the 
heart [383]. Enhanced NFATc3 and NFATc4 activities have been observed in atrial 
myocytes isolated from ATP-induced AF dogs [109]. Consistent with the above 
observations, we also found the activities of NFATc3 and NFATc4 were enhanced in our 
atrial tissues obtained from AF dog (Chapters 3&4) and AF patients (Chapter 3). In 
addition, our study in Chapter 4 further demonstrated that activation of NFAT also occurs 
in isolated atrial fibroblasts from our AF dogs. Notably, this is the first demonstration of 
AF-associated NFAT-changes in fibroblasts. Moreover, our findings suggest that enhanced 
NFAT activity appears to be a common cellular response to elevated Ca2+ entry in both AF-
cardiomyocytes and AF-fibroblasts.  
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The function of activated NFAT as a transcriptional repressor/activator has been previously 
described in many studies. Activation of NFATc3 was found to downregulate the 
expression of gene encoding Kv4.3 (main subunit underlying Ito channel) in ventricular 
myocytes [384-386]. Similar repressive effect of activated NFATc3 was also observed in 
murine urinary bladder smooth muscle cells, where it tunes down the transcription of the 
gene encoding KCa1.1 (subunit underling BK channel) [387]. In AF, enhanced NFAT 
activity was reported to negatively regulate the expression of Cav1.2 genes in atrial 
myocytes [109]. Intriguingly, NFAT activation was also found to regulate the expression of 
miRNAs. For example, enhanced NFAT activity transcriptionally activates the expression 
of miR-23 and miR-199 during cardiac hypertrophy [313, 314]. In agreement with the 
above observations, we also found the expression of miR-26 is under the control of NFAT 
(Chapters 3&4). However, in contrast to the positive regulation of miR-23 and miR-199 by 
NFAT, we found that NFAT act as a negative regulator for miR-26 (Chapters 3&4). Our 
findings thus offer a mechanistic explanation for why miR-26 is downregulated in AF. In 
addition, our findings that in vitro NFAT inhibition is able to downregulate the expression 
of Kir2.1 and TRPC3 protein, suggest that the calcineurin-NFAT system may also be 
responsible for IK1 and TRPC3 changes manifested during AF, indicating that this Ca2+-
dependent system is a common pathway involved in both electrical and structural 
remodeling associated with AF. More importantly, these findings also reveal the functional 
relevance of miR-26 in AF as an important mediator of the electrophysiological effects of 
Ca2+-dependent NFAT signaling, highlighting a central role of miR-26 in AF control. A 
schematic illustration of the involvement of calcineurin-NFAT system and the central role 
of miR-26 in AF-induced upregulation of IK1 and TRPC3 channels is shown in Figure 1.  
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Figure 1. A schematic illustration of the involvement of calcineurin-NFAT system and the 
central role of miR-26 in AF-induced upregulation of IK1 and TRPC3 channels. In AF, the 
rapid atrial activation causes the elevation of [Ca2+]i in both atrial myocytes and atrial 
fibroblasts, where the calcineurin-NFAT signaling is activated in response to the increased 
Ca2+ entry. Activated NFATc3 and NFATc4 are then translocated into the nucleus where 
they suppress the transcription of miR-26 genes. The resultant miR-26 reduction has two 
effects: 1) it causes the enhanced expression of Kir2.1 protein and its underlying IK1 in 
atrial myocytes, contributing to APD/ERP shortening and thereby adverse electrical 
remodeling; and 2) it increases the expression of TRPC3 protein as well as its underlying 
channel in atrial fibroblasts, leading to enhanced fibroblast proliferation and differentiation 
and thereby adverse structural remodeling. The consequences of both cases contribute to 
the development of reentry substrates, favoring AF. APD: action potential duration; ERP: 
effective refractory period. Note: green upward arrows indicate upregulation, whereas red 
downward arrows indicate downregulation.  
 
5.2.1.4   Therapeutic potential of miR-26 for AF  
Finally, our finding in Chapter 3 that in vivo overexpression of miR-26 is able to suppress 
AF induction and perpetuation, suggests the potential of miR-26 as a target for AF 
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management. As discussed in the introduction, AF-therapy is still a major challenge in the 
clinical practice, as none of the currently-available pharmacological or non 
pharmacological approaches is adequate to treat AF with an optimal effect [49]. Therefore, 
there is a great need for novel therapeutic approaches. Gene therapy may represent one of 
such therapeutic avenues, although it is still in its infancy. In fact, several virus-based gene 
therapies have already shown promises in the treatment of advanced Parkinson’s disease 
[388] and congenital retinal disease [389, 390]. Our findings thus suggest that miR-26 
could conceivably be a candidate for AF-targeting gene-therapy in the future. 
 
5.2.2 Discovery of TRPC3 as a novel player in AF 
Although it is not the main focus of this thesis, our findings related to the role of TRPC3 in 
cardiac fibroblast function in Chapter 4 help to improve our current knowledge about 
cardiac fibroblast biology. Previous studies have suggested that Ca2+ entry is essential for 
fibroblast functions (proliferation and differentiation) [158-162]. However, the fact that 
cardiac fibroblasts lack voltage-gated calcium channels has led to a speculation of the 
existence of other Ca2+ permeable ion channels in these cells [163]. In this context, our 
study in Chapter 4 has provided compelling evidence to show that TRPC3 channels may 
represent one of such candidates. We found that TRPC3 channels are abundantly expressed 
in atrial fibroblasts, where they are responsible for the Ca2+ influx and positively regulate 
the atrial fibroblasts proliferation and differentiation (Chapter 4). Mechanistically, we 
found that TRPC3-mediated Ca2+ entry affects atrial fibroblast functions by modulating 
Ca2+-dependent ERK 1/2 phosphorylation (Chapter 4). Our findings are consistent with the 
previous finding that mitogen-activated protein kinase cascade is critically involved in 
controlling fibroblast activation [391, 392]. Collectively, our findings postulate a novel 
cellular mechanism for the regulation of cardiac fibroblast activation, which may also be 
applicable to other cardiac disorders associated with fibroblast remodeling. In addition, our 
results reveal a novel aspect of biological functions of TRPC3: the role in controlling 
fibroblast activation.  
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More importantly, our findings that AF enhances the expression of TRPC3 and activates 
fibroblast via TRPC3-dependent Ca2+ entry mechanism (Chapter 4), provide a mechanistic 
explanation for why AF may itself promote atrial fibrosis, an important question related to 
AF pathophysiology that is insufficiently addressed by previous studies [144, 145]. A 
recent study has shown that TRPM7 is upregulated at mRNA and functional levels in atrial 
fibroblasts isolated from AF patients and may likely contribute to AF fibrogenesis via 
regulating the Ca2+ entry-dependent fibroblast proliferation and differentiation [168]. 
However, in contrast to this study, we found that TRPM7 protein remains unchanged in the 
atrial samples from our AF dogs, AF goats, and AF patients (Chapter 4), suggesting that the 
functional enhancement of TRPM7 as observed in AF is likely determined by the other 
regulatory mechanisms (e.g. membrane trafficking) rather than changes in expression. In 
addition, our findings that in vivo TRPC3 blockade is able to prevent enhanced 
proliferation and ECM-expression of fibroblasts and suppresses AF (Chapter 4), are 
consistent with an important role in fibroblast-mediated AF-promoting remodeling and 
strongly suggests the therapeutic potential of TRPC3 as a candidate target for AF 
prevention. 
         
5.2.3 Systematic identification of miRNA regulation of ion channel genes 
and its potential implications in arrhythmia associated with heart 
diseases 
Previous studies have pointed out the important role of miRNAs in arrhythmia via 
regulation of expression of cardiac ion channel genes at the post-transcriptional level [96, 
113, 204, 374]. However, due to the laborious nature of the experimental approach and the 
complexity of miRNA targeting activities, target identification has been a major challenge 
in miRNA research [250, 275] and experimental approaches, though being the ultimate path 
toward elucidating target genes, are low throughput and unable to provide a thorough view 
of miRNA targeting. One way to overcome this problem is to conduct the bioinformatic 
analysis by using various available computational prediction programs. In this regard, our 
studies in Chapter 2 took advantage of the bioinformatic tools and combined it with the 
miRNA expression analysis generated from experiments to obtain an overview of miRNA 
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targeting in regulation of cardiac ion channel genes. By applying this combinational 
analysis, we were able to identify a matrix of miRNAs in the heart which have the potential 
to regulate human cardiac ion channel genes (Chapter 2). Notably, this finding represents 
the first systematic analysis of miRNAs-based regulation of cardiac ion channel genes, and 
perhaps, one of the most important information brought up by this finding is the recognition 
that there is only a subset of cardiac-expressed miRNAs that could target the cardiac ion 
channel genes. This information may be used to rationally direct the future studies on 
miRNA regulation of ion channel genes. Another important finding of the study in Chapter 
2 is related to the subsequent application of the above bioinformatic analysis to three 
specific cardiac pathological settings (e.g. cardiac hypertrophy/heart failure, cardiac 
ischemia, and atrial fibrillation) that are known to be associated with the aberrant miRNAs 
expression profile and deregulated expression of ion channel genes. This analysis allowed 
us to translate the bioinformatic prediction into the biological perspective. Indeed, based on 
the above bioinformatic analysis of miRNA targeting, we are able to explain the 
experimentally-observed dysregulation of ion channel gene expression by the deregulation 
of the miRNAs under all these three pathological conditions, suggesting a potential 
implication of miRNA-mediated regulation of ion channel genes in arrhythmogenesis. 
Taken together, our findings indicate that multiple miRNAs may be involved in the 
electrical/ionic remodeling processes of cardiac diseases through altering their targeted ion 
channel genes expression in the heart, which has not been uncovered by previous 
experimental studies. 
 
5.3 Future Directions 
1. Can miR-26 overexpression interrupt the AF maintenance when AF is established? 
We have observed in Chapter 3 that in vivo overexpression of miR-26 is able to 
suppress AF susceptibility, suggesting the anti-AF effect of miR-26. Given that our 
experiments were primarily performed in normal animals, an extension of this study to 
an established AF animal model will certainly help to understand whether in vivo 
overexpression of miR-26 could also interrupt the AF maintenance if the AF is already 
established. For the AF animal model, we could consider using the ATP dog model (the 
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one that we used in Chapter 3). In this case, the cardiac overexpression of miR-26 can 
be achieved by directly injecting the miR-26 over-expressing adenovirus into the 
atrium. Alternatively, the cardiac overexpression of miR-26 can also be introduced by 
using the adeno-associated virus serotype 9 (AAV9), a recently-discovered virus that 
shows superior cardiac selectivity [248, 321], to achieve an improved cardiac 
specificity.  
2. What are the consequences of chronic miR-26 knockdown/overexpression in the 
context of AF? 
We have shown in Chapter 3 that AF vulnerability is substantially enhanced when 
cardiac expression of miR-26 is reduced, suggesting the causative role of miR-26 
reduction in AF promotion. Although, our subsequent experiments in Chapter 3 have 
already demonstrated that the AF-promoting effect of miR-26 knockdown is likely 
attributable to adverse electrical remodeling via the regulation of IK1 (Chapter 3), it is 
still unknown whether in vivo miR-26 knockdown may also promote AF by inducing 
atrial fibrosis. Given that our experiments were performed at one week after the initial 
attempt of miR-26 knockdown, which might not be sufficient for the development of 
fibrosis, the chronic effect of in vivo miR-26 knockdown will merit further 
investigation. This will help us to get a clearer picture of the role of miR-26 knockdown 
in AF promotion and will determine more precisely how the two miR-26-mediated 
remodeling processes contribute to AF induction and perpetuation. On the other hand, it 
will be also interesting to assess whether chronic miR-26 overexpression can prevent 
the AF-induced atrial fibrosis. 
3. What is the direct role of NFAT activation to AF susceptibility? 
We have demonstrated in Chapters3&4 that NFAT is centrally involved in the two 
miR-26-mediated pathways (NFAT/miR-26/Kir2.1 and NFAT/miR-26/TRPC3) leading 
to adverse electrical and structural remodeling during AF. However, the direct role of 
NFAT activation on AF induction and perpetuation remains unexplored. Thus, it will be 
particularly interesting to determine whether in vivo NFAT activation can render AF 
vulnerability, as this will help to gain more insights into the functional relevance of 
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NFAT activation in AF pathogenesis and to better dissect the relative contribute of the 
above pathways to AF induction and perpetuation.         
4. What is the potential implication of the synergistic interplay between miR-26 and 
TRPC3 in cardiac hypertrophy? 
Given that reduced miR-26 [350, 378] and enhanced TRPC3 [222, 379] expression 
have been consistently observed in cardiac hypertrophy, it is likely that the synergistic 
interplay between miR-26 and TRPC3 may also contribute to the fibrotic remodeling 
manifested in this pathological condition. This is a potentially-interesting direction 
which will be worthy of further investigation. 
 
5.4 Conclusion 
MiRNAs may importantly participate in arrhythmogenesis through altering the expression 
of cardiac ion channel genes in various cardiac pathological conditions. MiR-26 is critically 
involved in AF-associated electrical and structural remodeling and plays a central role in 
determining AF susceptibility via the regulation of IK1 and TRPC3 channel genes. Thus, 
our studies unravel a novel molecular control mechanism of AF at the miRNA level and 
reveal miR-26 as a novel and potentially-promising therapeutic target for AF. 
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